10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________________________________________________________________________________

FORM 10-Q

(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

OR

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                  to

Commission File No. 000-33043

OMNICELL, INC.

(Exact name of registrant as specified in its charter)

Delaware	94-3166458
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

4220 North Freeway

Fort Worth, TX 76137

(Address of registrant’s principal executive offices, including zip code)

(877) 415-9990

(Registrant’s telephone number, including area code)

    Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.001 par value	OMCL	NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý    No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý    No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	☒	Accelerated filer	☐	Non-accelerated filer	☐	Smaller reporting company	☐	Emerging growth company	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.									☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ý

As of October 27, 2023, there were 45,469,376 shares of the registrant’s common stock, $0.001 par value, outstanding.

OMNICELL, INC.

TABLE OF CONTENTS

		Page
PART I	FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets (Unaudited) as of September 30, 2023 and December 31, 2022	3
	Condensed Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 30, 2023 and 2022	4
	Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) for the three and nine months ended September 30, 2023 and 2022	5
	Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) for the three and nine months ended September 30, 2023 and 2022	6
	Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2023 and 2022	8
	Notes to Condensed Consolidated Financial Statements (Unaudited)	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	40
Item 4.	Controls and Procedures	40
PART II	OTHER INFORMATION	42
Item 1.	Legal Proceedings	42
Item 1A.	Risk Factors	42
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	43
Item 3.	Defaults Upon Senior Securities	43
Item 4.	Mine Safety Disclosures	43
Item 5.	Other Information	43
Item 6.	Exhibits	44
Signature		45

2

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

OMNICELL, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

	September 30, 2023		December 31, 2022
	(In thousands, except par value)
ASSETS
Current assets:
Cash and cash equivalents	$	446,840	$	330,362
Accounts receivable and unbilled receivables, net of allowances of $5,522 and $5,153, respectively	272,584		299,469
Inventories	116,144		147,549
Prepaid expenses	27,947		27,070
Other current assets	50,236		77,362
Total current assets	913,751		881,812
Property and equipment, net	106,880		93,961
Long-term investment in sales-type leases, net	41,631		32,924
Operating lease right-of-use assets	25,444		38,052
Goodwill	734,328		734,274
Intangible assets, net	218,861		242,906
Long-term deferred tax assets	35,964		22,329
Prepaid commissions	53,950		59,483
Other long-term assets	90,766		105,017
Total assets	$	2,221,575	$	2,210,758
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	49,920	$	63,389
Accrued compensation	44,065		73,455
Accrued liabilities	150,385		172,655
Deferred revenues, net	124,991		118,947
Total current liabilities	369,361		428,446
Long-term deferred revenues	55,053		37,385
Long-term deferred tax liabilities	1,565		2,095
Long-term operating lease liabilities	32,845		39,405
Other long-term liabilities	6,428		6,719
Convertible senior notes, net	568,887		566,571
Total liabilities	1,034,139		1,080,621
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	—		—
Common stock, $0.001 par value, 100,000 shares authorized; 55,746 and 55,030 shares issued; 45,463 and 44,747 shares outstanding, respectively	56		55
Treasury stock at cost, 10,283 shares outstanding, respectively	(290,319)		(290,319)
Additional paid-in capital	1,110,096		1,046,760
Retained earnings	384,732		390,728
Accumulated other comprehensive loss	(17,129)		(17,087)
Total stockholders’ equity	1,187,436		1,130,137
Total liabilities and stockholders’ equity	$	2,221,575	$	2,210,758

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

3

OMNICELL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands, except per share data)
Revenues:
Product revenues	$	188,755	$	246,565	$	562,906	$	706,246
Services and other revenues	109,908		101,494		325,359		292,027
Total revenues	298,663		348,059		888,265		998,273
Cost of revenues:
Cost of product revenues	106,311		134,023		323,800		374,175
Cost of services and other revenues	60,388		54,941		173,029		156,864
Total cost of revenues	166,699		188,964		496,829		531,039
Gross profit	131,964		159,095		391,436		467,234
Operating expenses:
Research and development	24,281		25,171		70,296		76,556
Selling, general, and administrative	103,971		115,459		332,643		354,644
Total operating expenses	128,252		140,630		402,939		431,200
Income (loss) from operations	3,712		18,465		(11,503)		36,034
Interest and other income (expense), net	3,670		(1,148)		9,912		(2,973)
Income (loss) before income taxes	7,382		17,317		(1,591)		33,061
Provision for (benefit from) income taxes	1,829		543		4,405		(995)
Net income (loss)	$	5,553	$	16,774	$	(5,996)	$	34,056
Net income (loss) per share:
Basic	$	0.12	$	0.38	$	(0.13)	$	0.77
Diluted	$	0.12	$	0.37	$	(0.13)	$	0.73
Weighted-average shares outstanding:
Basic	45,333		44,441		45,117		44,304
Diluted	45,595		45,819		45,117		46,759

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

4

OMNICELL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Net income (loss)	$	5,553	$	16,774	$	(5,996)	$	34,056
Other comprehensive loss:
Foreign currency translation adjustments	(2,953)		(6,770)		(42)		(15,735)
Other comprehensive loss	(2,953)		(6,770)		(42)		(15,735)
Comprehensive income (loss)	$	2,600	$	10,004	$	(6,038)	$	18,321

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

5

OMNICELL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)

	Common Stock			Treasury Stock			Additional Paid-In Capital		Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Stockholders’ Equity
	Shares	Amount		Shares	Amount
	(In thousands)
Balances as of December 31, 2022	55,030	$	55	(10,283)	$	(290,319)	$	1,046,760	$	390,728	$	(17,087)	$	1,130,137
Net loss	—	—		—	—		—		(15,000)		—		(15,000)
Other comprehensive income	—	—		—	—		—		—		1,479		1,479
Share-based compensation	—	—		—	—		15,180		—		—		15,180
Issuance of common stock under employee stock plans	322	—		—	—		12,114		—		—		12,114
Tax payments related to restricted stock units	—	—		—	—		(1,369)		—		—		(1,369)
Balances as of March 31, 2023	55,352	55		(10,283)	(290,319)		1,072,685		375,728		(15,608)		1,142,541
Net income	—	—		—	—		—		3,451		—		3,451
Other comprehensive income	—	—		—	—		—		—		1,432		1,432
Share-based compensation	—	—		—	—		15,148		—		—		15,148
Issuance of common stock under employee stock plans	136	1		—	—		3,088		—		—		3,089
Tax payments related to restricted stock units	—	—		—	—		(2,096)		—		—		(2,096)
Balances as of June 30, 2023	55,488	56		(10,283)	(290,319)		1,088,825		379,179		(14,176)		1,163,565
Net income	—	—		—	—		—		5,553		—		5,553
Other comprehensive loss	—	—		—	—		—		—		(2,953)		(2,953)
Share-based compensation	—	—		—	—		16,104		—		—		16,104
Issuance of common stock under employee stock plans	258	—		—	—		7,832		—		—		7,832
Tax payments related to restricted stock units	—	—		—	—		(2,665)		—		—		(2,665)
Balances as of September 30, 2023	55,746	$	56	(10,283)	$	(290,319)	$	1,110,096	$	384,732	$	(17,129)	$	1,187,436

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

6

OMNICELL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED) - CONTINUED

	Common Stock			Treasury Stock			Additional Paid-In Capital		Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Stockholders’ Equity
	Shares	Amount		Shares	Amount
	(In thousands)
Balances as of December 31, 2021	54,073	$	54	(9,894)	$	(238,109)	$	1,024,580	$	368,571	$	(8,407)	$	1,146,689
Net income	—	—		—	—		—		8,213		—		8,213
Other comprehensive loss	—	—		—	—		—		—		(2,555)		(2,555)
Share-based compensation	—	—		—	—		16,208		—		—		16,208
Issuance of common stock under employee stock plans	384	—		—	—		18,951		—		—		18,951
Tax payments related to restricted stock units	—	—		—	—		(4,322)		—		—		(4,322)
Stock repurchases	—	—		(389)	(52,210)		—		—		—		(52,210)
Cumulative effect of a change in accounting principle related to convertible debt	—	—		—	—		(72,742)		16,509		—		(56,233)
Balances as of March 31, 2022	54,457	54		(10,283)	(290,319)		982,675		393,293		(10,962)		1,074,741
Net income	—	—		—	—		—		9,069		—		9,069
Other comprehensive loss	—	—		—	—		—		—		(6,410)		(6,410)
Share-based compensation	—	—		—	—		17,213		—		—		17,213
Issuance of common stock under employee stock plans	114	1		—	—		2,171		—		—		2,172
Tax payments related to restricted stock units	—	—		—	—		(4,148)		—		—		(4,148)
Balances as of June 30, 2022	54,571	55		(10,283)	(290,319)		997,911		402,362		(17,372)		1,092,637
Net income	—	—		—	—		—		16,774		—		16,774
Other comprehensive loss	—	—		—	—		—		—		(6,770)		(6,770)
Share-based compensation	—	—		—	—		17,310		—		—		17,310
Issuance of common stock under employee stock plans	358	—		—	—		18,416		—		—		18,416
Tax payments related to restricted stock units	—	—		—	—		(2,972)		—		—		(2,972)
Balances as of September 30, 2022	54,929	$	55	(10,283)	$	(290,319)	$	1,030,665	$	419,136	$	(24,142)	$	1,135,395

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

7

OMNICELL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	Nine Months Ended September 30,
	2023		2022
	(In thousands)
Operating Activities
Net income (loss)	$	(5,996)	$	34,056
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	65,596		64,843
Loss on disposal of property and equipment	2,110		331
Share-based compensation expense	43,113		50,731
Deferred income taxes	(14,165)		(17,061)
Amortization of operating lease right-of-use assets	6,238		9,709
Impairment and abandonment of operating lease right-of-use assets related to facilities	7,815		5,390
Amortization of debt issuance costs	3,139		3,121
Changes in operating assets and liabilities:
Accounts receivable and unbilled receivables	27,050		(116,895)
Inventories	31,690		(32,269)
Prepaid expenses	(857)		(2,602)
Other current assets	1,521		6,692
Investment in sales-type leases	(8,839)		(17,336)
Prepaid commissions	5,533		8,801
Other long-term assets	2,539		4,189
Accounts payable	(13,358)		2,043
Accrued compensation	(29,390)		(27,940)
Accrued liabilities	3,749		11,678
Deferred revenues	23,628		17,667
Operating lease liabilities	(8,145)		(10,966)
Other long-term liabilities	(291)		1,446
Net cash provided by (used in) operating activities	142,680		(4,372)
Investing Activities
External-use software development costs	(10,240)		(9,648)
Purchases of property and equipment	(32,404)		(33,861)
Business acquisition, net of cash acquired	—		(3,392)
Purchase price adjustments from business acquisitions	—		5,484
Net cash used in investing activities	(42,644)		(41,417)
Financing Activities
Proceeds from issuances under stock-based compensation plans	23,035		39,539
Employees’ taxes paid related to restricted stock units	(6,130)		(11,442)
Change in customer funds, net	(6,615)		(402)
Stock repurchases	—		(52,210)
Net cash provided by (used in) financing activities	10,290		(24,515)
Effect of exchange rate changes on cash and cash equivalents	(464)		(1,425)
Net increase (decrease) in cash, cash equivalents, and restricted cash	109,862		(71,729)
Cash, cash equivalents, and restricted cash at beginning of period	352,835		355,620
Cash, cash equivalents, and restricted cash at end of period	$	462,697	$	283,891
Reconciliation of cash, cash equivalents, and restricted cash to the Condensed Consolidated Balance Sheets:
Cash and cash equivalents	$	446,840	$	266,402
Restricted cash included in other current assets	15,857		17,489
Cash, cash equivalents, and restricted cash at end of period	$	462,697	$	283,891
Supplemental disclosure of non-cash investing activities
Unpaid purchases of property and equipment	$	642	$	1,473
Transfers between inventory and property and equipment, net	$	—	$	314

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

8

OMNICELL, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1. Organization and Summary of Significant Accounting Policies

Business

Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products and related services are medication management solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” refer to Omnicell, Inc. and its subsidiaries, collectively.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of September 30, 2023 and December 31, 2022, the results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023 and 2022, and cash flows for the nine months ended September 30, 2023 and 2022. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 1, 2023, except as discussed in the section entitled “Recently Adopted Authoritative Guidance” below. The Company’s results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023, and cash flows for the nine months ended September 30, 2023 are not necessarily indicative of results that may be expected for the year ending December 31, 2023, or for any future period.

Principles of Consolidation

The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates.

The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. As of September 30, 2023, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities.

Segment Reporting

The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.

Recently Adopted Authoritative Guidance

In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The update addresses diversity in practice by requiring that an acquirer recognize and measure contract assets and liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. The Company adopted ASU 2021-08 beginning January 1, 2023 and will apply the guidance prospectively to acquisitions occurring on or after the adoption date.

9

Recently Issued Authoritative Guidance

There was no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date.

Note 2. Revenues

Revenue Recognition

The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories:

Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements. Solutions in this category include, but are not limited to, XT Series automated dispensing systems and products related to the Central Pharmacy Dispensing Service and IV Compounding Service.

Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards, which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, are designed to improve patient engagement and adherence to prescriptions.

Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements.

Advanced Services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth®, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, other software solutions, and services related to the Central Pharmacy Dispensing Service and IV Compounding Service.

The following table summarizes revenue recognition for each revenue category:

Revenue Category	Timing of Revenue Recognition	Income Statement Classification
Connected devices, software licenses, and other	Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer	Product
Consumables	Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer	Product
Technical services	Over time, as services are provided, typically ratably over the service term	Service
Advanced Services	Over time, as services are provided	Service

A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”) and Federal agencies that purchase under a Federal Supply Schedule Contract with the Department of Veterans Affairs (the “GSA Contract”). GPOs are often fully or partially owned by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company also pays the Industrial Funding Fee (“IFF”) to the Department of Veterans Affairs under the GSA Contract. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs and the IFF were $3.6 million and $4.8 million for the three months ended September 30, 2023 and 2022, respectively, and $9.5 million and $13.3 million for the nine months ended September 30, 2023 and 2022, respectively.

10

Disaggregation of Revenues

The following table summarizes the Company’s revenues disaggregated by revenue type for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Connected devices, software licenses, and other	$	167,560	$	226,415	$	500,182	$	650,125
Consumables	21,195		20,150		62,724		56,121
Technical services	57,303		53,914		167,851		156,386
Advanced Services	52,605		47,580		157,508		135,641
Total revenues	$	298,663	$	348,059	$	888,265	$	998,273

The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
United States	$	272,649	$	315,755	$	785,794	$	898,269
Rest of world (1)	26,014		32,304		102,471		100,004
Total revenues	$	298,663	$	348,059	$	888,265	$	998,273

_________________________________________________

(1)    No individual country represented more than 10% of total revenues.

Contract Assets and Contract Liabilities

The following table reflects the Company’s contract assets and contract liabilities:

	September 30, 2023		December 31, 2022
	(In thousands)
Short-term unbilled receivables, net (1)	$	20,275	$	25,763
Long-term unbilled receivables, net (2)	13,159		14,744
Total contract assets	$	33,434	$	40,507
Short-term deferred revenues, net	$	124,991	$	118,947
Long-term deferred revenues	55,053		37,385
Total contract liabilities	$	180,044	$	156,332

_________________________________________________

(1)    Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets.

(2)    Included in other long-term assets in the Condensed Consolidated Balance Sheets.

The portion of the transaction price allocated to the Company’s unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues.

Short-term deferred revenues of $125.0 million and $118.9 million include deferred revenues from product sales and service contracts, net of deferred cost of sales of $12.4 million and $15.8 million, as of September 30, 2023 and December 31, 2022, respectively. During the three and nine months ended September 30, 2023, the Company recognized revenues of $20.1 million and $106.2 million, respectively, that were included in the corresponding gross short-term deferred revenues balance of $134.7 million as of December 31, 2022. Long-term deferred revenues include deferred revenues from product sales and service contracts of $55.1 million and $37.4 million as of September 30, 2023 and December 31, 2022, respectively. Deferred revenues from product sales primarily relate to delivered and invoiced products, pending installation and acceptance. Deferred revenues from service contracts primarily relate to services that have been invoiced, where services have not yet been provided.

11

Short-term deferred revenues are expected to be recognized within the next twelve months. Long-term deferred revenues substantially consist of deferred revenues on long-term service contracts which have been invoiced and are expected to be recognized as revenue beyond twelve months, generally not more than ten years. The Company generally invoices customers for products upon shipment. Invoicing associated with the service portion of agreements is generally periodic and is billed on a monthly, quarterly, or annual basis, and in certain circumstances, multiple years are billed at one time.

In addition, the Company has remaining performance obligations associated with contracts for which the associated products have been accepted or associated services have started, but where invoicing has not yet occurred and therefore are not reflected in deferred revenue. These remaining performance obligations are comprised of the non-variable portions of technical services and Advanced Services provided under non-cancellable contracts with minimum commitments. Remaining performance obligations which are not included in deferred revenues are $344.8 million as of September 30, 2023. Remaining performance obligations are expected to be recognized ratably over the remaining terms of the associated contracts, which terms vary but are generally not more than ten years. Remaining performance obligations do not include product obligations, services where the associated product has not been accepted, services which have not yet started, variable portions of services, and certain other obligations.

Significant Customers

There were no customers that accounted for more than 10% of the Company’s total revenues for the three and nine months ended September 30, 2023 and 2022. Also, there were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of September 30, 2023 and December 31, 2022.

Note 3. Net Income (Loss) Per Share

The basic and diluted net income (loss) per share calculations for the three and nine months ended September 30, 2023 and 2022 were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands, except per share data)
Net income (loss)	$	5,553	$	16,774	$	(5,996)	$	34,056
Weighted-average shares outstanding – basic	45,333		44,441		45,117		44,304
Effect of dilutive securities from stock award plans	262		943		—		1,293
Effect of convertible senior notes	—		435		—		1,162
Weighted-average shares outstanding – diluted	45,595		45,819		45,117		46,759
Net income (loss) per share – basic	$	0.12	$	0.38	$	(0.13)	$	0.77
Net income (loss) per share – diluted	$	0.12	$	0.37	$	(0.13)	$	0.73
Anti-dilutive weighted-average shares related to stock award plans	2,727		810		3,536		689
Anti-dilutive weighted-average shares related to convertible senior notes and warrants	11,816		5,908		11,816		5,908

Note 4. Cash and Cash Equivalents and Fair Value of Financial Instruments

Cash and cash equivalents of $446.8 million and $330.4 million as of September 30, 2023 and December 31, 2022, respectively, consisted of bank accounts and highly-liquid U.S. Government money market funds held in sweep and asset management accounts with financial institutions of high credit quality. As of September 30, 2023 and December 31, 2022, cash equivalents were $429.7 million and $301.0 million, respectively, which consisted of money market funds held in sweep and asset management accounts.

Fair Value Hierarchy

The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. As of

12

September 30, 2023 and December 31, 2022, the fair value of the convertible senior notes was $518.6 million and $501.4 million, respectively, compared to their carrying values of $568.9 million and $566.6 million, respectively, which are net of unamortized debt issuance costs. Refer to Note 9, Debt and Credit Agreement, for further information regarding the Company’s credit facility and Note 10, Convertible Senior Notes, for further information regarding the Company’s convertible senior notes.

Note 5. Balance Sheet Components

Balance sheet details as of September 30, 2023 and December 31, 2022 are presented in the tables below:

	September 30, 2023		December 31, 2022
	(In thousands)
Inventories:
Raw materials	$	56,566	$	75,854
Work in process	2,738		9,280
Finished goods	56,840		62,415
Total inventories	$	116,144	$	147,549
Other current assets:
Funds held for customers, including restricted cash (1)	$	30,967	$	56,703
Net investment in sales-type leases, current portion	11,618		11,486
Prepaid income taxes	125		1,702
Other current assets	7,526		7,471
Total other current assets	$	50,236	$	77,362
Other long-term assets:
External-use software development costs, net	$	69,872	$	80,760
Unbilled receivables, net	13,159		14,744
Deferred debt issuance costs	1,235		2,058
Other long-term assets	6,500		7,455
Total other long-term assets	$	90,766	$	105,017
Accrued liabilities:
Operating lease liabilities, current portion	$	10,617	$	10,761
Customer fund liabilities	30,967		56,703
Advance payments from customers	10,549		11,556
Rebate liabilities	50,878		42,802
Group purchasing organization fees	5,290		7,723
Taxes payable	14,178		9,642
Other accrued liabilities	27,906		33,468
Total accrued liabilities	$	150,385	$	172,655

_________________________________________________

(1)    Includes restricted cash of $15.9 million and $22.5 million as of September 30, 2023 and December 31, 2022, respectively.

13

The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Beginning balance	$	(14,176)	$	(17,372)	$	(17,087)	$	(8,407)
Other comprehensive loss	(2,953)		(6,770)		(42)		(15,735)
Ending balance	$	(17,129)	$	(24,142)	$	(17,129)	$	(24,142)

Note 6. Property and Equipment

The following table represents the property and equipment balances as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
Equipment	$	95,891	$	91,391
Furniture and fixtures	4,898		5,154
Leasehold improvements	17,821		19,510
Purchased software and internal-use software development costs	97,860		76,327
Construction in progress	28,369		28,223
Property and equipment, gross	244,839		220,605
Accumulated depreciation and amortization	(137,959)		(126,644)
Total property and equipment, net	$	106,880	$	93,961

Depreciation and amortization expense of property and equipment was $6.7 million and $5.8 million for the three months ended September 30, 2023 and 2022, respectively, and $19.6 million and $16.7 million for the nine months ended September 30, 2023 and 2022, respectively.

The geographic location of the Company’s property and equipment, net, is based on the physical location in which it is located. The following table summarizes the geographic information for property and equipment, net, as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
United States	$	102,729	$	89,989
Rest of world (1)	4,151		3,972
Total property and equipment, net	$	106,880	$	93,961

_________________________________________________

(1)    No individual country represented more than 10% of total property and equipment, net.

14

Note 7. External-Use Software Development Costs

The carrying amounts of external-use software development costs as of September 30, 2023 and December 31, 2022 were as follows:

	September 30, 2023		December 31, 2022
	(In thousands)
Gross carrying amount	$	236,024	$	225,004
Accumulated amortization	(166,152)		(144,244)
External-use software development costs, net (1)	$	69,872	$	80,760

_________________________________________________

(1)     Included in other long-term assets in the Condensed Consolidated Balance Sheets.

The Company recorded $7.1 million and $7.3 million to cost of revenues for amortization of external-use software development costs for the three months ended September 30, 2023 and 2022, respectively, and $21.9 million and $21.5 million for the nine months ended September 30, 2023 and 2022, respectively.

The estimated future amortization expenses for external-use software development costs were as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	6,787
2024	24,747
2025	17,608
2026	12,069
2027	6,114
Thereafter	2,547
Total	$	69,872

Note 8. Goodwill and Intangible Assets

Goodwill

The following table represents changes in the carrying amount of goodwill:

	(In thousands)
Balance as of December 31, 2022	$	734,274
Foreign currency exchange rate fluctuations	54
Balance as of September 30, 2023	$	734,328

15

Intangible Assets, Net

The carrying amounts and useful lives of intangible assets as of September 30, 2023 and December 31, 2022 were as follows:

	September 30, 2023
	Gross carrying amount		Accumulated amortization		Foreign currency exchange rate fluctuations		Net carrying amount		Useful life (years)
	(In thousands, except for years)
Customer relationships	$	311,089	$	(113,844)	$	(1,482)	$	195,763	4 - 30
Acquired technology	84,876		(64,792)		—		20,084		4 - 20
Backlog	1,800		(1,575)		—		225		2
Trade names	9,200		(7,418)		—		1,782		5 - 12
Patents	2,430		(1,423)		—		1,007		2 - 20
Non-compete agreements	600		(600)		—		—		3
Total intangibles assets, net	$	409,995	$	(189,652)	$	(1,482)	$	218,861

 

	December 31, 2022
	Gross carrying amount		Accumulated amortization		Foreign currency exchange rate fluctuations		Net carrying amount		Useful life (years)
	(In thousands, except for years)
Customer relationships	$	311,089	$	(99,177)	$	(1,514)	$	210,398	4 - 30
Acquired technology	92,066		(64,299)		—		27,767		4 - 20
Backlog	1,800		(900)		—		900		2
Trade names	9,200		(6,633)		—		2,567		5 - 12
Patents	2,430		(1,306)		—		1,124		2 - 20
Non-compete agreements	600		(450)		—		150		3
Total intangibles assets, net	$	417,185	$	(172,765)	$	(1,514)	$	242,906

Amortization expense of intangible assets was $7.7 million and $8.7 million for the three months ended September 30, 2023 and 2022, respectively, and $24.1 million and $26.7 million for the nine months ended September 30, 2023 and 2022, respectively.

The estimated future amortization expenses for amortizable intangible assets were as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	7,483
2024	23,093
2025	21,056
2026	18,061
2027	16,754
Thereafter	132,414
Total	$	218,861

Note 9. Debt and Credit Agreement

On November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as amended, the “Prior A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative

16

agent. The Prior A&R Credit Agreement provided for (a) a five-year revolving credit facility of $500.0 million (the “Prior Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Prior Incremental Facility”). In addition, the Prior A&R Credit Agreement included a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Prior A&R Credit Agreement had an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings would be due and payable.

On September 22, 2020 and March 29, 2023, the Company entered into amendments to the Prior A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 10, Convertible Senior Notes, expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter, as well as to remove and replace the interest rate benchmark based on the London interbank offered rate (“LIBOR”) and related LIBOR-based mechanics applicable to borrowings under the A&R Credit Agreement with an interest rate benchmark based on the secured overnight financing rate (“SOFR”) as administered by the Federal Reserve Bank of New York and related SOFR-based mechanics.

Loans under the Prior Revolving Credit Facility bore interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Prior A&R Credit Agreement), plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Prior A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) Adjusted Term SOFR for a one month tenor plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Prior Revolving Credit Facility were subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Prior Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Prior Incremental Facility would be determined prior to the incurrence of such loans. The Company was permitted to make voluntary prepayments at any time without payment of a premium or penalty.

The Prior A&R Credit Agreement contained customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Prior A&R Credit Agreement also contained financial covenants that required the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the Prior A&R Credit Agreement contained certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.

Subsequent to the quarter ended September 30, 2023, the Company entered into a Second Amended and Restated Credit Agreement (the “Second A&R Credit Agreement”) on October 10, 2023, with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&R Credit Agreement supersedes the Prior A&R Credit Agreement and provides for (a) a five-year revolving credit facility of $350.0 million (the “Current Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to an amount equal to the sum of (i) the greater of $250.0 million or 100% of the adjusted consolidated EBITDA for the last four quarters and (ii) additional amounts subject to pro forma compliance with certain consolidated secured net leverage ratio (the “Current Incremental Facility”). In addition, the Second A&R Credit Agreement includes a letter of credit sub-limit of up to $15 million and a swing line loan sub-limit of up to $25 million. The Second A&R Credit Agreement has an expiration date of October 10, 2028, subject to acceleration under certain conditions, upon which date all remaining outstanding borrowings will be due and payable.

Loans under the Current Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Second A&R Credit Agreement), plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Second A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Current Revolving Credit Facility are subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Current Revolving Credit Facility. Subject to the terms and conditions of the Current Revolving Credit Facility or Current Incremental Facility, the Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. The availability of funds under the Current

17

Revolving Credit Facility may be subject to reduction in order to maintain compliance with the financial covenants under the Second A&R Credit Agreement.

The Second A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Second A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated secured net leverage ratio (not to exceed 3.00:1) and maintain a minimum consolidated interest coverage ratio (not to be less than 3.00:1). In addition, the Second A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.

The Company’s obligations under the Second A&R Credit Agreement and, at the election of the Company and the contracting counterparty, any secured swap obligations and banking services obligations owing to a lender (or an affiliate of a lender), are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the Second A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement.

As of both September 30, 2023 and December 31, 2022, the Company had $500.0 million of funds available under the Prior Revolving Credit Facility. As of September 30, 2023 and December 31, 2022, the Company had no outstanding balance under the Prior Revolving Credit Facility. The Company was in compliance with all covenants of the Prior A&R Credit Agreement as of September 30, 2023. Upon entry into the Second A&R Credit Agreement, the Company had $350.0 million of funds available under the Current Revolving Credit Facility.

Note 10. Convertible Senior Notes

0.25% Convertible Senior Notes due 2025

On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted.

The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions.

During the three months ended September 30, 2023 and December 31, 2022, none of the conditional conversion features of the Notes were triggered, and therefore, the Notes are not convertible during the fourth quarter of 2023, commencing on October 1, 2023, and were not convertible during the first quarter of 2023, commencing on January 1, 2023. Accordingly, the Company classified the Notes as a long-term liability in its Condensed Consolidated Financial Statements as of both September 30, 2023 and December 31, 2022. Whether the Notes will be convertible following the fourth fiscal quarter of 2023 will depend on the satisfaction of the conversion conditions in the future.

18

Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that could occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be.

If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of September 30, 2023, none of the criteria for a fundamental change or a conversion rate adjustment had been met.

As of September 20, 2023, the Company may redeem for cash all or any portion of the Notes, at its option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes.

The debt issuance costs associated with the Notes are being amortized to interest expense over the term of the Notes using an effective interest rate of 0.80%. As of September 30, 2023, the remaining life of the Notes and the related issuance cost accretion is approximately 2.0 years.

The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of September 30, 2023, the if-converted value of the Notes did not exceed the principal amount.

The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
Principal amount	$	575,000	$	575,000
Unamortized debt issuance costs	(6,113)		(8,429)
Convertible senior notes, net	$	568,887	$	566,571

The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Contractual coupon interest	$	359	$	359	$	1,078	$	1,078
Amortization of debt issuance costs	$	773	$	768	$	2,316	$	2,298

19

Convertible Note Hedge and Warrant Transactions

In connection with the issuance of the Notes in September 2020, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock.

The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Condensed Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes.

Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Condensed Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants.

Note 11. Lessor Leases

Sales-Type Leases

The Company enters into multi-year, sales-type lease agreements, with the leases varying in length from one to ten years. The Company optimizes cash flows by selling a majority of its sales-type leases, other than those relating to U.S. government hospitals and Advanced Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold.

The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Sales-type lease revenues	$	14,388	$	10,115	$	27,960	$	34,033
Cost of sales-type lease revenues	(7,141)		(5,357)		(14,183)		(16,963)
Selling profit on sales-type lease revenues	$	7,247	$	4,758	$	13,777	$	17,070

The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
Net minimum lease payments to be received	$	62,470	$	50,755
Less: Unearned interest income portion	(9,221)		(6,345)
Net investment in sales-type leases	53,249		44,410
Less: Current portion (1)	(11,618)		(11,486)
Long-term investment in sales-type leases, net	$	41,631	$	32,924

_________________________________________________

(1)    The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.

20

The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value.

The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	3,828
2024	13,431
2025	11,351
2026	9,053
2027	7,286
Thereafter	17,521
Total future minimum sales-type lease payments	62,470
Present value adjustment	(9,221)
Total net investment in sales-type leases	$	53,249

Operating Leases

The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Rental income	$	1,330	$	2,327	$	5,459	$	7,220

Note 12. Lessee Leases

The Company has operating leases for office buildings, data centers, office equipment, and vehicles. The Company’s leases have initial terms of one to twelve years. As of September 30, 2023, the Company did not have any additional material operating leases that were entered into, but not yet commenced.

The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	3,340
2024	12,266
2025	9,604
2026	8,942
2027	7,334
Thereafter	8,054
Total operating lease payments	49,540
Present value adjustment	(6,078)
Total operating lease liabilities (1)	$	43,462

_________________________________________________

(1)    Amount consists of a current and long-term portion of operating lease liabilities of $10.6 million and $32.8 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities in the Condensed Consolidated Balance Sheets.

21

Operating lease costs were $2.6 million and $4.0 million for the three months ended September 30, 2023 and 2022, respectively, and $8.2 million and $12.8 million for the nine months ended September 30, 2023 and 2022, respectively. Short-term lease costs and variable lease costs were not material for the three and nine months ended September 30, 2023 and 2022. The Company recorded impairment and abandonment charges to operating lease right-of-use assets of $7.8 million during the nine months ended September 30, 2023, and $0.3 million and $5.4 million during the three and nine months ended September 30, 2022, respectively, in connection with restructuring activities to reduce its real estate footprint and for optimization of certain leased facilities. The impairment and abandonment charges were recorded to selling, general, and administrative expenses on the Company’s Condensed Consolidated Statements of Operations. Refer to Note 16, Restructuring Expenses, for additional information regarding the Company’s restructuring activities.

The following table summarizes supplemental cash flow information related to the Company’s operating leases for the nine months ended September 30, 2023 and 2022:

	Nine Months Ended September 30,
	2023		2022
	(In thousands)
Cash paid for amounts included in the measurement of lease liabilities	$	10,100	$	13,178
Right-of-use assets obtained in exchange for new lease liabilities	$	1,758	$	12,177

The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
Weighted-average remaining lease term, years	4.6		5.0
Weighted-average discount rate, %	5.7	%	5.7	%

Note 13. Commitments and Contingencies

Purchase Obligations

In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. As of September 30, 2023, the Company had non-cancelable purchase commitments of $118.7 million, of which $78.1 million are expected to be paid within the year ending December 31, 2023.

Ransomware Incident

During the nine months ended September 30, 2023, the Company did not incur any material expenses or recoveries related to the previously disclosed ransomware incident. During the three months ended September 30, 2022, the Company incurred $1.0 million of expenses related to the ransomware incident, and during the nine months ended September 30, 2022, the Company incurred $13.5 million of expenses related to the ransomware incident, partially offset by $11.1 million of expected insurance recoveries. Expenses include costs to investigate and remediate the ransomware incident, as well as legal and other professional services, all of which were expensed as incurred. For the three and nine months ended September 30, 2022, the Company included net expenses related to the ransomware incident in cost of revenues of $0.1 million and $0.3 million, respectively; in research and development of $0.2 million and $0.2 million, respectively; and in selling, general, and administrative expenses of $0.7 million and $1.9 million, respectively, in the Company’s Condensed Consolidated Statements of Operations.

As of September 30, 2023, the Company has incurred $13.6 million of cumulative expenses related to the ransomware incident since it was detected, partially offset by $11.6 million of insurance recoveries, all of which have been received as of September 30, 2023.

Legal Proceedings

The Company is currently involved in various legal proceedings.

As required under ASC 450, Contingencies, the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any material accrual for contingent liabilities associated with any current legal proceedings based on its belief that any potential material loss, while reasonably possible, is not probable. Furthermore, any possible range of loss in such matters cannot be reasonably estimated at this time. The Company believes that it has valid defenses with respect to legal proceedings pending against it. However,

22

litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of legal proceedings or because of the diversion of management’s attention and the creation of significant expenses, regardless of outcome.

The Company is not a party to any legal proceedings that management believes may have a material impact on the Company’s financial position or results of operations.

Note 14. Income Taxes

The Company generally provides for income taxes in interim periods based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. For the nine months ended September 30, 2023, the Company recorded a provision for income taxes of $4.4 million by applying its estimated annual effective tax rate to its year-to-date measure of ordinary income and adjusted for $5.6 million of discrete income tax expense primarily from equity compensation. For the nine months ended September 30, 2022, the Company recorded a benefit from income taxes of $1.0 million by applying its estimated annual effective tax rate to its year-to-date measure of ordinary income and included a net discrete income tax benefit of $6.9 million, primarily due to a tax benefit from equity compensation.

The 2023 annual effective tax rate before discrete items differed from the statutory rate of 21% primarily due to the favorable benefit of the research and development credits and a foreign-derived intangible income (“FDII”) benefit deduction, partially offset by unfavorable impact of the non-deductible compensation and equity charges and Global Intangible Low-Taxed Income (“GILTI”) tax inclusion. The 2022 annual effective tax rate before discrete items differed from the statutory rate of 21% primarily due to the unfavorable impact of state income taxes, non-deductible compensation and equity charges, and GILTI tax inclusion, partially offset by the favorable impact of research and development credits and an FDII deduction.

On August 16, 2022, the Inflation Reduction Act of 2022 (the “IRA”) was signed into law and introduced a 15% corporate alternative minimum tax for tax years beginning after December 31, 2022 and levies a 1% excise tax on net stock repurchases after December 31, 2022. These provisions did not have an impact on the Company’s provision for income taxes for the nine months ended September 30, 2023.

As of September 30, 2023 and December 31, 2022, the Company had gross unrecognized tax benefits of $10.1 million and $9.3 million, respectively. The Company recognizes interest and penalties related to uncertain tax positions in interest and other income (expense), net in the Condensed Consolidated Statements of Operations. Accrued interest and penalties are included within other long-term liabilities on the Condensed Consolidated Balance Sheets. As of September 30, 2023 and December 31, 2022, the amount of accrued interest and penalties was $0.4 million and $0.2 million, respectively.

The Company files income tax returns in the United States and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examinations by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, France, and the United Kingdom. With few exceptions, as of September 30, 2023, the Company was no longer subject to U.S., state, and foreign tax examinations for years before 2019, 2018, and 2018, respectively.

Although the Company believes it has adequately provided for unrecognized tax benefits, the provisions on these positions may change as revised estimates are made or the underlying matters are settled or otherwise resolved. It is not possible at this time to reasonably estimate changes in the unrecognized tax benefits within the next twelve months.

Note 15. Employee Benefits and Share-Based Compensation

Share-Based Compensation Expense

The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Cost of product and service revenues	$	2,213	$	2,203	$	6,489	$	6,607
Research and development	1,917		3,054		5,220		7,912
Selling, general, and administrative	10,852		12,053		31,404		36,212
Total share-based compensation expense	$	14,982	$	17,310	$	43,113	$	50,731

23

During the three and nine months ended September 30, 2023, the Company capitalized approximately $1.1 million and $3.3 million, respectively, of non-cash share-based compensation expense to internal-use and external-use software development costs related to internal labor. The Company did not capitalize any material non-cash share-based compensation expense to inventory during the three and nine months ended September 30, 2023 and 2022, or any material non-cash share-based compensation expense to internal-use and external-use software development costs during the three and nine months ended September 30, 2022.

Employee Stock Purchase Plan (“ESPP”)

The following assumptions were used to value shares under the ESPP for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Expected life, years	0.5 - 2.0		0.5 - 2.0		0.5 - 2.0		0.5 - 2.0
Expected volatility, %	32.0% - 63.9%		28.8% - 44.8%		31.7% - 63.9%		28.8% - 45.6%
Risk-free interest rate, %	0.2% - 5.5%		0.1% - 3.2%		0.1% - 5.5%		0.1% - 3.2%
Dividend yield, %	—	%	—	%	—	%	—	%

For the nine months ended September 30, 2023 and 2022, employees purchased approximately 353,000 and 316,000 shares of common stock, respectively, under the ESPP at a weighted-average price of $46.68 and $67.63, respectively. As of September 30, 2023, the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $2.0 million and is expected to be recognized over a weighted-average period of 1.6 years.

Stock Options

The following assumptions were used to value stock options granted pursuant to the Company’s 2009 Equity Incentive Plan, as amended, (the “2009 Plan”) for the nine months ended September 30, 2023. There were no stock options granted during the three months ended September 30, 2023, and the three and nine months ended September 30, 2022.

	Nine Months Ended September 30,
	2023
Expected life, years	3.2
Expected volatility, %	44.8	%
Risk-free interest rate, %	3.7	%
Estimated forfeiture rate, %	10.0	%
Dividend yield, %	—	%

The following table summarizes the stock option activity under the 2009 Plan during the nine months ended September 30, 2023:

	Number of Shares	Weighted-Average Exercise Price		Weighted-Average Remaining Years	Aggregate Intrinsic Value
	(In thousands, except per share data)
Outstanding at December 31, 2022	2,434	$	68.65	6.1	$	7,887
Granted	200	55.60
Exercised	(157)	41.85
Expired	(177)	80.44
Forfeited	(180)	74.17
Outstanding at September 30, 2023	2,120	$	67.96	5.0	$	3,418
Exercisable at September 30, 2023	1,801	$	66.84	4.9	$	3,418
Vested and expected to vest at September 30, 2023 and thereafter	2,103	$	67.90	5.0	$	3,418

24

The weighted-average fair value per share of options granted during the nine months ended September 30, 2023 was $19.48. The intrinsic value of options exercised during the three months ended September 30, 2023 and 2022 was $0.5 million and $7.6 million, respectively, and during the nine months ended September 30, 2023 and 2022 was $3.1 million and $23.1 million, respectively.

As of September 30, 2023, total unrecognized compensation cost related to unvested stock options was $5.3 million, which is expected to be recognized over a weighted-average vesting period of 0.9 years.

Restricted Stock Units (“RSUs”)

The following table summarizes the RSU activity under the 2009 Plan during the nine months ended September 30, 2023:

	Number of Shares	Weighted-Average Grant Date Fair Value		Weighted-Average Remaining Years	Aggregate Intrinsic Value
	(In thousands, except per share data)
Outstanding at December 31, 2022	1,117	$	115.75	1.6	$	56,297
Granted (Awarded)	675	64.44
Vested (Released)	(252)	117.13
Forfeited	(304)	112.82
Outstanding and unvested at September 30, 2023	1,236	$	87.89	1.7	$	55,649

As of September 30, 2023, total unrecognized compensation cost related to RSUs was $78.2 million, which is expected to be recognized over the remaining weighted-average vesting period of 3.1 years.

Restricted Stock Awards (“RSAs”)

The following table summarizes the RSA activity under the 2009 Plan during the nine months ended September 30, 2023:

	Number of Shares	Weighted-Average Grant Date Fair Value
	(In thousands, except per share data)
Outstanding at December 31, 2022	13	$	109.39
Granted (Awarded)	24	70.96
Vested (Released)	(13)	109.39
Outstanding and unvested at September 30, 2023	24	$	70.96

As of September 30, 2023, total unrecognized compensation cost related to RSAs was $1.0 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.6 years.

Performance-Based Stock Unit Awards (“PSUs”)

The following table summarizes the PSU activity under the 2009 Plan during the nine months ended September 30, 2023:

	Number of Shares	Weighted-Average Grant Date Fair Value
	(In thousands, except per share data)
Outstanding at December 31, 2022	135	$	147.42
Granted	65	122.29
Vested	(35)	127.40
Forfeited	(66)	153.68
Outstanding and unvested at September 30, 2023	99	$	129.36

25

As of September 30, 2023, total unrecognized compensation cost related to PSUs was approximately $6.7 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.4 years.

Summary of Shares Reserved for Future Issuance under Equity Incentive Plans

The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of September 30, 2023:

	Number of Shares
	(In thousands)
Stock options outstanding	2,120
Non-vested restricted stock awards	1,359
Shares authorized for future issuance	2,417
ESPP shares available for future issuance	3,250
Total shares reserved for future issuance	9,146

Stock Repurchase Programs

On August 2, 2016, the Company’s Board of Directors (the “Board”) authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2014 Repurchase Program”). During the first quarter of 2022, the 2014 Repurchase Program was completed, and as of September 30, 2023, the maximum dollar value of shares that may yet be purchased under the 2016 Repurchase Program was $2.7 million. The 2016 Repurchase Program does not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the 2016 Repurchase Program at any time.

During the nine months ended September 30, 2022, the Company repurchased approximately 389,300 shares of its common stock under the repurchase programs at an average price of $134.11 per share for an aggregate purchase price of approximately $52.2 million. During the three and nine months ended September 30, 2023 and the three months ended September 30, 2022, the Company did not repurchase any of its outstanding common stock under the 2016 Repurchase Program.

Note 16. Restructuring Expenses

During the first quarter of 2022, the Company initiated certain domestic and international restructuring initiatives, in order to enhance and streamline certain engineering functions for its domestic operations, and to realign its international sales organization to better serve its customers in various international markets. During the third quarter of 2022, the Company initiated restructuring initiatives associated with the integration and functionalization of certain acquisitions, primarily the 340B Link business acquisition, to further accelerate the expansion of the Company’s pharmacy inventory management capabilities. During the three and nine months ended September 30, 2022, the restructuring plans incurred $1.8 million and $5.3 million, respectively, of employee severance costs and related expenses. As of September 30, 2023, there was no material unpaid balance related to these restructuring plans.

On November 23, 2022, the Company committed to a plan to reduce the Company’s headcount (the “Plan”), as part of the Company’s expense containment efforts being implemented due to ongoing macroeconomic headwinds. During the first quarter of 2023, as a result of continued exploration of expense containment measures, the Company committed to further reduce its headcount across many of its functions, and also committed to reduce its real estate footprint to align with its broader hybrid work strategy and in an effort to further reduce costs. During the three months ended September 30, 2023, the Company recorded an immaterial reversal of previously recognized restructuring expenses associated with the Plan. During the nine months ended September 30, 2023, the Company incurred $5.5 million of employee severance costs and related expenses, net of reversals, in connection with the Plan. As of September 30, 2023, the Company has incurred $22.9 million of cumulative restructuring expense, net of reversals, related to employee severance costs and related expenses since the inception of the Plan. As of September 30, 2023 and December 31, 2022, the unpaid balance related to the Plan was $1.0 million and $18.2 million, respectively.

Refer to Note 12, Lessee Leases, for information regarding the Company’s restructuring activities for the reduction of its real estate footprint and optimization of certain leased facilities.

26

The following table summarizes the total employee-related restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Cost of product and service revenues	$	(280)	$	444	$	102	$	600
Research and development	(25)		272		467		1,866
Selling, general, and administrative	(276)		1,078		4,885		2,855
Total restructuring expense, net of reversals	$	(581)	$	1,794	$	5,454	$	5,321

Note 17. Subsequent Events

Second Amended and Restated Credit Agreement

On October 10, 2023, the Company entered into the Second A&R Credit Agreement with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&R Credit Agreement supersedes the Company’s Prior A&R Credit Agreement. Refer to Note 9, Debt and Credit Agreement, for additional information.

Restructuring Plan

On November 2, 2023, the Company announced a plan to reduce the Company’s headcount and real estate footprint (the “2023 Plan”) as part of the Company’s expense containment initiatives and other actions to reduce discretionary spending being implemented due to challenging industry dynamics and macroeconomic conditions. In connection with the 2023 Plan, the Company estimates that it will incur approximately $12 million to $18 million of nonrecurring restructuring and related charges, consisting of (i) approximately $9 million to $12 million of cash-based charges related to the reduction in headcount, which primarily consist of employee severance and benefits costs and (ii) approximately $3 million to $6 million of non-cash charges related to office closure, which the Company expects to incur the majority of charges in the fourth quarter of 2023 with remaining charges incurred in future periods. The Company expects to substantially complete the 2023 Plan, including cash payments, by the end of the second quarter of 2024, subject to local laws and consultation requirements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS AND FACTORS THAT MAY AFFECT FUTURE RESULTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statements are contained throughout this Quarterly Report on Form 10-Q including in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements include, but are not limited to, statements about:

•our expectations regarding our future sales pipeline and bookings;

•the extent and timing of future revenues, including the amounts of our current backlog;

•the size or growth of our market or market share;

•our beliefs about drivers of demand for our products, services, and solutions, opportunities in certain market categories, and continued expansion in these market categories, as well as our belief that our technology, services, and solutions within these market categories position us well to address the needs of retail, acute, post-acute, and specialty pharmacy providers;

•continued investment in the industry vision of the Autonomous Pharmacy, our beliefs about the anticipated benefits of such investments, and our expectations regarding continued growth in current and future subscription and cloud-based offerings as we execute on this vision;

•our goal of advancing our platform with the development of new products, services, or solutions or the enhancement of existing products, services, or solutions;

27

•growth opportunities presented by new products, services, solutions, and markets;

•our projected target revenues, operating costs, and cash flows;

•our ability to align our intelligent infrastructure development and global workforce headcount with our current business expectations;

•our goal to deliver on the industry vision of the Autonomous Pharmacy, as well as our plan to migrate our customers from an on-premise infrastructure to our cloud-based platform;

•our belief that our solutions that support the industry vision of the Autonomous Pharmacy, are strongly aligned with trends in the healthcare market, and are well-positioned to address the evolving needs of healthcare institutions;

•our expectation to continue to acquire companies, businesses, products, services, or technologies and to effectively integrate or manage these acquired companies, businesses, products, services, or technologies;

•our ability to secure adequate supplies of raw materials and components utilized in the manufacture of our products of a quality that we require, on a timely basis, and at acceptable prices;

•our containment of the impacts of the ransomware incident we experienced in May 2022, and any further impacts on the Company, including its business, operating results, cash flow, or financial condition;

•our expected future uses of cash and the sufficiency of our sources of funding;

•our ability to generate cash from operations and our estimates regarding the sufficiency of our cash resources; and

•our expectations about the impact of epidemics, pandemics, or other major public health crises, such as the COVID-19 pandemic, and the associated containment measures, on our workforce and operations as well as those of our customers and suppliers, and the effect on our business, operating results, cash flow, or financial condition.

In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goals,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “target,” “will,” “would,” and variations of these terms and similar expressions.

Forward-looking statements are based on our current expectations and assumptions, and are subject to known and unknown risks and uncertainties, many of which are beyond our control, which may cause our actual results, performance, or achievements to be materially different from those expressed or implied in the forward-looking statements. Such risks and uncertainties include those described throughout this Quarterly Report on Form 10-Q, including Part I - Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II - Item 1A. “Risk Factors,” as well as in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 1, 2023. Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements should be considered in light of these risks and uncertainties. You should carefully read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed as exhibits, as well as other documents we file with, or furnish to, the SEC from time to time, with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements in this Quarterly Report on Form 10-Q represent our current estimates and assumptions and speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, future events, even if new information becomes available in the future, or otherwise.

Other Information

All references in this Quarterly Report on Form 10-Q to “Omnicell,” “our,” “us,” “we,” or “the Company” collectively refer to Omnicell, Inc., a Delaware corporation, and its subsidiaries. The term “Omnicell, Inc.” refers only to Omnicell, Inc., excluding its subsidiaries.

We own various registered and unregistered trademarks and service marks used in our business, some of which appear in this Quarterly Report on Form 10-Q, including Omnicell®. This Quarterly Report on Form 10-Q may also include the trademarks and service marks of other companies. Such trademarks and service marks are the marks of their respective owners.

28

OVERVIEW

Our Business

Omnicell, a leader in transforming the pharmacy care delivery model, is committed to solving the critical challenges inherent in medication management and elevating the role of clinicians within healthcare as an essential component of care delivery. Omnicell is focused on not only helping its customers optimize medication management in each setting of care, but also placing the patient at the center and helping its customers optimize medication management across all care settings from inpatient to outpatient. We are doing so with an industry-leading medication management intelligent infrastructure to equip and empower pharmacists and pharmacies with the ability to focus on clinical care rather than administrative tasks. This intelligent infrastructure provides the critical foundation for customers to realize the industry vision of the Autonomous Pharmacy, a vision defined by pharmacy leaders for improving operational efficiencies and ultimately targeting zero-error medication management.

Facilities worldwide use our automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. Institutional and retail pharmacies across North America and the United Kingdom leverage our innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. We sell our product and consumable solutions together with related service offerings. Revenues generated in the United States represented 91% of our total revenues for both the three months ended September 30, 2023 and 2022, and 88% and 90% for the nine months ended September 30, 2023 and 2022, respectively.

Over the past several years, our business has expanded from a single-point solution to a platform of products and services that will help to further advance the industry vision of the Autonomous Pharmacy. This expansion has resulted in larger deal sizes across multiple products, services, and implementations for customers and, we believe, more comprehensive, valuable, and enduring relationships. As our business evolves, we continue to evaluate the metrics and methods we use to measure the success of our business.

We utilize bookings as an indicator of the success of our business. We define bookings generally as: (i) the value of non-cancelable contracts for our connected devices, software products, and Advanced Services (although, for those Advanced Services contracts without a minimum commitment, bookings only include the amount of revenue that has been recognized once the services have been provided); and (ii) for our consumables, the value of orders placed through our Omnicell Storefront online platform or through written or telephonic orders. We typically exclude technical services and other less significant items ancillary to our products and services, such as freight revenue from bookings. As noted, the portfolio of products, solutions and services we offer has evolved. As a result, the ordering process for certain of our solutions has also evolved. For example, orders for certain of our solutions may not include a purchase order. Connected devices and software license bookings are recorded as revenue upon customer acceptance of the installation or receipt of goods. Revenues from Advanced Services bookings are recorded over the contractual term.

We generally provide installation planning and consulting as part of most connected device product sales, which is typically included in the initial price of the solution. To help ensure the maximum availability of our systems, our customers typically purchase technical services contracts (maintenance and support) in increments of one to five years. In addition to connected device product sales, we provide a range of services to our customers. We also provide Advanced Services such as Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), EnlivenHealth, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, and other software solutions, which typically are provided over 2-7 years.

29

The following table summarizes each revenue category:

Revenue Category	Revenue Type	Income Statement Classification	Included in Bookings
Connected devices, software licenses, and other	Nonrecurring	Product	Yes (1)
Consumables	Recurring	Product	Yes
Technical services	Recurring	Service	No
Advanced Services (2) (3)	Recurring	Service	Yes

_________________________________________________

(1)    Certain other insignificant revenue streams ancillary to our products and services, such as freight revenue, are not included in bookings.

(2)    Includes Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), EnlivenHealth, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, and other software solutions.

(3)    For those Advanced Services contracts without a minimum commitment, bookings only include the amount of revenue that has been recognized once the services have been provided.

Our full-time employee headcount was approximately 3,890 and 4,230 on September 30, 2023 and December 31, 2022, respectively. The decrease in employee headcount reflects the impact of the restructuring plan announced in November 2022.

Operating Segments

We manage our operations as a single segment for the purposes of assessing performance and making operating decisions. Our Chief Operating Decision Maker (“CODM”) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Omnicell at the consolidated level using information about our revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of Omnicell as one operating segment, which is the same as our reporting segment.

Business Strategy

The U.S. spent a total of $633.5 billion on prescription drugs that accounted for 14% of National Health Expenditures in 2022, and prescription drugs impact the vast majority of patients in virtually all settings of care. We believe there are significant challenges facing the practice of pharmacy today including, but not limited to, labor shortages, medication errors, drug shortages, medication loss due to drug diversion, significant medication waste and expiration costs, a high level of manual processes, complexity around compliance requirements, high healthcare worker turnover rates affecting tenure and expertise, hospitalizations from adverse drug events in outpatient settings, high variability in outcomes, and limited inventory visibility. Each of these challenges can translate into a major economic impact for hospitals and health systems. We recognize that some of these challenges can create capital budget and labor constraints for our customers in the near-term that may impact the potential timing of contracting for, or implementing, our products, solutions, or services. However, we believe that over time these significant challenges to the practice of pharmacy should drive demand for increased digitization, visibility, and insights that our solutions are designed to enable. Because of this, we find that our solutions are well positioned to address the evolving needs of healthcare institutions and therefore present opportunities for growth over the long-term.

In an effort to address these challenges and deliver solutions to help drive positive medication management outcomes, we continue to make significant investments in our research and development efforts to further advance the industry vision of the Autonomous Pharmacy. Furthermore, we believe a combination of technology, expertise and intelligence is needed in each care setting and across the entire continuum of care. We are focused on delivering solutions to help our customers realize the industry vision of the Autonomous Pharmacy and drive positive medication management outcomes with outstanding customer experience through a mature channel in four market categories:

•Point of Care. As a market leader, we expect to continue expansion into this product market as customers increase the use of our dispensing systems in more areas within their hospitals. However, we recognize that the current macroeconomic environment, with significant labor constraints, may impact our customers’ considerations in the near term when determining to implement new workflows that may affect those same stressed labor pools. As our XT Series cabinet is largely through the replacement, upgrade, and expansion cycle of older models of automated dispensing systems, we are seeing demand moderate. Over time, we believe that should labor shortages continue to challenge the delivery of healthcare services, deploying solutions and workflows that are intended to save nursing time, such as our XT Series, will be essential. We also believe there is an opportunity for us to expand this offering and define a new standard for dispensing systems in perioperative settings. We believe our

30

current solutions within the Point of Care market and new innovation and services will continue to help customers drive improved outcomes.

•Central Pharmacy and IV Compounding. This market represents the beginning of the medication management process in acute care settings, and, we believe, it is a significant automation opportunity for high volumes of manual, repetitive, and error-prone processes that are often common in pharmacies today. Manual medication dispensing processes are usually labor intensive, error-prone, and may lead to excess medication waste and expirations for our healthcare partners. Automating the central pharmacy dispensing process should enable customers to reallocate pharmacy labor, enhance dispensing accuracy and patient safety, and reduce medication waste and expirations. Likewise, the manual compounding of sterile IV preparations can be error-prone and create significant patient safety risks, and outsourcing sterile IV compounding could lead to increased medication costs. As a result, we believe IV automation provides a significant opportunity to enhance patient safety and reduce costs. Because adoption of our Central Pharmacy and IV automation solution is still nascent, we believe that the implementation of new solutions (as well as upgrading older technology) will be accelerated by combining technology, expertise, and intelligence into a comprehensive offering that is designed to deliver improved outcomes. Despite the potential headwinds from the lack of clarity in the current regulatory environment for IV automation, we anticipate that these bundled solutions will become more critical as health systems continue to face labor shortages, increased financial pressure, and supply chain disruptions.

•Specialty Pharmacy and 340B Program. We believe that health systems will invest in more revenue-generating activities that are intended to improve patient outcomes by utilizing specialty pharmacies and the 340B Drug Pricing Program, which allow hospitals and health systems to stretch federal resources and expand patient access to healthcare by requiring manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations. Specialty drugs are used for treatment of complex conditions and often require intensive patient management and specialized workflows for dispensing and care coordination. Specialty medications are projected to account for nearly 60% of U.S. total spending on medications, with total spending projected to be approximately $420 billion in 2025. Specialty pharmacies serve as the connection between patients, prescribing physicians, and payers and work to streamline access and adherence to these specialty drugs. We believe a solution that addresses start-up and managed services for health systems that is designed to optimize their specialty pharmacy programs and the related pharmaceutical aspects of patient care will help ensure continuity of care and should contribute to the revenue and profitability of those organizations. We believe that a fully optimized specialty pharmacy operation represents one of the largest economic opportunities for hospitals and health systems.

•Retail, Institutional, and Payer. We believe the Retail, Institutional, and Payer market represents a significant opportunity as healthcare evolves. A majority of all prescription drugs are distributed in non-hospital settings. The COVID-19 pandemic accelerated the shift of outpatient care from hospitals and physician offices to other, more convenient settings, such as retail pharmacies and the home (including through telehealth technologies). New technologies and updated state board regulations appear to be spurring innovation by retail pharmacies, which, combined with the move to value-based care, we believe will drive the adoption of solutions that are intended to help providers and payers engage patients in new ways that improve patient care, reduce the total cost of care, and lead to more profitable operations. Because of the complexity of relationships between payers and providers, as well as the large number of retail pharmacies, including a significant number of independent pharmacies, we believe a network of established relationships between payers, providers and pharmacies will also be important.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our discussion and analysis of our financial condition and results of operations are based on our Condensed Consolidated Financial Statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. We regularly review our estimates and assumptions, which are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of certain assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates and assumptions.

We believe the following critical accounting policies are affected by significant judgments and estimates used in the preparation of our Condensed Consolidated Financial Statements:

•Revenue recognition;

31

•Lessor leases;

•Allowance for credit losses;

•Inventory;

•Internal-use and external-use software development costs;

•Lessee leases;

•Valuation and impairment of goodwill and intangible assets;

•Business combinations;

•Share-based compensation; and

•Accounting for income taxes.

There were no material changes in the matters for which we make critical accounting estimates in the preparation of our Condensed Consolidated Financial Statements during the nine months ended September 30, 2023 as compared to those disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2022, except as discussed in “Recently Adopted Authoritative Guidance” in Note 1, Organization and Summary of Significant Accounting Policies, of the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.

Recently Issued Authoritative Guidance

Refer to “Recently Issued Authoritative Guidance” in Note 1, Organization and Summary of Significant Accounting Policies, of the Notes to Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial position, and cash flows.

RESULTS OF OPERATIONS

Total Revenues

	Three Months Ended September 30,
					Change in
	2023		2022		$		%
	(Dollars in thousands)
Product revenues	$	188,755	$	246,565	$	(57,810)	(23)%
Percentage of total revenues	63%		71%
Services and other revenues	109,908		101,494		8,414		8%
Percentage of total revenues	37%		29%
Total revenues	$	298,663	$	348,059	$	(49,396)	(14)%

Product revenues represented 63% and 71% of total revenues for the three months ended September 30, 2023 and 2022, respectively. Product revenues decreased by $57.8 million, primarily due to lower volumes from our automated dispensing systems business primarily as a result of ongoing health systems capital budget and labor constraints.

Services and other revenues represented 37% and 29% of total revenues for the three months ended September 30, 2023 and 2022, respectively. Services and other revenues include revenues from technical services and Advanced Services offerings. Services and other revenues increased by $8.4 million, primarily due to increased customer demand for our Advanced Services offerings and continued growth in our installed customer base as well as the impact of pricing actions.

Our international sales represented 9% of total revenues for both the three months ended September 30, 2023 and 2022, and are expected to be affected by foreign currency exchange rate fluctuations. We are unable to predict the extent to which revenues in future periods will be impacted by changes in foreign currency exchange rates.

32

	Nine Months Ended September 30,
					Change in
	2023		2022		$		%
	(Dollars in thousands)
Product revenues	$	562,906	$	706,246	$	(143,340)	(20)%
Percentage of total revenues	63%		71%
Services and other revenues	325,359		292,027		33,332		11%
Percentage of total revenues	37%		29%
Total revenues	$	888,265	$	998,273	$	(110,008)	(11)%

Product revenues represented 63% and 71% of total revenues for the nine months ended September 30, 2023 and 2022, respectively. Product revenues decreased by $143.3 million, primarily due to lower volumes from our automated dispensing systems business primarily as a result of ongoing health systems capital budget and labor constraints, partially offset by an increase of $6.6 million in revenues from consumables.

Services and other revenues represented 37% and 29% of total revenues for the nine months ended September 30, 2023 and 2022, respectively. Services and other revenues include revenues from technical services and Advanced Services offerings. Services and other revenues increased by $33.3 million, primarily due to increased customer demand for our Advanced Services offerings and continued growth in our installed customer base as well as the impact of pricing actions.

Our international sales represented 12% and 10% of total revenues for the nine months ended September 30, 2023 and 2022, respectively, and are expected to be affected by foreign currency exchange rate fluctuations. We are unable to predict the extent to which revenues in future periods will be impacted by changes in foreign currency exchange rates.

Our ability to grow revenues is dependent on our ability to continue to obtain orders from customers, which may be dependent upon customers’ capital equipment budgets and/or capital equipment approval cycles, our ability to produce quality products and consumables to fulfill customer demand, the volume of installations we are able to complete, our ability to meet customer needs by providing a quality installation experience, our ability to develop new or enhance existing solutions, and our flexibility in workforce allocations among customers to complete installations on a timely basis. The timing of our product revenues for equipment is primarily dependent on when our customers’ schedules and/or staffing levels allow for installations.

Cost of Revenues and Gross Profit

Cost of revenues is primarily comprised of three general categories: (i) standard product costs which account for the majority of the product cost of revenues that are provided to customers, and are inclusive of purchased material, labor to build the product, and overhead costs associated with production; (ii) costs of providing services and installation costs, including costs of personnel and other expenses; and (iii) other costs, including variances in standard costs and overhead, scrap costs, rework, provisions for excess and obsolete inventory, and amortization of software development costs and intangibles.

	Three Months Ended September 30,
					Change in
	2023		2022		$		%
	(Dollars in thousands)
Cost of revenues:
Cost of product revenues	$	106,311	$	134,023	$	(27,712)	(21)%
As a percentage of related revenues	56%		54%
Cost of services and other revenues	60,388		54,941		5,447		10%
As a percentage of related revenues	55%		54%
Total cost of revenues	$	166,699	$	188,964	$	(22,265)	(12)%
As a percentage of total revenues	56%		54%
Gross profit	$	131,964	$	159,095	$	(27,131)	(17)%
Gross margin	44%		46%

33

Cost of revenues for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 decreased by $22.3 million, primarily driven by a $27.7 million decrease in cost of product revenues, partially offset by a $5.4 million increase in cost of services and other revenues.

The decrease in cost of product revenues was primarily driven by the decrease in product revenues of $57.8 million for the three months ended September 30, 2023 compared to the three months ended September 30, 2022. The decrease in cost of product revenues has not decreased proportionally with the decrease in product revenues for the three months ended September 30, 2023, primarily due to certain fixed costs, such as labor and overhead. In addition, the decrease in cost of product revenues was also driven by lower inventory-related costs as pricing for semiconductors, steel, freight, and other costs has decreased from the prior period. The increase in cost of services and other revenues was primarily driven by the increase in services and other revenues of $8.4 million for the three months ended September 30, 2023 compared to the three months ended September 30, 2022.

The overall decrease in gross margin primarily relates to lower product revenues for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 whereas the decrease in cost of product revenues has not decreased proportionally with the decrease in product revenues, primarily due to certain fixed costs, such as labor and overhead. The decrease is partially offset by lower inventory-related costs. Our gross profit for the three months ended September 30, 2023 was $132.0 million, as compared to $159.1 million for the three months ended September 30, 2022.

	Nine Months Ended September 30,
					Change in
	2023		2022		$		%
	(Dollars in thousands)
Cost of revenues:
Cost of product revenues	$	323,800	$	374,175	$	(50,375)	(13)%
As a percentage of related revenues	58%		53%
Cost of services and other revenues	173,029		156,864		16,165		10%
As a percentage of related revenues	53%		54%
Total cost of revenues	$	496,829	$	531,039	$	(34,210)	(6)%
As a percentage of total revenues	56%		53%
Gross profit	$	391,436	$	467,234	$	(75,798)	(16)%
Gross margin	44%		47%

Cost of revenues for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 decreased by $34.2 million, primarily driven by a $50.4 million decrease in cost of product revenues, partially offset by a $16.2 million increase in cost of services and other revenues.

The decrease in cost of product revenues was primarily driven by the decrease in product revenues of $143.3 million for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022. The decrease in cost of product revenues has not decreased proportionally with the decrease in product revenues for the nine months ended September 30, 2023, primarily due to certain fixed costs, such as labor and overhead. In addition, the decrease in cost of product revenues was also driven by lower inventory-related costs as pricing for semiconductors, steel, freight, and other costs has decreased from the prior period. The increase in cost of services and other revenues was primarily driven by the increase in services and other revenues of $33.3 million for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022.

The overall decrease in gross margin primarily relates to lower product revenues for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 whereas the decrease in cost of product revenues has not decreased proportionally with the decrease in product revenues, primarily due to certain fixed costs, such as labor and overhead. The decrease is partially offset by lower inventory-related costs. Our gross profit for the nine months ended September 30, 2023 was $391.4 million, as compared to $467.2 million for the nine months ended September 30, 2022.

34

Operating Expenses and Interest and Other Income (Expense), Net

	Three Months Ended September 30,
					Change in
	2023		2022		$		%
	(Dollars in thousands)
Operating expenses:
Research and development	$	24,281	$	25,171	$	(890)	(4)%
As a percentage of total revenues	8%		7%
Selling, general, and administrative	103,971		115,459		(11,488)		(10)%
As a percentage of total revenues	35%		33%
Total operating expenses	$	128,252	$	140,630	$	(12,378)	(9)%
As a percentage of total revenues	43%		40%
Interest and other income (expense), net	$	3,670	$	(1,148)	$	4,818	(420)%

Research and Development. Research and development expenses decreased by $0.9 million for the three months ended September 30, 2023 compared to the three months ended September 30, 2022. The decrease was primarily driven by cost saving initiatives, including the impact from lower consulting expenses.

Selling, General, and Administrative. Selling, general, and administrative expenses decreased by $11.5 million for the three months ended September 30, 2023 compared to the three months ended September 30, 2022. The decrease was primarily due to a decrease of $3.4 million in consulting expenses, a decrease of $2.7 million in commission expenses, a decrease of $2.2 million in freight out, a decrease of $1.4 million in employee-related expenses for restructuring initiatives, a decrease of $1.4 million in rent expense, and a decrease of $1.2 million of ransomware-related expenses, net of insurance recoveries, incurred during the three months ended September 30, 2022. The decrease was partially offset by $1.3 million of executives transition costs incurred during the three months ended September 30, 2023.

Interest and Other Income (Expense), Net. Interest and other income (expense), net changed by $4.8 million for the three months ended September 30, 2023 compared to the three months ended September 30, 2022, primarily driven by a $4.5 million increase in other income and a $0.3 million decrease in other expense. The increase in other income during the three months ended September 30, 2023 as compared to the three months ended September 30, 2022 is primarily attributable to higher interest income received due to higher interest rates and higher cash and cash equivalents balances.

	Nine Months Ended September 30,
					Change in
	2023		2022		$		%
	(Dollars in thousands)
Operating expenses:
Research and development	$	70,296	$	76,556	$	(6,260)	(8)%
As a percentage of total revenues	8%		8%
Selling, general, and administrative	332,643		354,644		(22,001)		(6)%
As a percentage of total revenues	37%		36%
Total operating expenses	$	402,939	$	431,200	$	(28,261)	(7)%
As a percentage of total revenues	45%		43%
Interest and other income (expense), net	$	9,912	$	(2,973)	$	12,885	(433)%

Research and Development. Research and development expenses decreased by $6.3 million for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022. The decrease was primarily attributed to a decrease of $5.2 million in consulting expenses, a decrease in employee-related expenses for restructuring initiatives of $1.4 million, a decrease due to the timing of capitalized software projects of $1.3 million and other decreases from cost saving initiatives, partially offset by an increase of $3.8 million in employee-related expenses due to increased headcount.

35

Selling, General, and Administrative. Selling, general, and administrative expenses decreased by $22.0 million for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022. The decrease was primarily due to a decrease of $5.8 million in commissions expenses, a decrease of $4.9 million in employee-related expenses, a decrease of $4.5 million in consulting expenses, a decrease of $3.4 million in freight out, a decrease of $3.3 million in travel expenses, and a decrease of $2.6 million in temporary labor expenses. The decrease is also driven by $2.3 million of ransomware-related expenses, net of insurance recoveries, incurred during the nine months ended September 30, 2022. The decrease is partially offset by an increase of $2.0 million in employee-related expenses for restructuring initiatives, an increase of $2.4 million for impairment and abandonment charges of operating lease right-of-use assets in connection with restructuring activities of certain leased facilities, as well as an increase of $2.2 million in executives transition costs incurred during the nine months ended September 30, 2023.

Interest and Other Income (Expense), Net. Interest and other income (expense), net changed by $12.9 million for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022, primarily driven by a $12.1 million increase in other income and a $0.8 million decrease in other expense. The increase in other income during the nine months ended September 30, 2023 as compared to the nine months ended September 30, 2022 is primarily attributable to higher interest income received due to higher interest rates and higher cash and cash equivalents balances.

Provision for (Benefit from) Income Taxes

	Three Months Ended September 30,
					Change in
	2023		2022		$		%
	(Dollars in thousands)
Provision for income taxes	$	1,829	$	543	$	1,286	237%

	Nine Months Ended September 30,
					Change in
	2023		2022		$		%
	(Dollars in thousands)
Provision for (benefit from) income taxes	$	4,405	$	(995)	$	5,400	(543)%

For the nine months ended September 30, 2023, we recorded a provision for income taxes of $4.4 million by applying our estimated annual effective tax rate to our year-to-date measure of ordinary income and adjusted for $5.6 million of discrete income tax expense primarily from equity compensation. For the nine months ended September 30, 2022, we recorded a benefit from income taxes of $1.0 million, and included a net discrete income tax benefit of $6.9 million, primarily due to a $5.1 million tax benefit from equity compensation. The change in the provision for income taxes for the nine months ended September 30, 2023 compared to the benefit from income taxes for the same period in 2022 was primarily due to a decrease in excess tax benefit from equity compensation, as well as the change in income (loss) before income taxes.

Refer to Note 14, Income Taxes, of the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information.

LIQUIDITY AND CAPITAL RESOURCES

We had cash and cash equivalents of $446.8 million at September 30, 2023 compared to $330.4 million at December 31, 2022. All of our cash and cash equivalents are invested in bank accounts and money market funds held in sweep and asset management accounts with financial institutions of high credit quality.

Our cash position and working capital at September 30, 2023 and December 31, 2022 were as follows:

	September 30, 2023		December 31, 2022
	(In thousands)
Cash and cash equivalents	$	446,840	$	330,362
Working capital	$	544,390	$	453,366

Our ratio of current assets to current liabilities was 2.5:1 and 2.1:1 at September 30, 2023 and December 31, 2022, respectively.

36

Sources of Cash

Revolving Credit Facility

On November 15, 2019, we entered into an Amended and Restated Credit Agreement (as amended, the “Prior A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. The Prior A&R Credit Agreement provided for (a) a five-year revolving credit facility of $500.0 million (the “Prior Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Prior Incremental Facility”). In addition, the Prior A&R Credit Agreement included a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million.

On September 22, 2020 and March 29, 2023, we entered into amendments to the Prior A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 10, Convertible Senior Notes, expand our flexibility to repurchase our common stock and make other restricted payments, and replace the total net leverage covenant, as well as to remove and replace the interest rate benchmark based on the London interbank offered rate (“LIBOR”) and related LIBOR-based mechanics applicable to borrowings under the A&R Credit Agreement with an interest rate benchmark based on the secured overnight financing rate (“SOFR”) as administered by the Federal Reserve Bank of New York and related SOFR-based mechanics.

On October 10, 2023, we entered into a Second Amended and Restated Credit Agreement (the “Second A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&R Credit Agreement supersedes the Prior A&R Credit Agreement and provides for (a) a five-year revolving credit facility of $350.0 million (the “Current Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to an amount equal to the sum of (i) the greater of $250.0 million and 100% of the adjusted consolidated EBITDA for the last four quarters and (ii) additional amounts subject to pro forma compliance with certain consolidated secured net leverage ratio (the “Current Incremental Facility”). In addition, the Second A&R Credit Agreement includes a letter of credit sub-limit of up to $15 million and a swing line loan sub-limit of up to $25 million. The Second A&R Credit Agreement has an expiration date of October 10, 2028, subject to acceleration under certain conditions, upon which date all remaining outstanding borrowings will be due and payable.

As of September 30, 2023, we had $500.0 million of funds available and no outstanding balance under the Prior Revolving Credit Facility. As of September 30, 2023, we were in compliance with all covenants under the Prior A&R Credit Agreement. Upon entry into the Second A&R Credit Agreement, we had $350.0 million of funds available under the Current Revolving Credit Facility. Refer to Note 9, Debt and Credit Agreement, of the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information. We expect to use future loans under the Current Revolving Credit Facility, if any, for working capital, potential acquisitions, and other general corporate purposes.

Uses of Cash

Our future uses of cash are expected to be primarily for working capital, capital expenditures, and other contractual obligations. We also expect a continued use of cash for potential acquisitions and acquisition-related activities, as well as repurchases of our common stock.

The 2016 Repurchase Program has a total of $2.7 million remaining for future repurchases as of September 30, 2023, which may result in additional use of cash. There were no stock repurchases during the nine months ended September 30, 2023. Refer to “Stock Repurchase Programs” under Note 15, Employee Benefits and Share-Based Compensation, of the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information.

Based on our current business plan and backlog, we believe that our existing cash and cash equivalents, our anticipated cash flows from operations, cash generated from the exercise of employee stock options and purchases under our Employee Stock Purchase Plan (“ESPP”), along with the availability of funds under the Revolving Credit Facility will be sufficient to meet our cash needs for working capital, capital expenditures, potential acquisitions, and other contractual obligations for at least the next twelve months. For periods beyond the next twelve months, we also anticipate that our net operating cash flows plus existing balances of cash and cash equivalents will suffice to fund the continued growth of our business.

37

Cash Flows

The following table summarizes, for the periods indicated, selected items in our Condensed Consolidated Statements of Cash Flows:

	Nine Months Ended September 30,
	2023		2022
	(In thousands)
Net cash provided by (used in):
Operating activities	$	142,680	$	(4,372)
Investing activities	(42,644)		(41,417)
Financing activities	10,290		(24,515)
Effect of exchange rate changes on cash and cash equivalents	(464)		(1,425)
Net increase (decrease) in cash, cash equivalents, and restricted cash	$	109,862	$	(71,729)

Operating Activities

We expect cash from our operating activities to fluctuate in future periods as a result of a number of factors, including the timing of our billings and collections, our operating results, and the timing of other liability payments.

Net cash provided by operating activities was $142.7 million for the nine months ended September 30, 2023, primarily consisting of a net loss of $6.0 million adjusted for non-cash items of $113.8 million and changes in assets and liabilities of $34.9 million. The non-cash items primarily consisted of depreciation and amortization expense of $65.6 million, share-based compensation expense of $43.1 million, impairment and abandonment of operating lease right-of-use assets related to facilities of $7.8 million, amortization of operating lease right-of-use assets of $6.2 million, amortization of debt issuance costs of $3.1 million, and a change in deferred income taxes of $14.2 million. Changes in assets and liabilities include cash inflows primarily from (i) a decrease in inventories of $31.7 million primarily due to management of inventory levels to align with the current forecasted demand, (ii) a decrease in accounts receivable and unbilled receivables of $27.1 million primarily due to the timing of billings, shipments, and collections, as well as the impacts of lower revenues, (iii) an increase in deferred revenues of $23.6 million primarily due to an increase in billings for certain service and subscription offerings, (iv) a decrease in prepaid commissions of $5.5 million, (v) an increase in accrued liabilities of $3.7 million, (vi) a decrease in other long-term assets of $2.5 million, and (vii) a decrease in other current assets of $1.5 million. These cash inflows were partially offset by (i) a decrease in accrued compensation of $29.4 million primarily due to a decrease in the accrual for restructuring initiatives, lower commissions, as well as timing of payroll and ESPP purchases, (ii) a decrease in accounts payable of $13.4 million primarily due to an overall decrease in spending, as well as timing of payments, (iii) an increase in investment in sales-type leases of $8.8 million primarily due to the acceptance of certain Advanced Services products under sales-type lease arrangements, and (iv) a decrease in operating lease liabilities of $8.1 million.

Net cash used in operating activities was $4.4 million for the nine months ended September 30, 2022, primarily consisting of net income of $34.1 million adjusted for non-cash items of $117.1 million, offset by changes in assets and liabilities of $155.6 million. The non-cash items primarily consisted of depreciation and amortization expense of $64.8 million, share-based compensation expense of $50.7 million, amortization of operating lease right-of-use assets of $9.7 million, impairment and abandonment of operating lease right-of-use assets of $5.4 million, amortization of debt issuance costs of $3.1 million, and a change in deferred income taxes of $17.1 million. Changes in assets and liabilities include cash outflows from (i) an increase in accounts receivable and unbilled receivables of $116.9 million primarily due to an increase in billings driven by overall business growth and the timing of shipments and collections, (ii) an increase in inventories of $32.3 million primarily to support forecasted sales, including advanced purchases of certain components, such as semiconductors, as well as higher costs of inventory and timing of shipments, (iii) a decrease in accrued compensation of $27.9 million primarily due to a decrease in accrued commissions and bonuses, as well as timing of payroll and ESPP purchases, (iv) an increase in investment in sales-type leases of $17.3 million primarily due to the increase in sales-type lease revenues associated with certain Advanced Services products, (v) a decrease in operating lease liabilities of $11.0 million, and (vi) an increase in prepaid expenses of $2.6 million. These cash outflows were partially offset by (i) an increase in deferred revenues of $17.7 million primarily due to an increase in billings driven by the timing of shipments in order to meet customers’ implementation schedules and recognition of revenues for products requiring installation, (ii) an increase in accrued liabilities of $11.7 million primarily due to an increase in taxes payable, (iii) a decrease in prepaid commissions of $8.8 million, (iv) a decrease in other current assets, net of funds held for customers, of $6.7 million primarily due to a decrease in prepaid income taxes, (v) a decrease in other long-term assets of $4.2 million, (vi) an increase in accounts payable of $2.0 million, and (vii) an increase in other long-term liabilities of $1.4 million.

38

Investing Activities

Net cash used in investing activities was $42.6 million for the nine months ended September 30, 2023, which consisted of capital expenditures of $32.4 million for property and equipment, and $10.2 million for external-use software development costs.

Net cash used in investing activities was $41.4 million for the nine months ended September 30, 2022, which consisted of $3.4 million consideration paid for the acquisition of Hub and Spoke Innovations, net of cash acquired, capital expenditures of $33.9 million for property and equipment, and $9.6 million for costs of software development for external use, partially offset by purchase price adjustments from business acquisitions of $5.5 million.

Financing Activities

Net cash provided by financing activities was $10.3 million for the nine months ended September 30, 2023, primarily due to $23.0 million in proceeds from employee stock option exercises and ESPP purchases, partially offset by $6.1 million in employees’ taxes paid related to restricted stock unit vesting and a net change in the customer funds balances of $6.6 million.

Net cash used in financing activities was $24.5 million for the nine months ended September 30, 2022, primarily due to $52.2 million for repurchases of our stock, and $11.4 million in employees’ taxes paid related to restricted stock unit vesting, partially offset by $39.5 million in proceeds from employee stock option exercises and ESPP purchases.

Contractual Obligations

There have been no significant changes during the nine months ended September 30, 2023 to the contractual obligations disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” set forth in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2022.

Contractual obligations as of September 30, 2023 were as follows:

	Payments Due By Period
	Total		Remainder of 2023		2024 - 2025		2026 - 2027		2028 and thereafter
	(In thousands)
Operating leases (1)	$	49,540	$	3,340	$	21,870	$	16,276	$	8,054
Purchase obligations (2)	118,658		78,055		40,471		132		—
Convertible senior notes (3)	577,875		—		577,875		—		—
Total (4)	$	746,073	$	81,395	$	640,216	$	16,408	$	8,054

_________________________________________________

(1)Commitments under operating leases relate primarily to leased office buildings, data centers, office equipment, and vehicles. Refer to Note 12, Lessee Leases, of the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information.

(2)We purchase components from a variety of suppliers and use contract manufacturers to provide manufacturing services for our products. During the normal course of business, we issue purchase orders with estimates of our requirements several months ahead of the delivery dates. These amounts are associated with agreements that are enforceable and legally binding. The amounts under such contracts are included in the table above because we believe that cancellation of these contracts is unlikely and we expect to make future cash payments according to the contract terms or in similar amounts for similar materials.

(3)We issued convertible senior notes in September 2020 that are due in September 2025. The obligations presented above include both principal and interest for these notes. Although these notes mature in 2025, they may be converted into cash and shares of our common stock prior to maturity if certain conditions are met. Any conversion prior to maturity can result in repayment of the principal amounts sooner than the scheduled repayment as indicated in the table above. Refer to Note 10, Convertible Senior Notes, of the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information.

(4)Refer to Note 13, Commitments and Contingencies, of the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information.

39

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risks related to fluctuations in foreign currency exchange rates and interest rates.

Foreign Currency Exchange Risk

We operate in foreign countries which expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which are the British Pound and the Euro. In order to manage foreign currency risk, at times we enter into foreign exchange forward contracts to mitigate risks associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities of our foreign subsidiaries. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We do not enter into derivative contracts for trading purposes. As of September 30, 2023, we did not have any outstanding foreign exchange forward contracts.

Interest Rate Fluctuation Risk

We are exposed to interest rate risk through our borrowing activities. As of September 30, 2023, there was no outstanding balance under the Prior A&R Credit Agreement. Upon entry into the Second A&R Credit Agreement on October 10, 2023, we had $350.0 million of funds available under the Current Revolving Credit Facility. Refer to Note 9, Debt and Credit Agreement, of the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information.

The net carrying amount under our convertible senior notes was $568.9 million as of September 30, 2023. Although our convertible senior notes are based on a fixed rate, changes in interest rates could impact the fair value of such notes. As of September 30, 2023, the fair market value of our convertible senior notes was $518.6 million. Refer to Note 4, Cash and Cash Equivalents and Fair Value of Financial Instruments, and Note 10, Convertible Senior Notes, of the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information.

We have used, and in the future we may use, interest rate swap agreements to protect against adverse fluctuations in interest rates by reducing our exposure to variability in cash flows relating to interest payments on a portion of our outstanding debt. We do not hold or issue any derivative financial instruments for speculative trading purposes. As of September 30, 2023, we did not have any outstanding interest rate swap agreements.

There were no significant changes in our market risk exposures during the nine months ended September 30, 2023 as compared to the market risk exposures disclosed in “Quantitative and Qualitative Disclosures About Market Risk,” set forth in Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 1, 2023.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. These disclosure controls and procedures are designed to ensure that the information required to be disclosed by us in this Quarterly Report on Form 10-Q was (i) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and regulations and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

Based on such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this report.

Limitations on Effectiveness of Controls

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of financial statements for external purposes in accordance with GAAP. All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable assurance that the objectives of the internal control system are met.

40

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the three months ended September 30, 2023.

41

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The information set forth under “Legal Proceedings” in Note 13, Commitments and Contingencies, of the Notes accompanying the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q is incorporated herein by reference.

ITEM 1A. RISK FACTORS

Other than the updates provided below, please refer to Part I - Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the U.S. Securities and Exchange Commission on March 1, 2023.

We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position.

On November 15, 2019, we refinanced our existing senior secured credit facility pursuant to an amended and restated agreement with certain lenders, and Wells Fargo Bank, National Association, as administrative agent (as amended, the “Prior A&R Credit Agreement”). The Prior A&R Credit Agreement provided for a five-year revolving credit facility of $500.0 million and an uncommitted incremental loan facility of up to $250.0 million. As of December 31, 2022, there were no outstanding balances under the Prior A&R Credit Agreement.

Subsequently, on October 10, 2023, we refinanced the Prior A&R Credit Agreement pursuant to a second amended and restated agreement with certain lenders, and Wells Fargo Bank, National Association, as administrative agent (the “Second A&R Credit Agreement”). The Second A&R Credit Agreement provides for a five-year revolving credit facility of $350.0 million and an uncommitted incremental loan facility of up to an amount equal to the sum of (x) the greater of $250.0 million and 100% of the adjusted consolidated EBITDA for the last four quarters and (y) additional amounts subject to pro forma compliance with certain consolidated secured net leverage ratio.

In addition, on September 25, 2020, we issued $575.0 million aggregate principal amount of 0.25% Convertible Senior Notes due 2025 (the “Notes”), pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between us and U.S. Bank National Association, as trustee. We used a portion of the proceeds from the issuance of the Notes to repay all outstanding borrowings under the revolving credit facility at the time.

Our debt may limit our ability to borrow additional funds or use our existing cash flow for working capital, capital expenditures, acquisitions, or other general business purposes or may require us to use a substantial portion of our cash flow for debt service payments; limit our flexibility to plan for, or react to, changes in our business and industry; place us at a competitive disadvantage compared to our less leveraged competitors; and increase our vulnerability to the impact of adverse economic and industry conditions.

Our ability to make payments of the principal, to pay interest, or to refinance our indebtedness, including the Notes, depends on our future performance, which is subject to economic, financial, competitive, and other factors beyond our control. Our business may not continue to, and we cannot provide assurance that our business will, generate cash flow from operations in the future sufficient to fund our cash requirements, service our debt or make necessary capital expenditures. Our failure to generate sufficient cash flow to pay our debts could have a material adverse effect on our business. In addition, if we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as borrowing more money, selling assets, restructuring debt, or obtaining additional equity capital on terms that may be onerous or highly dilutive. Any of these actions still may not be sufficient to allow us to service our debt obligations, could increase the risks related to our business or our ability to service or repay our indebtedness or may otherwise have an adverse effect on our business.

Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at the time of any such refinancing. We may not be able to engage in any of these activities or to do so on desirable terms, which could result in a default on our debt obligations. In addition, as more fully described below in the risk factor captioned “Covenants in our Second A&R Credit Agreement restrict our business and operations in many ways, and if we do not effectively manage our compliance with these covenants, our business, operating results, cash flow, or financial condition could be adversely affected,” the Second A&R Credit Agreement includes customary restrictive covenants that impose operating and financial restrictions on us.

42

Covenants in our Second A&R Credit Agreement restrict our business and operations in many ways, and if we do not effectively manage our compliance with these covenants, our financial conditions and operating results could be adversely affected.

The Second A&R Credit Agreement contains various customary covenants that require us to provide financial and other information reporting as well as notice upon certain events and limit or restrict our ability and/or our subsidiaries’ ability to, among other things, incur or assume liens or additional debt or provide guarantees in respect of obligations of other persons; issue redeemable preferred stock; pay dividends or distributions or redeem or repurchase capital stock; prepay, redeem, or repurchase certain debt; make loans, investments, acquisitions, and capital expenditures; enter into agreements that restrict distributions from our subsidiaries; sell assets and capital stock of our subsidiaries; enter into certain transactions with affiliates; and consolidate or merge with or into, or sell substantially all of our assets to, another person.

The Second A&R Credit Agreement also includes financial covenants requiring us (i) not to exceed a maximum consolidated secured net leverage ratio of 3.00:1 and (ii) to maintain a minimum consolidated interest coverage ratio of 3.00:1. Our ability to comply with these financial covenants may be affected by events beyond our control. Our failure to comply with any of the covenants under the Second A&R Credit Agreement could result in a default under the terms of the Second A&R Credit Agreement, which could permit the administrative agent or the lenders to declare all or part of any outstanding borrowings to be immediately due and payable or foreclose on our assets, or to refuse to permit additional borrowings under the revolving credit facility, which could restrict our operations, particularly our ability to respond to changes in our business or to take specified actions to take advantage of certain business opportunities that may be presented to us. In addition, if we are unable to repay those amounts, the administrative agent and the lenders under the Second A&R Credit Agreement could proceed against the collateral granted to them to secure that debt and foreclose on our assets, which would seriously harm our business.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

During the three months ended September 30, 2023, we did not repurchase any shares of our common stock under our repurchase program. Refer to “Stock Repurchase Programs” under Note 15, Employee Benefits and Share-Based Compensation, of the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Securities Trading Plans of Directors and Officers

During the three months ended September 30, 2023, none of our directors or officers adopted or terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement (as each term is defined in Item 408(a) of Regulation S-K).

43

ITEM 6. EXHIBITS

		Incorporated By Reference
Exhibit Number	Exhibit Description	Form	Exhibit	Filing Date
10.1*	Omnicell, Inc. Executive Severance Plan	8-K	10.1	8/3/2023
10.2*	Separation Agreement dated August 4, 2023 by and between Omnicell, Inc. and Peter J. Kuipers	8-K	10.1	8/10/2023
10.3+*	Form of Restricted Stock Unit Notice and Form of Global Restricted Stock Unit Award Agreement for 2009 Equity Incentive Plan, as amended (August 2023)
10.4*	Separation Agreement dated October 4, 2023 by and between Omnicell, Inc. and Christine M. Mellon	8-K	10.1	10/5/2023
10.5	Second Amended and Restated Credit Agreement, dated as of October 10, 2023, among Omnicell, Inc., the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent	8-K	10.1	10/16/2023
31.1+	Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)
31.2+	Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)
32.1+	Certification of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)
101.INS+	Inline XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH+	Inline XBRL Taxonomy Extension Schema Document
101.CAL+	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB+	Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE+	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104+	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

_________________________________________________

*    Indicates a management contract, compensation plan, or arrangement.

+    Filed herewith.

44

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		OMNICELL, INC.
Date:	November 3, 2023	By:	/s/ Nchacha E. Etta
			Nchacha E. Etta, Executive Vice President & Chief Financial Officer (principal financial officer and duly authorized officer)

45

EX-10.3

Exhibit 10.3

Global Restricted Stock Unit Award	Omnicell, Inc.
Grant Notice	4220 North Freeway
	Fort Worth, Texas 76137

Name: Employee ID:

You have been granted a Restricted Stock Unit Award in Omnicell, Inc. Common Stock as follows:

Type of Award:	Restricted Stock Unit (RSU)
Grant No.:
Equity Incentive Plan:	2009 Equity Incentive Plan
Date of Grant:
Shares Subject to Award:
Fair Market Value per Unit:
Total Price of Stock Unit:

Vesting Date Number of Shares Vesting on Vesting Date

Delivery Schedule: Pursuant to Section 6 of the 2009 Equity Incentive Plan Global Restricted Stock Unit Award Agreement (the “Global Restricted Stock Unit Award Agreement”), the Company shall deliver on each vesting date one share of Common Stock for each Stock Unit which vests on such date, less any shares to be withheld pursuant to Section 10 of such Global Restricted Stock Unit Award Agreement.

By your acceptance of this Restricted Stock Unit Grant, you agree that this award is granted under and governed by the terms and conditions of this Grant Notice, Omnicell, Inc.’s 2009 Equity Incentive Plan (as amended from time to time) (the “Plan”) and by the terms and conditions of the Global Restricted Stock Unit Award Agreement which is attached hereto.

You understand and agree that as of the Date of Grant, this Grant Notice, the Global Restricted Stock Unit Award Agreement and the Plan set forth the entire understanding between you and Omnicell, Inc. regarding the grant set forth herein, and the underlying Common Stock, and supersede all prior oral and written agreements on that subject.

Chief Financial Officer

Attachment: Global Restricted Stock Unit Award Agreement

1.

Omnicell, Inc.

2009 Equity Incentive Plan

Global Restricted Stock Unit Award Agreement

Amended by the Compensation Committee of the Board of Directors Effective August 8, 2023

Pursuant to the Restricted Stock Unit Grant Notice (“Grant Notice”) and this Global Restricted Stock Unit Award Agreement, including any country-specific appendix thereto (the “Appendix” and collectively, the “Agreement”) and in consideration of your services, Omnicell, Inc. (the “Company”) has awarded you a Restricted Stock Unit Award (the “Award”) under its 2009 Equity Incentive Plan (the “Plan”). Your Award is granted to you effective as of the Date of Grant set forth in the Grant Notice for this Award. This Agreement shall be deemed to be agreed to by the Company and you upon the acceptance by you of the Grant Notice to which it is attached. Defined terms not explicitly defined in this Agreement shall have the same meanings given to them in the Plan. In the event of any conflict between the terms in this Agreement and the Plan, the terms of the Plan shall control. The details of your Award, in addition to those set forth in the Grant Notice and the Plan, are as follows.

1.GRANT OF THE AWARD. This Award represents the right to be issued on a future date the number of shares of the Company’s Common Stock as indicated in the Grant Notice. As of the Date of Grant, the Company will credit to a bookkeeping account maintained by the Company for your benefit (the “Account”) the number of shares of Common Stock subject to the Award. This Award was granted in consideration of your future services to the Company or an Affiliate. Except as otherwise provided herein, you will not be required to make any payment to the Company (other than services to the Company or an Affiliate) with respect to your receipt of the Award, the vesting of the shares or the delivery of the underlying Common Stock.

2.VESTING. Subject to the limitations contained herein, your Award will vest, if at all, in accordance with the vesting schedule provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service (provided further that (i) subject to clause (ii) below, if at the time of termination of your Continuous Service you hold a position of Executive Vice President or above with the Company or its subsidiaries and your termination of your Continuous Service is by the Company without Cause, then any portion of the Award that was scheduled to vest within 12 months following the date of termination shall continue to vest and be settled in accordance with the vesting schedule during such 12-month period following your termination of Continuous Service, subject to your continued compliance with your obligations under Section 17, or (ii)(a) if your Continuous Service is terminated by the Company without Cause or (b) if immediately prior to an event giving rise to Good Reason (as defined in the Company’s Executive Severance Plan in effect immediately prior to the consummation of a Change in Control) you hold a position of Senior Vice President or above with the Company or its subsidiaries, and you resign for Good Reason , in either case within 24 months following the occurrence of a Change in Control (the termination pursuant to this clause (ii), a “CIC Qualifying Termination”), then any unvested portion of the Award shall fully vest and be settled upon such CIC Qualifying Termination, subject to your continued compliance with your obligations under Section 17. For purposes of your Award, a termination of your Continuous Service will be deemed

2.

to have occurred as of the date you are no longer actively providing services to the Company or an Affiliate (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or otherwise rendering services, or the terms of your employment or other service agreement, if any). Your employment or service relationship will not be extended by any notice period (e.g., your period of service will not be extended by any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or otherwise rendering services, or the terms of your employment or service agreement, if any). The Committee shall have the exclusive discretion to determine when you are no longer providing Continuous Services for purposes of your Award (including whether you may still be considered to be providing services while on a leave of absence). Upon such termination of your Continuous Service, the shares credited to the Account that were not vested on the date of such termination or which are not scheduled to vest following your termination of Continuous Service in accordance with the terms of this Award or as otherwise determined by the Committee, will be forfeited at no cost to the Company and you will have no further right, title or interest in or to such underlying shares of Common Stock. For the avoidance of doubt, service during any portion of the vesting period shall not entitle you to vest in a pro rata portion of the Award.

3.NUMBER OF SHARES.

(a)The number of shares subject to your Award may be adjusted from time to time for Capitalization Adjustments, as provided in the Plan.

(b)Any shares, cash or other property that becomes subject to the Award pursuant to this Section 3, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other shares covered by your Award.

(c)Notwithstanding the provisions of this Section 3, no fractional shares or rights for fractional shares of Common Stock shall be created pursuant to this Section 3. The Board shall, in its discretion, determine an equivalent benefit for any fractional shares or fractional shares that might be created by the adjustments referred to in this Section 3.

4.COMPLIANCE WITH LAW. You may not be issued any shares under your Award unless either (i) the shares are registered under the Securities Act; or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Your Award also must comply with other applicable securities and exchange control laws and regulations relevant to the Company and the offer of the RSUs and the underlying shares of Common Stock, and you will not receive such shares if the Company determines that such receipt would not be in material compliance with such laws and regulations. You understand that the Company is under no obligation to register or qualify the shares of Common Stock with the SEC or any state or non-U.S. securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the shares of Common Stock. Further, you agree that the Company shall have unilateral authority to amend this Agreement without your consent, to the extent necessary to comply with securities or other laws applicable to the issuance of shares of Common Stock.

3.

5.LIMITATIONS ON TRANSFER. Your Award is not transferable, except by will or by applicable laws of descent and distribution. In addition to any other limitation on transfer created by applicable securities laws, you agree not to assign, hypothecate, donate, encumber or otherwise dispose of any interest in any of the shares of Common Stock subject to the Award until the shares are issued to you in accordance with Section 6 of this Agreement. After the shares have been issued to you, you are free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein and applicable securities laws as well as Company policies regarding its Common Stock. Notwithstanding the foregoing and to the extent permitted by applicable laws, (i) by delivering written notice to the Company, in a form satisfactory to the Company, you may designate a third party who, in the event of your death, shall thereafter be entitled to receive any distribution of Common Stock to which you were entitled at the time of your death pursuant to this Agreement or (ii) upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your right to receive the distribution of Common Stock or other consideration hereunder, pursuant to a domestic relations order or marital settlement agreement that contains the information required by the Company to effectuate the transfer. You are required to notify the Company’s legal department prior to finalizing any domestic relations order or marital settlement to confirm that the terms of such domestic relations order or marital settlement comply with this Agreement and the Plan.

6.DATE OF ISSUANCE. Subject to the terms of this Agreement, the Company will deliver to you a number of shares of the Company’s Common Stock equal to the number of vested shares subject to your Award, including any additional shares received pursuant to Section 3 above that relate to those vested shares within 60 days following the applicable vesting date(s) or vesting event. However, if a scheduled delivery date falls on a date that is not a U.S. business day, such delivery date shall instead fall on the next following U.S. business day. The form of such delivery (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.

7.DIVIDENDS. You shall receive no benefit or adjustment to your Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment as provided in Section 9(a) of the Plan; provided, however, that this sentence shall not apply with respect to any shares of Common Stock that are delivered to you in connection with your Award after such shares have been delivered to you.

8.RESTRICTIVE LEGENDS. The shares issued under your Award shall be endorsed with appropriate legends determined by the Company.

9.AWARD NOT A SERVICE CONTRACT.

(a)Your Continuous Service with the Company or an Affiliate is not for any specified term and may be terminated by you or by the Company or an Affiliate at any time, for any reason. Nothing in this Agreement (including, but not limited to, the vesting of your Award pursuant to the schedule set forth in Section 2 herein or the issuance of the shares subject to your Award), the Plan or any covenant of good faith and fair dealing that may be found implicit in this Agreement or the Plan

4.

shall: (i) confer upon you any right to continue in the employ of, or affiliation with, the Company or an Affiliate; (ii) constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or affiliation; (iii) confer any right or benefit under this Agreement or the Plan unless such right or benefit has specifically accrued under the terms of this Agreement or Plan; or (iv) deprive the Company or an Affiliate of the right to terminate you and without regard to any future vesting opportunity that you may have.

(b)    By accepting this Award, you acknowledge and agree that the right to continue vesting in the Award pursuant to the schedule set forth in Section 2 is earned only by continuing to provide Continuous Service (not through the act of being hired, being granted this Award or any other award or benefit) and that the Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a “reorganization”). You further acknowledge and agree that such a reorganization could result in the termination of your Continuous Service, or the termination of Affiliate status of your employer and the loss of benefits available to you under this Agreement, including but not limited to, the termination of the right to continue vesting in the Award. You further acknowledge and agree that this Agreement, the Plan, the transactions contemplated hereunder and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit in any of them do not constitute an express or implied promise of continued engagement for the term of this Agreement, for any period, or at all, and shall not interfere in any way with your right or the Company’s right to terminate your Continuous Service at any time.

(c)    No claim or entitlement to compensation or damages shall arise from forfeiture of the Awards resulting from the termination of your Continuous Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any).

10.RESPONSIBILITY FOR TAXES/SECTION 409A.

(a)You acknowledge that, regardless of any action taken by the Company or, if different, the Affiliate employing or otherwise retaining your services (the “Employer”), the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (“Tax-Related Items”), is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer. You further acknowledge that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including, but not limited to, the grant, vesting or settlement of the Award, the subsequent sale of shares of Common Stock acquired pursuant to such settlement and the receipt of any dividends; and (ii) do not commit to and are under

5.

no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you are subject to Tax-Related Items in more than one jurisdiction, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

On or before the time you receive a distribution of the shares in respect of your Award, or at any time thereafter as requested by the Company and/or the Employer, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the Tax-Related Items. Except as provided below, the Company shall withhold from the shares of Common Stock issuable to you to satisfy the Tax-Related Items. By your acceptance of the Award, you agree that: (i) in the event that such withholding from the shares of Common Stock is problematic under applicable tax or securities law or has materially adverse accounting consequences, the Company shall instead withhold from any other compensation paid to you by the Company or the Employer in partial or full satisfaction of the Tax-Related Items, and (ii) the Company may determine in its sole discretion to instead withhold from any other compensation paid to you by the Company or the Employer in partial or full satisfaction of the Tax-Related Items, provided that if you are subject to reporting obligations under Section 16 of the Exchange Act, exercise of such discretion is subject to the prior approval and direction of the Committee. In no way limiting the foregoing, the Company is hereby authorized to withhold shares of Common Stock that are otherwise to be issued and delivered to you under this Award in partial or full satisfaction of the Tax-Related Items; provided, however, that no shares of Common Stock shall be withheld with a value exceeding the minimum amount of tax required to be withheld by law. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you are deemed to have been issued the full number of shares of Common Stock subject to the vested Award, notwithstanding that a number of the shares of Common Stock are held back solely for the purpose of paying the Tax-Related Items.

(b)You agree to pay the Company or the Employer any amount of Tax- Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. Unless the obligation for Tax-Related Items is satisfied, the Company shall have no obligation to deliver to you any Common Stock.

(c)In the event the obligation of the Company and/or any Affiliate to withhold arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the withholding obligation was greater than the amount, if any, withheld by the Company and/or any Affiliate, you agree to indemnify and hold the Company and its Affiliates harmless from any failure by the Company and/or any Affiliate to withhold the proper amount.

6.

(d)To the extent Section 409A of the Code (“Section 409A”) applies to the Award, the Award shall be administered and interpreted in accordance with the requirements thereof, and each settlement hereunder shall be considered a separate installment payment. Without limitation, if you are a “specified employee” within the meaning of Section 409A, to the extent required to avoid accelerated taxation and penalties under Section 409A, the Common Stock that would otherwise be delivered to you pursuant to the Award during the six-month period immediately following your “separation from service” within the meaning of Section 409A (a “Separation from Service”) will instead be delivered on the six-month anniversary of your Separation from Service (or your death, if earlier). In addition, in the event (i) the vesting of the RSUs is accelerated in connecting with a CIC Qualifying Termination and the Change in Control under the Plan is not a “change in control event” under Section 409A or (ii) the Award vests under Section 9(c) of the Plan and the Corporate Transaction (as defined in the Plan) is not a “change in control event” under Section 409A or accelerated settlement would otherwise be prohibited under Section 409A, then the unvested portion of the Award shall fully vest as of such termination of Continuous Service or Corporate Transaction, as applicable, and shall be settled in accordance with the vesting schedule set forth in the Grant Notice to the extent required to comply with Section 409A.

11.UNSECURED OBLIGATION. Your Award is unfunded, and as a holder of a vested Award, you shall be considered an unsecured creditor of the Company with respect to the Company’s obligation, if any, to issue shares pursuant to this Agreement. You shall not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this Agreement until such shares are issued to you pursuant to Section 6 of this Agreement. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.

12.NOTICES. Any notices provided for in your Award or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address provided to the Company. Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this Award by electronic means or to request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

13.NATURE OF GRANT. In accepting the grant, you acknowledge, understand and agree that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan;

7.

(b)the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Awards, or benefits in lieu of Awards, even if Awards have been granted in the past;

(c)all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company;

(d)you are voluntarily participating in the Plan;

(e)the Awards and the shares of Common Stock subject to the Awards, and the income from and value of same, are not intended to replace any pension rights or compensation;

(f)the Awards and the shares of Common Stock subject to the Awards, and the income from and value of same, are not part of normal or expected compensation for purposes of, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, pension or retirement or welfare benefits or similar mandatory payments;

(g)the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty;

(h)unless otherwise agreed with the Company, the Awards and the shares of Common Stock acquired under the Plan, and the income from and value of same, are not granted as consideration for, or in connection with, any service you may provider as a director of any parent company or Affiliate;

(i)unless otherwise provided in the Plan or by the Company in its discretion, the Awards and the benefits evidenced by this Agreement, do not create any entitlement to have the Awards or any such benefits transferred to or assumed by another company, nor to be exchanged, cashed out or substituted for in connection with any corporate transaction affecting the Common Stock; and

(j)neither the Company, the Employer nor any Subsidiary or Affiliate of the Company shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Awards or of any amounts due to you pursuant to the settlement of the Awards or the subsequent sale of any shares of Common Stock acquired upon settlement.

14.NO ADVICE REGARDING GRANT. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying shares of Common Stock. You should consult with your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.

8.

15.DATA PRIVACY. If you would like to participate in the Plan, you will need to review the information provided in this Section 15 and, where applicable, declare consent to the processing and/or transfer of personal data as described below.

(a)Data Collection and Usage. The Company collects, processes and uses personal data about you, including but not limited to, your name, home address, email address and telephone number, date of birth, social insurance number, passport number or other identification number, salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Awards or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in your favor, which the Company receives from you or your Employer (“Personal Data”). In order you to participate in the Plan, the Company will collect Personal Data for purposes of allocating shares of Common Stock and implementing, administering and managing the Plan.

(b)Stock Plan Administration and Service Providers. The Company may transfer Personal Data to Morgan Stanley/E*TRADE (“Service Provider”), an independent service provider based in the U.S., which is assisting the Company with the implementation, administration and management of the Plan. Service Provider may open an account for you to receive and trade shares of Common Stock. You may be asked to acknowledge, or agree to, separate terms and data processing practices with Service Provider, with such agreement being a condition to the ability to participate in the Plan.

(c)International Data Transfers. Personal Data will be transferred from your country to the U.S., where the Company and its service providers are based. You understand and acknowledge that the U.S. might have enacted data privacy laws that are less protective or otherwise different from those applicable in your country of residence. The Company’s legal basis, where required, for the transfer of Data is your consent.

(d)Data Retention. The Company will use Personal Data only as long as necessary to implement, administer and manage your participation in the Plan or as required to comply with legal or regulatory obligations, including, without limitation, under tax and securities laws. When the Company no longer needs Personal Data for any of the above purposes, the Company will cease to use Personal Data for this purpose. If the Company keeps Personal Data longer, it would be to satisfy legal or regulatory obligations and the Company’s legal basis is your consent.

(e)Data Subject Rights. You understand that you may have a number of rights under data privacy laws in your jurisdiction. Subject to the conditions set out in the applicable law and depending on where you are based, such rights may include the right to (i) request access to, or copies of, Personal Data processed by the Company, (ii) rectification of incorrect Personal Data, (iii) deletion of Personal Data, (iv) restrictions on the processing of Personal Data, (v) object to

9.

the processing of Personal Data for legitimate interests, (vi) portability of Personal Data, (vii) lodge complaints with competent authorities in your jurisdiction, and/or to (viii) receive a list with the names and addresses of any potential recipients of Personal Data. To receive clarification regarding these rights or to exercise these rights, you can contact GDPR@omnicell.com or our EU Data Protection Officer as follows:

2B Advice GmbH

Joseph-Schumpeter-Allee 25, 53227 Bonn, Germany

Telephone: +49 228 926165 120

E-Mail: omnicell@2b-advice.com

(f)Voluntariness and Consequences of Consent Denial or Withdrawal. You hereby unambiguously consent to the collection, use and transfer, in electronic or other form, of your Personal Data, as described above and in any other grant materials, by and among, as applicable, your Employer, the Company and any Affiliate for the exclusive purpose of implementing, administering and managing your participation in the Plan. You understand that you may, at any time, refuse or withdraw the consents herein, in any case without cost, by contacting in writing your human resources representative. If you do not consent or later seek to revoke your consent, your employment status or service with your Employer will not be affected; the only consequence of refusing or withdrawing consent is that the Company would not be able to grant the Awards or other equity awards to you or administer or maintain such awards. Therefore, you understand that refusing or withdrawing consent may affect your ability to participate in the Plan. For more information on the consequences of refusal to consent or withdrawal of consent, you should contact your local human resources representative.

Declaration of Consent. By accepting the Awards and indicating consent by signing the Grant Notice or through the Company’s online acceptance procedure, you explicitly declare your consent to the entirety of the Personal Data processing operations described above including, without limitation, the onward transfer of Personal Data by the Company to the Service Provider or, as the case may be, a different service provider of the Company in the U.S.

16.MISCELLANEOUS.

(a)The rights and obligations of the Company under your Award shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company’s successors and assigns. Your rights and obligations under your Award may only be assigned with the prior written consent of the Company.

(b)You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award.

10.

(c)You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award, and fully understand all provisions of your Award.

(d)This Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.

(e)All obligations of the Company under the Plan and this Agreement shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.

17.RESTRICTIVE COVENANTS. As a condition to receiving the Award, you hereby agree to the covenants set forth below.

(a)Acknowledgements. Pursuant to your Continuous Service with the Company, you have or will have access to, and knowledge of, Confidential Information of the Company. You acknowledge that any unauthorized use (including use for your own benefit or to the benefit of others), transfer, or disclosure by you of such confidential information can place the Company at a competitive disadvantage and cause damage, financial and otherwise, to its business. Notwithstanding the foregoing, you acknowledge and confirm your understanding that nothing in this Agreement limits your ability to communicate with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board (“NLRB”), the Occupational Safety and Health Administration, the Securities and Exchange Commission, or any other federal, state, or local governmental agency or commission (“GovernmentAgencies”) or otherwise testify, assist, or participate in any investigation, hearing, or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. Additionally, nothing in this Agreement shall be construed to prohibit you from engaging in protected concerted activity under the National Labor Relations Act for the purpose of collective bargaining or other mutual aid or protection, including, without limitation, (i) making disclosures concerning this Agreement in aid of such concerted activities, (ii) filing unfair labor practice charges, (iii) assisting others who are filing such charges, and (iv) cooperating with the investigative process or the NLRB or other Government Agencies. You further acknowledge that, because of the knowledge of and access to such confidential information that you have acquired or will have acquired during your Continuous Service, you will be in a position to compete unfairly with the Company following the termination of your Continuous Service.

As used in this Agreement, “Confidential Information” means (1) information of the Company, to the extent not considered a Trade Secret under applicable law that: (a) relates to the Business of the Company, (ii) possess an element of value to the Company, (iii) is not generally known to the Company’s competitors, and (iv) would damage the Company if disclosed; or (2) information

11.

of any third party provided to the Company that the Company is obligated to treat as confidential (such third party to be referred to as the “Third Party”), including, but not limited to, information provided to the Company by its licensors, suppliers, or Customers. Subject to the foregoing general definition, Confidential Information includes, but is not limited to: (a) business plans; (b) the composition, description, or characteristics of current or contemplated products of the Company; (c) pricing information, such as price lists; (d) proprietary software and reports derived from said software; (e) advertising or marketing plans; (f) information regarding independent contractors, employees, licensors, suppliers, customers, or any Third Party, including, but not limited to, customer lists compiled by the Company, and customer or market information compiled by the Company; and (g) information concerning the Company’s financial structure or condition, the Company’s prospects or plans, its marketing and sales programs, the Company’s research and development information, the Company’s contemplated or actual mergers and acquisitions, stock splits and divestitures, and its methods and procedures of operation. Confidential Information shall not include any information that: (x) is or becomes generally available to the public other than as a result of an unauthorized disclosure; (y) has been independently developed and disclosed by others without violating this Agreement or the legal rights of any party; or (z) otherwise enters the public domain through lawful means.

As used in this Agreement, “Trade Secret” means the Company’s trade secrets as defined by applicable statutory or common law.

(b)    Non-Competition. During the term of your Continuous Service and for the twelve (12) months thereafter (“RestrictedPeriod”), you will not, except as authorized by the Company, perform the same or similar tasks that you performed on behalf of the Company during your last twelve (12) months of Continuous Service (“CompetitiveTasks”) on behalf of any entity in competition with the Company contained on the then current “Competing Organization” list of such entities available under the Legal Policy Library section of the Company’s intranet site at: https://omnicell.sharepoint.com/sites/OmnicellPolicies/PolicyProcedures/Omnicell%20Competing%20Organization%20List.pdf (“Competitors”) anywhere the Company does Business (“Restricted Territory”). This provision shall be limited to performing Competitive Tasks only in the area(s) of the Business in which you worked or for which you had responsibility during your last twelve (12) months of Continuous Service with the Company. As used in this Agreement, “Business” means the development, manufacture, sale, or marketing of manufactured automated systems for medication management in hospitals and other healthcare settings, and medication adherence packaging and patient engagement software used by retail pharmacies. This provision does not apply to you if you live in California or Minnesota. If the enforcement of this restriction post-employment is not permitted under applicable law, then your Restricted Period will only be for the term of your Continuous Service for purposes of this Section 17(b).

12.

(c)    Non-Solicitation of Customers. During the Restricted Period, you will not directly or indirectly solicit any person or entity to whom the Company has sold products or services, directly solicited to sell its products or services, or cultivated a relationship intended to increase the sales of the Company’s products or services in the previous twelve (12) months (“Customers”) of the Company in the Restricted Territory with whom you had Contact for the purpose of selling or providing any products orservices competitive with those offered by the Company. As used in this Agreement, “Contact” means any interaction that takes place in the last twelve (12) months of your Continuous Service with the Company and is between you and a Customer: (i) with whom you dealt on behalf of the Company; (ii) whose dealings with the Company were coordinated or supervised by you; (iii) about whom you obtained trade secrets or confidential information in the ordinary course of business as a result of your work performed on behalf of the Company; or (iv) who purchases products or services from the Company, the sale or provision of which directly results or resulted in compensation, commissions, or earnings for you. Nothing in this Section shall be construed to prohibit you from soliciting: (a) a Customer that has terminated its business relationship with the Company (for reasons other than being solicited or encouraged by you to do so); (b) a product line or service line competitive with one that the Company no longer offers; or (c) a product line or service line with which you had no involvement while working for the Company and about which you did not learn Confidential Information.

Non-Solicitation of Customers For California and Colorado Employees Only: During the Restricted Period, you will not directly or indirectly use the Company’s Trade Secrets to solicit any Customer of the Company with whom you had Contact for the purpose of selling or providing any products or services competitive with those offered by the Company. Nothing in this Section shall be construed to prohibit you from soliciting: (a) a Customer that has terminated its business relationship with the Company (for reasons other than being solicited or encouraged by you to do so); (b) a product line or service line competitive with one that the Company no longer offers; or (c) a product line or service line with which you had no involvement while working for the Company and about which you did not learn Confidential Information.

(d)    Non-Recruit of Employees. During the Restricted Period, you will not, directly or indirectly, solicit, recruit or induce any employee to terminate his or her employment relationship with the Company in order to work for you or any other person or entity engaged in the Business.

(e)    Remedies for Violation of Restrictive Covenants. You agree that, if you breach any of the provisions of this Section 17: (i) the Company shall be entitled to all of its remedies at law or in equity, including money damages and injunctive relief; (ii) in the event of such breach, in addition to the Company’s other remedies, any unvested portion of the Award will be immediately forfeited and deemed canceled, and you agree to immediately transfer back to the Company any shares that vested during the 18 months prior to the date of your termination of

13.

Continuous Service (or if applicable law mandates a maximum time that is shorter than 18 months, then for a period of time equal to the shorter maximum period) any such shares still held by you and to pay immediately to the Company the fair market value (determined as of the applicable vesting date or vesting event) of any such shares not still held by you; and (iii) the Company shall also be entitled to an accounting and repayment from you of all profits, compensation, commissions, remuneration or benefits that you (and/or the applicable Competitor) directly or indirectly have realized or may realize as a result of or in connection with any breach of these covenants, and such remedy shall be in addition to and not in limitation of any injunctive relief or other rights or remedies to which the Company may be entitled at law or in equity.

(f)    Reasonable and Necessary. You agree that the covenants set forth in this Section 17 are reasonable and necessary for the protection of the Company’s legitimate business interest, that they do not impose a greater restraint than is necessary to protect the goodwill or other business interests of the Company, that they contain reasonable limitations as to time and scope of activity to be restrained, that they do not unduly restrict your ability to earn a living, and that they are not unduly burdensome to you.

(g)    Severability of Restrictive Covenants. Each provision of this Section 17 constitutes an entirely separate and independent restriction and the duration, extent, and application of each of the restrictive covenants contained herein are no greater than is necessary for the protection of the Company’s interests. If any part or provision of this Section 17 is held unenforceable, it shall be severed and shall not affect any other part of this Section 17.

18.GOVERNING PLAN DOCUMENT. Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. Except as expressly provided herein, in the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan shall control.

19.LANGUAGE. You acknowledge that you are sufficiently proficient in English or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement. If you have received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.

20.SEVERABILITY. If all or any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.

14.

21.CHOICE OF LAW; VENUE. The interpretation, performance and enforcement of this Agreement will be governed by the law of the state of Delaware without regard to such state’s conflicts of laws rules. For purposes of any action, lawsuit or other proceedings brought to enforce this Agreement, relating to it, or arising from it, the parties hereby submit to and consent to the sole and exclusive jurisdiction of the courts of the state of Delaware, or any federal court sitting in the state of Delaware, and no other courts, where this grant is made and/or to be performed.

22.AMENDMENT. This Agreement may not be modified, amended or terminated except by an instrument in writing, signed or otherwise accepted by you and by a duly authorized representative of the Company. Notwithstanding the foregoing, this Agreement may be amended solely by the Board by a writing which specifically states that it is amending this Agreement, so long as a copy of such amendment is delivered to you, and provided that no such amendment adversely affecting your rights hereunder in a material manner may be made without your written consent. Without limiting the foregoing, the Board reserves the right, by written notice to you, to impose new provisions or to change the existing provisions of this Agreement in any way it may deem necessary or advisable for legal or administrative reasons to carry out the purpose of the grant.

23.INSIDER TRADING RESTRICTIONS/MARKET ABUSE LAWS. You acknowledge that you may be subject to insider trading restrictions and/or market abuse laws in applicable jurisdictions, including but not limited to the United States, your country, the broker’s country and the country or countries in which the Common Stock is listed, which may affect your ability, directly or indirectly, to purchase or sell, or attempt to sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (e.g., Awards), or rights linked to the value of shares of Common Stock, during such times as you are considered to have “inside information” regarding the Company (as defined by the laws in the applicable jurisdiction(s)). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before possessing the inside information. Furthermore, you understand that you may be prohibited from (i) disclosing the inside information to any third party, including fellow employees and (ii) “tipping” third parties by sharing with them Company insider information, or otherwise causing third parties to buy or sell Company securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may apply to you under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any applicable restrictions, and you should speak to your personal advisor on this matter.

24.FOREIGN ASSET/ACCOUNT REPORTING REQUIREMENTS. If you reside in a country outside the United States, there may be certain foreign asset and/or account reporting requirements which may affect your ability to acquire or hold shares of Common Stock or cash received from participating in the Plan (including from any dividends paid on shares of Common Stock) in a brokerage account or bank outside of your country. You may be required to report such accounts, assets or related transactions to the tax or other authorities in your country. You may also be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to your country within a certain time after receipt. It is your responsibility to comply with such regulations and you should speak to your personal legal advisor on this matter.

25.APPENDIX. Notwithstanding any provisions in this Agreement, the Award grant shall be subject to any special terms and conditions set forth in any Appendix to this Agreement

15.

for your country. Moreover, if you relocate to one of the countries included in the Appendix, the special terms and conditions for such country, if any, will apply to you, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. The Appendix constitutes part of this Agreement.

26.IMPOSITION OF OTHER REQUIREMENTS. The Company reserves the right to impose other requirements on your participation in the Plan, on the Awards and on any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.

27.WAIVER. You acknowledge that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other Participant.

28.ELECTRONIC DELIVERY AND ACCEPTANCE. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

* * * * *

16.

Appendix

Omnicell, Inc.

2009 Equity Incentive Plan

Global Restricted Stock Unit Award Agreement

Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Global Restricted Stock Unit Agreement (the “Agreement”) or the Plan.

Terms and Conditions

This Appendix includes additional terms and conditions that govern the Restricted Stock Unit Award (“RSUs”) granted to you under the Plan if you work and/or reside in one of the countries listed below. This Appendix forms part of the Agreement.

If you are a citizen or resident of a country other than the one in which you are currently residing and/or working, transfer employment and/or residency to another country after the Date of Grant, or are considered a resident of another country for local law purposes, the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall be applicable to you.

Notifications

This Appendix also includes information regarding exchange control and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control and other laws in effect in the respective countries as of August 2023. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you not rely on the information in this Appendix as the only source of information relating to the consequences of participation in the Plan because the information may be out of date at the time you vest in the RSUs and acquire shares of Common Stock or sell shares of Common Stock acquired under the Plan.

In addition, the information contained herein is general in nature and may not apply to your particular situation and the Company is not in a position to assure you of any particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.

Finally, if you are a citizen or resident of a country other than the one in which you are currently residing and/or working, transfer employment and/or residency to another country after the Date of Grant, or are considered a resident of another country for local law purposes, the information contained herein may not apply to you in the same manner.

17.

Australia

Notifications

Securities Law Information. This offer of RSUs is being made under Division 1A, Part 7.12 of the Corporations Act 2001 (Cth). Please note that if you offer shares of Common Stock for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law. You should obtain legal advice on your disclosure obligations prior to making any such offer.

Tax Information. The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies (subject to the conditions in the Act).

Canada

Terms and Conditions

Settlement of RSUs. Notwithstanding any discretion in the Plan or anything to the contrary in the Agreement, the RSUs do not provide any right for you, as a resident of Canada, to receive a cash payment and the RSUs shall be paid in shares of Common Stock only.

Nature of Grant. The following provision replaces Section 2 of the Agreement:

Subject to the limitations contained herein, your Award will vest, if at all, in accordance with the vesting schedule provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service.

For purposes of the Award, a termination of your Continuous Service will be deemed to occur as of the date that is the earlier of (i) the date of your termination, (ii) the date you receive notice of termination, or (iii) the date you are no longer actively providing services and will not be extended by any notice period (e.g., active service would not include any contractual notice period or any period of “garden leave” or similar period mandated under Canadian laws or the terms of your employment or service agreement, if any), regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or providing services or the terms of your employment or service agreement, if any; unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Awards under the Plan, if any, will terminate as of such date; in the event that the date you are no longer actively providing services cannot be reasonably determined under the terms of this Agreement and the Plan, the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of your Award (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation explicitly requires continued vesting during a statutory notice period, your right to vest in the Awards, if any, will terminate effective as of the last date of the minimum statutory notice period but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.

18.

Notifications

Securities Law Information. The sale of shares of Common Stock acquired under the Plan may not take place in Canada. This requirement will be satisfied where the shares of Common Stock are sold by the designated broker under the Plan through the facilities of the U.S. stock exchange on which the shares of Common Stock are currently listed (i.e., the Nasdaq stock market).

Foreign Asset/Account Reporting Information. Canadian residents are required to report their foreign specified property (e.g., shares of Common Stock) on form T1135 (Foreign Income Verification Statement) if the total cost of the foreign specified property exceeds C$100,000 at any time in the year. The RSUs must be reported—generally at a nil cost—if the C$100,000 threshold is exceeded because of other foreign specific property held by you. The shares of Common Stock acquired under the Plan must be reported and their cost generally is the adjusted cost base (“ACB”) of the shares of Common Stock. The ACB ordinarily would equal the fair market value of the shares of Common Stock at the time of acquisition, but if such Canadian resident owns other shares of Common Stock, this ACB may have to be averaged with the ACB of the other shares. The form T1135 generally must be filed by April 30 of the following year. Canadian residents should consult with a personal advisor to ensure compliance with the applicable reporting requirements.

France

Terms and Conditions

RSUs Not Tax-Qualified. The RSUs granted under this Agreement are not intended to qualify for special tax and social security treatment pursuant to Sections L. 225-197-1 to L. 225-197-5 and Sections L. 22-10-59 to L. 22-10-60 of the French Commercial Code, as amended.

Language Consent. By accepting the RSUs, you confirm having read and understood the Plan and Agreement, including all terms and conditions included therein, which were provided in the English language. You accept the terms of those documents accordingly.

En acceptant les droits sur des actions assujettis à restrictions (« restricted stock units » ou « RSUs »), vous confirmez avoir lu et compris le Plan et le Contrat, en ce compris tous les termes et conditions de ces documents, qui ont été fournis en langue anglaise. Vous acceptez les dispositions de ces documents en connaissance de cause.

Notifications

Foreign Asset/Account Reporting Information. French residents holding cash or securities (including shares of Common Stock) outside of France or maintaining a foreign bank or brokerage account (including accounts opened or closed during the tax year) must declare such assets and accounts to the French tax authorities when filing an annual tax return. Failure to comply could trigger significant penalties.

19.

Germany

Notifications

Exchange Control Information. Cross-border payments in excess of €12,500 must be reported monthly to the German Federal Bank (Bundesbank). If you make or receive a payment in excess of this amount (including if you acquire shares of Common Stock with a value in excess of this amount under the Plan or sell shares of Common Stock via a foreign broker, bank, or service provider and receive proceeds in excess of this amount) and/or if the Company or your Employer withholds or sells shares of Common Stock with a value in excess of this amount to cover Tax-Related Items, you must report the payment to Bundesbank either electronically using the “General Statistics Reporting Portal” (“Allgemeines Meldeportal Statistik”) available at the Bundesbank’s website (www.bundesbank.de) or via such other method (e.g., by email or telephone) as is permitted by Bundesbank. The report must be submitted monthly or within other such timing as is permitted or required by Bundesbank.

Foreign Asset/Account Reporting Information. If your acquisition of shares acquired under the Plan leads to a so-called qualified participation at any point during the calendar year, you may need to report the acquisition when you file your tax return for the relevant year. A qualified participation is attained if (i) you own at least 1% of the Company and the value of the shares of Common Stock acquired exceeds €150,000 or (ii) you hold shares of Common Stock exceeding 10% of the Company’s total Common Stock.

India

Notifications

Exchange Control Information. You understand that you must repatriate any cash dividends paid on shares of Common Stock acquired under the Plan and any proceeds from the sale of such shares of Common Stock to India within a certain period of time after receipt of the proceeds. You will receive a foreign inward remittance certificate (“FIRC”) from the bank where you deposit the foreign currency. You should maintain the FIRC as evidence of the repatriation of funds in the event the Reserve Bank of India or the Employer requests proof of repatriation. It is your responsibility to comply with the applicable exchange control laws in India.

Foreign Asset/Account Reporting Information. You are required to declare any foreign bank accounts and any foreign financial assets (including shares of Common Stock held outside India) in your annual tax return. You acknowledge that you are responsible for complying with this reporting obligation and you should confer with your personal tax advisor in this regard.

20.

United Arab Emirates

Notifications

Securities Law Information. Participation in the Plan is being offered only to eligible employees and is in the nature of providing equity incentives to employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development has approved the Plan or the Agreement nor taken steps to verify the information set out therein, and has no responsibility for such documents.

United Kingdom

Terms and Conditions

Settlement. The following provision supplements Section 3 of the Agreement:

Notwithstanding any discretion contained in the Plan or the Agreement, the RSUs will not be settled in cash or a combination of cash and shares of Common Stock. The RSUs will be settled only in shares of Common Stock.

Responsibility for Taxes. This provision supplements Section 10 of the Agreement:

Without limitation to Section 10 of the Agreement, you hereby agree that you are liable for any Tax-Related Items related to your participation in the Plan and hereby covenant to pay such Tax- Related Items, as and when requested by the Company or (if different) the Employer or by HM Revenue & Customs (“HMRC”) (or any other tax or relevant authority). You also hereby agree to indemnify and keep indemnified the Company and (if different) the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax or relevant authority) on your behalf.

Notwithstanding the foregoing, if you are an executive officer or director (as within the meaning of Section 13(k) of the Exchange Act), the terms of the immediately foregoing provision will not apply. Instead, any Tax-Related Items not collected or paid may constitute a benefit to you on which additional income tax and National Insurance Contributions (“NICs”) may be payable. You understand that you will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying to the Company and/or the Employer (as appropriate) the amount of any employee NICs due on this additional benefit, which can be recovered by any means set out in the Agreement.

National Insurance Contributions Acknowledgment. As a condition of participation in the Plan and the vesting of the RSUs, you agree to accept any liability for secondary Class 1 NICs which may be payable by the Company and/or the Employer in connection with the RSUs and any event giving rise to Tax-Related Items (the “Employer NICs”). Without limitation to the

21.

foregoing, you agree to execute a joint election with the Company, the form of such joint election being formally approved by HMRC (the “Joint Election”), and any other required consent or election. You further agree to execute such other joint elections as may be required between you and any successor to the Company and/or the Employer. You further agree that the Company and/or the Employer may collect the Employer NICs from you by any of the means set forth in Section 10 of the Agreement. You must enter into the Joint Election concurrent with the execution of the Agreement.

If you do not enter into a Joint Election prior to the vesting of the RSUs or if approval of the Joint Election has been withdrawn by HMRC, the RSUs shall become null and void without any liability to the Company and/or the Employer.

22.

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Randall A. Lipps, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Omnicell, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 3, 2023	/s/ Randall A. Lipps
	Randall A. Lipps
	President and Chief Executive Officer
	(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Nchacha E. Etta, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Omnicell, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 3, 2023	/s/ Nchacha E. Etta
	Nchacha E. Etta
	Executive Vice President & Chief Financial Officer
	(Principal Financial Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Randall A. Lipps, the President and Chief Executive Officer of Omnicell, Inc. (the “Company”), and Nchacha E. Etta, the Executive Vice President & Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1.The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Quarterly Report”), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In witness whereof, the undersigned have set their hands hereto as of the 3rd day of November, 2023.

/s/ Randall A. Lipps	/s/ Nchacha E. Etta
Randall A. Lipps	Nchacha E. Etta
President and Chief Executive Officer	Executive Vice President & Chief Financial Officer
(Principal Executive Officer)	(Principal Financial Officer)

“This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Omnicell, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.”

XML

Cover - shares	9 Months Ended
	Sep. 30, 2023	Oct. 27, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	000-33043
Entity Registrant Name	OMNICELL, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3166458
Entity Address, Address Line One	4220 North Freeway
Entity Address, City or Town	Fort Worth
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	76137
City Area Code	877
Local Phone Number	415-9990
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	OMCL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		45,469,376
Entity Central Index Key	0000926326
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3

XML

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 446,840	$ 330,362
Accounts receivable and unbilled receivables, net of allowances of $5,522 and $5,153, respectively	272,584	299,469
Inventories	116,144	147,549
Prepaid expenses	27,947	27,070
Other current assets	50,236	77,362
Total current assets	913,751	881,812
Property and equipment, net	106,880	93,961
Long-term investment in sales-type leases, net	41,631	32,924
Operating lease right-of-use assets	25,444	38,052
Goodwill	734,328	734,274
Intangible assets, net	218,861	242,906
Long-term deferred tax assets	35,964	22,329
Prepaid commissions	53,950	59,483
Other long-term assets	90,766	105,017
Total assets	2,221,575	2,210,758
Current liabilities:
Accounts payable	49,920	63,389
Accrued compensation	44,065	73,455
Accrued liabilities	150,385	172,655
Deferred revenues, net	124,991	118,947
Total current liabilities	369,361	428,446
Long-term deferred revenues	55,053	37,385
Long-term deferred tax liabilities	1,565	2,095
Long-term operating lease liabilities	32,845	39,405
Other long-term liabilities	6,428	6,719
Convertible senior notes, net	568,887	566,571
Total liabilities	1,034,139	1,080,621
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	0	0
Common stock, $0.001 par value, 100,000 shares authorized; 55,746 and 55,030 shares issued; 45,463 and 44,747 shares outstanding, respectively	56	55
Treasury stock at cost, 10,283 shares outstanding, respectively	(290,319)	(290,319)
Additional paid-in capital	1,110,096	1,046,760
Retained earnings	384,732	390,728
Accumulated other comprehensive loss	(17,129)	(17,087)
Total stockholders’ equity	1,187,436	1,130,137
Total liabilities and stockholders’ equity	$ 2,221,575	$ 2,210,758

XML

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for credit losses on accounts receivable and unbilled receivables	$ 5,522	$ 5,153
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000	5,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000	100,000
Common Stock, shares issued (in shares)	55,746	55,030
Common stock, shares outstanding (in shares)	45,463	44,747
Treasury stock, shares outstanding (in shares)	10,283	10,283

XML

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues	$ 298,663	$ 348,059	$ 888,265	$ 998,273
Cost of revenues	166,699	188,964	496,829	531,039
Gross profit	131,964	159,095	391,436	467,234
Operating expenses:
Research and development	24,281	25,171	70,296	76,556
Selling, general, and administrative	103,971	115,459	332,643	354,644
Total operating expenses	128,252	140,630	402,939	431,200
Income (loss) from operations	3,712	18,465	(11,503)	36,034
Interest and other income (expense), net	3,670	(1,148)	9,912	(2,973)
Income (loss) before income taxes	7,382	17,317	(1,591)	33,061
Provision for (benefit from) income taxes	1,829	543	4,405	(995)
Net income (loss)	$ 5,553	$ 16,774	$ (5,996)	$ 34,056
Net income (loss) per share:
Basic (in dollars per share)	$ 0.12	$ 0.38	$ (0.13)	$ 0.77
Diluted (in dollars per share)	$ 0.12	$ 0.37	$ (0.13)	$ 0.73
Weighted-average shares outstanding:
Basic (in shares)	45,333	44,441	45,117	44,304
Diluted (in shares)	45,595	45,819	45,117	46,759
Product revenues
Revenues	$ 188,755	$ 246,565	$ 562,906	$ 706,246
Cost of revenues	106,311	134,023	323,800	374,175
Services and other revenues
Revenues	109,908	101,494	325,359	292,027
Cost of revenues	$ 60,388	$ 54,941	$ 173,029	$ 156,864

XML

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 5,553	$ 16,774	$ (5,996)	$ 34,056
Other comprehensive loss:
Foreign currency translation adjustments	(2,953)	(6,770)	(42)	(15,735)
Other comprehensive loss	(2,953)	(6,770)	(42)	(15,735)
Comprehensive income (loss)	$ 2,600	$ 10,004	$ (6,038)	$ 18,321

XML

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Cumulative effect of a change in accounting principle related to convertible debt	Common Stock	Treasury Stock	Additional Paid-In Capital	Additional Paid-In Capital Cumulative effect of a change in accounting principle related to convertible debt	Retained Earnings	Retained Earnings Cumulative effect of a change in accounting principle related to convertible debt	Accumulated Other Comprehensive Income (Loss)
Balance at beginning of period (in shares) at Dec. 31, 2021			54,073,000
Balance at beginning of period at Dec. 31, 2021	$ 1,146,689	$ (56,233)	$ 54	$ (238,109)	$ 1,024,580	$ (72,742)	$ 368,571	$ 16,509	$ (8,407)
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2021				(9,894,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	8,213						8,213
Other comprehensive income (loss)	(2,555)								(2,555)
Share-based compensation	16,208				16,208
Issuance of common stock under employee stock plans (in shares)			384,000
Issuance of common stock under employee stock plans	18,951				18,951
Tax payments related to restricted stock units	(4,322)				(4,322)
Stock repurchases (in shares)				(389,000)
Stock repurchases	(52,210)			$ (52,210)
Balance at end of period (in shares) at Mar. 31, 2022			54,457,000
Balance at end of period at Mar. 31, 2022	1,074,741		$ 54	$ (290,319)	982,675		393,293		(10,962)
Balance at end of period, Treasury stock (in shares) at Mar. 31, 2022				(10,283,000)
Balance at beginning of period (in shares) at Dec. 31, 2021			54,073,000
Balance at beginning of period at Dec. 31, 2021	1,146,689	$ (56,233)	$ 54	$ (238,109)	1,024,580	$ (72,742)	368,571	$ 16,509	(8,407)
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2021				(9,894,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	34,056
Other comprehensive income (loss)	(15,735)
Balance at end of period (in shares) at Sep. 30, 2022			54,929,000
Balance at end of period at Sep. 30, 2022	1,135,395		$ 55	$ (290,319)	1,030,665		419,136		(24,142)
Balance at end of period, Treasury stock (in shares) at Sep. 30, 2022				(10,283,000)
Balance at beginning of period (in shares) at Mar. 31, 2022			54,457,000
Balance at beginning of period at Mar. 31, 2022	1,074,741		$ 54	$ (290,319)	982,675		393,293		(10,962)
Balance at beginning of period, Treasury stock (in shares) at Mar. 31, 2022				(10,283,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	9,069						9,069
Other comprehensive income (loss)	(6,410)								(6,410)
Share-based compensation	17,213				17,213
Issuance of common stock under employee stock plans (in shares)			114,000
Issuance of common stock under employee stock plans	2,172		$ 1		2,171
Tax payments related to restricted stock units	(4,148)				(4,148)
Balance at end of period (in shares) at Jun. 30, 2022			54,571,000
Balance at end of period at Jun. 30, 2022	1,092,637		$ 55	$ (290,319)	997,911		402,362		(17,372)
Balance at end of period, Treasury stock (in shares) at Jun. 30, 2022				(10,283,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	16,774						16,774
Other comprehensive income (loss)	(6,770)								(6,770)
Share-based compensation	17,310				17,310
Issuance of common stock under employee stock plans (in shares)			358,000
Issuance of common stock under employee stock plans	18,416				18,416
Tax payments related to restricted stock units	(2,972)				(2,972)
Balance at end of period (in shares) at Sep. 30, 2022			54,929,000
Balance at end of period at Sep. 30, 2022	$ 1,135,395		$ 55	$ (290,319)	1,030,665		419,136		(24,142)
Balance at end of period, Treasury stock (in shares) at Sep. 30, 2022				(10,283,000)
Balance at beginning of period (in shares) at Dec. 31, 2022	44,747,000		55,030,000
Balance at beginning of period at Dec. 31, 2022	$ 1,130,137		$ 55	$ (290,319)	1,046,760		390,728		(17,087)
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2022	(10,283,000)			(10,283,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ (15,000)						(15,000)
Other comprehensive income (loss)	1,479								1,479
Share-based compensation	15,180				15,180
Issuance of common stock under employee stock plans (in shares)			322,000
Issuance of common stock under employee stock plans	12,114				12,114
Tax payments related to restricted stock units	(1,369)				(1,369)
Balance at end of period (in shares) at Mar. 31, 2023			55,352,000
Balance at end of period at Mar. 31, 2023	$ 1,142,541		$ 55	$ (290,319)	1,072,685		375,728		(15,608)
Balance at end of period, Treasury stock (in shares) at Mar. 31, 2023				(10,283,000)
Balance at beginning of period (in shares) at Dec. 31, 2022	44,747,000		55,030,000
Balance at beginning of period at Dec. 31, 2022	$ 1,130,137		$ 55	$ (290,319)	1,046,760		390,728		(17,087)
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2022	(10,283,000)			(10,283,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ (5,996)
Other comprehensive income (loss)	$ (42)
Balance at end of period (in shares) at Sep. 30, 2023	45,463,000		55,746,000
Balance at end of period at Sep. 30, 2023	$ 1,187,436		$ 56	$ (290,319)	1,110,096		384,732		(17,129)
Balance at end of period, Treasury stock (in shares) at Sep. 30, 2023	(10,283,000)			(10,283,000)
Balance at beginning of period (in shares) at Mar. 31, 2023			55,352,000
Balance at beginning of period at Mar. 31, 2023	$ 1,142,541		$ 55	$ (290,319)	1,072,685		375,728		(15,608)
Balance at beginning of period, Treasury stock (in shares) at Mar. 31, 2023				(10,283,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	3,451						3,451
Other comprehensive income (loss)	1,432								1,432
Share-based compensation	15,148				15,148
Issuance of common stock under employee stock plans (in shares)			136,000
Issuance of common stock under employee stock plans	3,089		$ 1		3,088
Tax payments related to restricted stock units	(2,096)				(2,096)
Balance at end of period (in shares) at Jun. 30, 2023			55,488,000
Balance at end of period at Jun. 30, 2023	1,163,565		$ 56	$ (290,319)	1,088,825		379,179		(14,176)
Balance at end of period, Treasury stock (in shares) at Jun. 30, 2023				(10,283,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	5,553						5,553
Other comprehensive income (loss)	(2,953)								(2,953)
Share-based compensation	16,104				16,104
Issuance of common stock under employee stock plans (in shares)			258,000
Issuance of common stock under employee stock plans	7,832				7,832
Tax payments related to restricted stock units	$ (2,665)				(2,665)
Balance at end of period (in shares) at Sep. 30, 2023	45,463,000		55,746,000
Balance at end of period at Sep. 30, 2023	$ 1,187,436		$ 56	$ (290,319)	$ 1,110,096		$ 384,732		$ (17,129)
Balance at end of period, Treasury stock (in shares) at Sep. 30, 2023	(10,283,000)			(10,283,000)

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating Activities
Net income (loss)	$ (5,996)	$ 34,056
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	65,596	64,843
Loss on disposal of property and equipment	2,110	331
Share-based compensation expense	43,113	50,731
Deferred income taxes	(14,165)	(17,061)
Amortization of operating lease right-of-use assets	6,238	9,709
Impairment and abandonment of operating lease right-of-use assets related to facilities	7,815	5,390
Amortization of debt issuance costs	3,139	3,121
Changes in operating assets and liabilities:
Accounts receivable and unbilled receivables	27,050	(116,895)
Inventories	31,690	(32,269)
Prepaid expenses	(857)	(2,602)
Other current assets	1,521	6,692
Investment in sales-type leases	(8,839)	(17,336)
Prepaid commissions	5,533	8,801
Other long-term assets	2,539	4,189
Accounts payable	(13,358)	2,043
Accrued compensation	(29,390)	(27,940)
Accrued liabilities	3,749	11,678
Deferred revenues	23,628	17,667
Operating lease liabilities	(8,145)	(10,966)
Other long-term liabilities	(291)	1,446
Net cash provided by (used in) operating activities	142,680	(4,372)
Investing Activities
External-use software development costs	(10,240)	(9,648)
Purchases of property and equipment	(32,404)	(33,861)
Business acquisition, net of cash acquired	0	(3,392)
Purchase price adjustments from business acquisitions	0	5,484
Net cash used in investing activities	(42,644)	(41,417)
Financing Activities
Proceeds from issuances under stock-based compensation plans	23,035	39,539
Employees’ taxes paid related to restricted stock units	(6,130)	(11,442)
Change in customer funds, net	(6,615)	(402)
Stock repurchases	0	(52,210)
Net cash provided by (used in) financing activities	10,290	(24,515)
Effect of exchange rate changes on cash and cash equivalents	(464)	(1,425)
Net increase (decrease) in cash, cash equivalents, and restricted cash	109,862	(71,729)
Cash, cash equivalents, and restricted cash at beginning of period	352,835	355,620
Cash, cash equivalents, and restricted cash at end of period	462,697	283,891
Reconciliation of cash, cash equivalents, and restricted cash to the Condensed Consolidated Balance Sheets:
Cash and cash equivalents	446,840	266,402
Restricted cash included in other current assets	15,857	17,489
Cash, cash equivalents, and restricted cash at end of period	462,697	283,891
Supplemental disclosure of non-cash investing activities
Unpaid purchases of property and equipment	642	1,473
Transfers between inventory and property and equipment, net	$ 0	$ 314

XML

Organization and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

Organization and Summary of Significant Accounting Policies

Business

Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products and related services are medication management solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” refer to Omnicell, Inc. and its subsidiaries, collectively.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of September 30, 2023 and December 31, 2022, the results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023 and 2022, and cash flows for the nine months ended September 30, 2023 and 2022. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 1, 2023, except as discussed in the section entitled “Recently Adopted Authoritative Guidance” below. The Company’s results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023, and cash flows for the nine months ended September 30, 2023 are not necessarily indicative of results that may be expected for the year ending December 31, 2023, or for any future period.

Principles of Consolidation

The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates.

The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. As of September 30, 2023, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities.

Segment Reporting

The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.

Recently Adopted Authoritative Guidance

In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The update addresses diversity in practice by requiring that an acquirer recognize and measure contract assets and liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. The Company adopted ASU 2021-08 beginning January 1, 2023 and will apply the guidance prospectively to acquisitions occurring on or after the adoption date.

Recently Issued Authoritative Guidance

There was no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date.

XML

Revenues

9 Months Ended

Sep. 30, 2023

Revenue Recognition [Abstract]

Revenues

Revenues

Revenue Recognition

The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories:

Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements. Solutions in this category include, but are not limited to, XT Series automated dispensing systems and products related to the Central Pharmacy Dispensing Service and IV Compounding Service.

Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards, which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, are designed to improve patient engagement and adherence to prescriptions.

Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements.

Advanced Services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth®, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, other software solutions, and services related to the Central Pharmacy Dispensing Service and IV Compounding Service.

The following table summarizes revenue recognition for each revenue category:

Revenue Category	Timing of Revenue Recognition	Income Statement Classification
Connected devices, software licenses, and other	Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer	Product
Consumables	Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer	Product
Technical services	Over time, as services are provided, typically ratably over the service term	Service
Advanced Services	Over time, as services are provided	Service

A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”) and Federal agencies that purchase under a Federal Supply Schedule Contract with the Department of Veterans Affairs (the “GSA Contract”). GPOs are often fully or partially owned by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company also pays the Industrial Funding Fee (“IFF”) to the Department of Veterans Affairs under the GSA Contract. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs and the IFF were $3.6 million and $4.8 million for the three months ended September 30, 2023 and 2022, respectively, and $9.5 million and $13.3 million for the nine months ended September 30, 2023 and 2022, respectively.

Disaggregation of Revenues

The following table summarizes the Company’s revenues disaggregated by revenue type for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Connected devices, software licenses, and other	$	167,560	$	226,415	$	500,182	$	650,125
Consumables	21,195		20,150		62,724		56,121
Technical services	57,303		53,914		167,851		156,386
Advanced Services	52,605		47,580		157,508		135,641
Total revenues	$	298,663	$	348,059	$	888,265	$	998,273

The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
United States	$	272,649	$	315,755	$	785,794	$	898,269
Rest of world (1)	26,014		32,304		102,471		100,004
Total revenues	$	298,663	$	348,059	$	888,265	$	998,273

_________________________________________________

(1)    No individual country represented more than 10% of total revenues.

Contract Assets and Contract Liabilities

The following table reflects the Company’s contract assets and contract liabilities:

	September 30, 2023		December 31, 2022
	(In thousands)
Short-term unbilled receivables, net (1)	$	20,275	$	25,763
Long-term unbilled receivables, net (2)	13,159		14,744
Total contract assets	$	33,434	$	40,507
Short-term deferred revenues, net	$	124,991	$	118,947
Long-term deferred revenues	55,053		37,385
Total contract liabilities	$	180,044	$	156,332

_________________________________________________

(1)    Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets.

(2)    Included in other long-term assets in the Condensed Consolidated Balance Sheets.

The portion of the transaction price allocated to the Company’s unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues.

Short-term deferred revenues of $125.0 million and $118.9 million include deferred revenues from product sales and service contracts, net of deferred cost of sales of $12.4 million and $15.8 million, as of September 30, 2023 and December 31, 2022, respectively. During the three and nine months ended September 30, 2023, the Company recognized revenues of $20.1 million and $106.2 million, respectively, that were included in the corresponding gross short-term deferred revenues balance of $134.7 million as of December 31, 2022. Long-term deferred revenues include deferred revenues from product sales and service contracts of $55.1 million and $37.4 million as of September 30, 2023 and December 31, 2022, respectively. Deferred revenues from product sales primarily relate to delivered and invoiced products, pending installation and acceptance. Deferred revenues from service contracts primarily relate to services that have been invoiced, where services have not yet been provided.

Short-term deferred revenues are expected to be recognized within the next twelve months. Long-term deferred revenues substantially consist of deferred revenues on long-term service contracts which have been invoiced and are expected to be recognized as revenue beyond twelve months, generally not more than ten years. The Company generally invoices customers for products upon shipment. Invoicing associated with the service portion of agreements is generally periodic and is billed on a monthly, quarterly, or annual basis, and in certain circumstances, multiple years are billed at one time.

In addition, the Company has remaining performance obligations associated with contracts for which the associated products have been accepted or associated services have started, but where invoicing has not yet occurred and therefore are not reflected in deferred revenue. These remaining performance obligations are comprised of the non-variable portions of technical services and Advanced Services provided under non-cancellable contracts with minimum commitments. Remaining performance obligations which are not included in deferred revenues are $344.8 million as of September 30, 2023. Remaining performance obligations are expected to be recognized ratably over the remaining terms of the associated contracts, which terms vary but are generally not more than ten years. Remaining performance obligations do not include product obligations, services where the associated product has not been accepted, services which have not yet started, variable portions of services, and certain other obligations.

Significant Customers

There were no customers that accounted for more than 10% of the Company’s total revenues for the three and nine months ended September 30, 2023 and 2022. Also, there were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of September 30, 2023 and December 31, 2022.

XML

Net Income (Loss) Per Share

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Net Income (Loss) Per Share

Net Income (Loss) Per Share

The basic and diluted net income (loss) per share calculations for the three and nine months ended September 30, 2023 and 2022 were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands, except per share data)
Net income (loss)	$	5,553	$	16,774	$	(5,996)	$	34,056
Weighted-average shares outstanding – basic	45,333		44,441		45,117		44,304
Effect of dilutive securities from stock award plans	262		943		—		1,293
Effect of convertible senior notes	—		435		—		1,162
Weighted-average shares outstanding – diluted	45,595		45,819		45,117		46,759
Net income (loss) per share – basic	$	0.12	$	0.38	$	(0.13)	$	0.77
Net income (loss) per share – diluted	$	0.12	$	0.37	$	(0.13)	$	0.73
Anti-dilutive weighted-average shares related to stock award plans	2,727		810		3,536		689
Anti-dilutive weighted-average shares related to convertible senior notes and warrants	11,816		5,908		11,816		5,908

XML

Cash and Cash Equivalents and Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Cash and Cash Equivalents and Fair Value of Financial Instruments

Cash and Cash Equivalents and Fair Value of Financial Instruments

Cash and cash equivalents of $446.8 million and $330.4 million as of September 30, 2023 and December 31, 2022, respectively, consisted of bank accounts and highly-liquid U.S. Government money market funds held in sweep and asset management accounts with financial institutions of high credit quality. As of September 30, 2023 and December 31, 2022, cash equivalents were $429.7 million and $301.0 million, respectively, which consisted of money market funds held in sweep and asset management accounts.

Fair Value Hierarchy

The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. As of

September 30, 2023 and December 31, 2022, the fair value of the convertible senior notes was $518.6 million and $501.4 million, respectively, compared to their carrying values of $568.9 million and $566.6 million, respectively, which are net of unamortized debt issuance costs. Refer to Note 9, Debt and Credit Agreement, for further information regarding the Company’s credit facility and Note 10, Convertible Senior Notes, for further information regarding the Company’s convertible senior notes.

XML

Balance Sheet Components

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Components

Balance Sheet Components

Balance sheet details as of September 30, 2023 and December 31, 2022 are presented in the tables below:

	September 30, 2023		December 31, 2022
	(In thousands)
Inventories:
Raw materials	$	56,566	$	75,854
Work in process	2,738		9,280
Finished goods	56,840		62,415
Total inventories	$	116,144	$	147,549
Other current assets:
Funds held for customers, including restricted cash (1)	$	30,967	$	56,703
Net investment in sales-type leases, current portion	11,618		11,486
Prepaid income taxes	125		1,702
Other current assets	7,526		7,471
Total other current assets	$	50,236	$	77,362
Other long-term assets:
External-use software development costs, net	$	69,872	$	80,760
Unbilled receivables, net	13,159		14,744
Deferred debt issuance costs	1,235		2,058
Other long-term assets	6,500		7,455
Total other long-term assets	$	90,766	$	105,017
Accrued liabilities:
Operating lease liabilities, current portion	$	10,617	$	10,761
Customer fund liabilities	30,967		56,703
Advance payments from customers	10,549		11,556
Rebate liabilities	50,878		42,802
Group purchasing organization fees	5,290		7,723
Taxes payable	14,178		9,642
Other accrued liabilities	27,906		33,468
Total accrued liabilities	$	150,385	$	172,655

_________________________________________________

(1)    Includes restricted cash of $15.9 million and $22.5 million as of September 30, 2023 and December 31, 2022, respectively.

The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Beginning balance	$	(14,176)	$	(17,372)	$	(17,087)	$	(8,407)
Other comprehensive loss	(2,953)		(6,770)		(42)		(15,735)
Ending balance	$	(17,129)	$	(24,142)	$	(17,129)	$	(24,142)

XML

Property and Equipment

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and Equipment

The following table represents the property and equipment balances as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
Equipment	$	95,891	$	91,391
Furniture and fixtures	4,898		5,154
Leasehold improvements	17,821		19,510
Purchased software and internal-use software development costs	97,860		76,327
Construction in progress	28,369		28,223
Property and equipment, gross	244,839		220,605
Accumulated depreciation and amortization	(137,959)		(126,644)
Total property and equipment, net	$	106,880	$	93,961

Depreciation and amortization expense of property and equipment was $6.7 million and $5.8 million for the three months ended September 30, 2023 and 2022, respectively, and $19.6 million and $16.7 million for the nine months ended September 30, 2023 and 2022, respectively.

The geographic location of the Company’s property and equipment, net, is based on the physical location in which it is located. The following table summarizes the geographic information for property and equipment, net, as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
United States	$	102,729	$	89,989
Rest of world (1)	4,151		3,972
Total property and equipment, net	$	106,880	$	93,961

_________________________________________________

(1)    No individual country represented more than 10% of total property and equipment, net.

XML

External-Use Software Development Costs

9 Months Ended

Sep. 30, 2023

Research and Development [Abstract]

External-Use Software Development Costs

External-Use Software Development Costs

The carrying amounts of external-use software development costs as of September 30, 2023 and December 31, 2022 were as follows:

	September 30, 2023		December 31, 2022
	(In thousands)
Gross carrying amount	$	236,024	$	225,004
Accumulated amortization	(166,152)		(144,244)
External-use software development costs, net (1)	$	69,872	$	80,760

_________________________________________________

(1)     Included in other long-term assets in the Condensed Consolidated Balance Sheets.

The Company recorded $7.1 million and $7.3 million to cost of revenues for amortization of external-use software development costs for the three months ended September 30, 2023 and 2022, respectively, and $21.9 million and $21.5 million for the nine months ended September 30, 2023 and 2022, respectively.

The estimated future amortization expenses for external-use software development costs were as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	6,787
2024	24,747
2025	17,608
2026	12,069
2027	6,114
Thereafter	2,547
Total	$	69,872

XML

Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Goodwill and Intangible Assets

Goodwill

The following table represents changes in the carrying amount of goodwill:

	(In thousands)
Balance as of December 31, 2022	$	734,274
Foreign currency exchange rate fluctuations	54
Balance as of September 30, 2023	$	734,328

Intangible Assets, Net

The carrying amounts and useful lives of intangible assets as of September 30, 2023 and December 31, 2022 were as follows:

	September 30, 2023
	Gross carrying amount		Accumulated amortization		Foreign currency exchange rate fluctuations		Net carrying amount		Useful life (years)
	(In thousands, except for years)
Customer relationships	$	311,089	$	(113,844)	$	(1,482)	$	195,763	4 - 30
Acquired technology	84,876		(64,792)		—		20,084		4 - 20
Backlog	1,800		(1,575)		—		225		2
Trade names	9,200		(7,418)		—		1,782		5 - 12
Patents	2,430		(1,423)		—		1,007		2 - 20
Non-compete agreements	600		(600)		—		—		3
Total intangibles assets, net	$	409,995	$	(189,652)	$	(1,482)	$	218,861

 

	December 31, 2022
	Gross carrying amount		Accumulated amortization		Foreign currency exchange rate fluctuations		Net carrying amount		Useful life (years)
	(In thousands, except for years)
Customer relationships	$	311,089	$	(99,177)	$	(1,514)	$	210,398	4 - 30
Acquired technology	92,066		(64,299)		—		27,767		4 - 20
Backlog	1,800		(900)		—		900		2
Trade names	9,200		(6,633)		—		2,567		5 - 12
Patents	2,430		(1,306)		—		1,124		2 - 20
Non-compete agreements	600		(450)		—		150		3
Total intangibles assets, net	$	417,185	$	(172,765)	$	(1,514)	$	242,906

Amortization expense of intangible assets was $7.7 million and $8.7 million for the three months ended September 30, 2023 and 2022, respectively, and $24.1 million and $26.7 million for the nine months ended September 30, 2023 and 2022, respectively.

The estimated future amortization expenses for amortizable intangible assets were as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	7,483
2024	23,093
2025	21,056
2026	18,061
2027	16,754
Thereafter	132,414
Total	$	218,861

XML

Debt and Credit Agreement

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Debt and Credit Agreement

Debt and Credit AgreementOn November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as amended, the “Prior A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative

agent. The Prior A&R Credit Agreement provided for (a) a five-year revolving credit facility of $500.0 million (the “Prior Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Prior Incremental Facility”). In addition, the Prior A&R Credit Agreement included a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Prior A&R Credit Agreement had an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings would be due and payable.

On September 22, 2020 and March 29, 2023, the Company entered into amendments to the Prior A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 10, Convertible Senior Notes, expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter, as well as to remove and replace the interest rate benchmark based on the London interbank offered rate (“LIBOR”) and related LIBOR-based mechanics applicable to borrowings under the A&R Credit Agreement with an interest rate benchmark based on the secured overnight financing rate (“SOFR”) as administered by the Federal Reserve Bank of New York and related SOFR-based mechanics.

Loans under the Prior Revolving Credit Facility bore interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Prior A&R Credit Agreement), plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Prior A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) Adjusted Term SOFR for a one month tenor plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Prior Revolving Credit Facility were subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Prior Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Prior Incremental Facility would be determined prior to the incurrence of such loans. The Company was permitted to make voluntary prepayments at any time without payment of a premium or penalty.

The Prior A&R Credit Agreement contained customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Prior A&R Credit Agreement also contained financial covenants that required the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the Prior A&R Credit Agreement contained certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.

Subsequent to the quarter ended September 30, 2023, the Company entered into a Second Amended and Restated Credit Agreement (the “Second A&R Credit Agreement”) on October 10, 2023, with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&R Credit Agreement supersedes the Prior A&R Credit Agreement and provides for (a) a five-year revolving credit facility of $350.0 million (the “Current Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to an amount equal to the sum of (i) the greater of $250.0 million or 100% of the adjusted consolidated EBITDA for the last four quarters and (ii) additional amounts subject to pro forma compliance with certain consolidated secured net leverage ratio (the “Current Incremental Facility”). In addition, the Second A&R Credit Agreement includes a letter of credit sub-limit of up to $15 million and a swing line loan sub-limit of up to $25 million. The Second A&R Credit Agreement has an expiration date of October 10, 2028, subject to acceleration under certain conditions, upon which date all remaining outstanding borrowings will be due and payable.

Loans under the Current Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Second A&R Credit Agreement), plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Second A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Current Revolving Credit Facility are subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Current Revolving Credit Facility. Subject to the terms and conditions of the Current Revolving Credit Facility or Current Incremental Facility, the Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. The availability of funds under the Current

Revolving Credit Facility may be subject to reduction in order to maintain compliance with the financial covenants under the Second A&R Credit Agreement.

The Second A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Second A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated secured net leverage ratio (not to exceed 3.00:1) and maintain a minimum consolidated interest coverage ratio (not to be less than 3.00:1). In addition, the Second A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.

The Company’s obligations under the Second A&R Credit Agreement and, at the election of the Company and the contracting counterparty, any secured swap obligations and banking services obligations owing to a lender (or an affiliate of a lender), are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the Second A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement.

As of both September 30, 2023 and December 31, 2022, the Company had $500.0 million of funds available under the Prior Revolving Credit Facility. As of September 30, 2023 and December 31, 2022, the Company had no outstanding balance under the Prior Revolving Credit Facility. The Company was in compliance with all covenants of the Prior A&R Credit Agreement as of September 30, 2023. Upon entry into the Second A&R Credit Agreement, the Company had $350.0 million of funds available under the Current Revolving Credit Facility.

Convertible Senior Notes

0.25% Convertible Senior Notes due 2025

On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted.

The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions.

During the three months ended September 30, 2023 and December 31, 2022, none of the conditional conversion features of the Notes were triggered, and therefore, the Notes are not convertible during the fourth quarter of 2023, commencing on October 1, 2023, and were not convertible during the first quarter of 2023, commencing on January 1, 2023. Accordingly, the Company classified the Notes as a long-term liability in its Condensed Consolidated Financial Statements as of both September 30, 2023 and December 31, 2022. Whether the Notes will be convertible following the fourth fiscal quarter of 2023 will depend on the satisfaction of the conversion conditions in the future.

Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that could occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be.

If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of September 30, 2023, none of the criteria for a fundamental change or a conversion rate adjustment had been met.

As of September 20, 2023, the Company may redeem for cash all or any portion of the Notes, at its option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes.

The debt issuance costs associated with the Notes are being amortized to interest expense over the term of the Notes using an effective interest rate of 0.80%. As of September 30, 2023, the remaining life of the Notes and the related issuance cost accretion is approximately 2.0 years.

The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of September 30, 2023, the if-converted value of the Notes did not exceed the principal amount.

The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
Principal amount	$	575,000	$	575,000
Unamortized debt issuance costs	(6,113)		(8,429)
Convertible senior notes, net	$	568,887	$	566,571

The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Contractual coupon interest	$	359	$	359	$	1,078	$	1,078
Amortization of debt issuance costs	$	773	$	768	$	2,316	$	2,298

Convertible Note Hedge and Warrant Transactions

In connection with the issuance of the Notes in September 2020, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock.

The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Condensed Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes.

Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Condensed Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants.

XML

Convertible Senior Notes

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Convertible Senior Notes

Debt and Credit AgreementOn November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as amended, the “Prior A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative

agent. The Prior A&R Credit Agreement provided for (a) a five-year revolving credit facility of $500.0 million (the “Prior Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Prior Incremental Facility”). In addition, the Prior A&R Credit Agreement included a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The Prior A&R Credit Agreement had an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings would be due and payable.

On September 22, 2020 and March 29, 2023, the Company entered into amendments to the Prior A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 10, Convertible Senior Notes, expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter, as well as to remove and replace the interest rate benchmark based on the London interbank offered rate (“LIBOR”) and related LIBOR-based mechanics applicable to borrowings under the A&R Credit Agreement with an interest rate benchmark based on the secured overnight financing rate (“SOFR”) as administered by the Federal Reserve Bank of New York and related SOFR-based mechanics.

Loans under the Prior Revolving Credit Facility bore interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Prior A&R Credit Agreement), plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Prior A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) Adjusted Term SOFR for a one month tenor plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Prior Revolving Credit Facility were subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Prior Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Prior Incremental Facility would be determined prior to the incurrence of such loans. The Company was permitted to make voluntary prepayments at any time without payment of a premium or penalty.

The Prior A&R Credit Agreement contained customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Prior A&R Credit Agreement also contained financial covenants that required the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the Prior A&R Credit Agreement contained certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.

Subsequent to the quarter ended September 30, 2023, the Company entered into a Second Amended and Restated Credit Agreement (the “Second A&R Credit Agreement”) on October 10, 2023, with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&R Credit Agreement supersedes the Prior A&R Credit Agreement and provides for (a) a five-year revolving credit facility of $350.0 million (the “Current Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to an amount equal to the sum of (i) the greater of $250.0 million or 100% of the adjusted consolidated EBITDA for the last four quarters and (ii) additional amounts subject to pro forma compliance with certain consolidated secured net leverage ratio (the “Current Incremental Facility”). In addition, the Second A&R Credit Agreement includes a letter of credit sub-limit of up to $15 million and a swing line loan sub-limit of up to $25 million. The Second A&R Credit Agreement has an expiration date of October 10, 2028, subject to acceleration under certain conditions, upon which date all remaining outstanding borrowings will be due and payable.

Loans under the Current Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the Adjusted Term SOFR (as defined in the Second A&R Credit Agreement), plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the Second A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) the Adjusted Term SOFR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Current Revolving Credit Facility are subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Current Revolving Credit Facility. Subject to the terms and conditions of the Current Revolving Credit Facility or Current Incremental Facility, the Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. The availability of funds under the Current

Revolving Credit Facility may be subject to reduction in order to maintain compliance with the financial covenants under the Second A&R Credit Agreement.

The Second A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Second A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated secured net leverage ratio (not to exceed 3.00:1) and maintain a minimum consolidated interest coverage ratio (not to be less than 3.00:1). In addition, the Second A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy.

The Company’s obligations under the Second A&R Credit Agreement and, at the election of the Company and the contracting counterparty, any secured swap obligations and banking services obligations owing to a lender (or an affiliate of a lender), are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the Second A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement.

As of both September 30, 2023 and December 31, 2022, the Company had $500.0 million of funds available under the Prior Revolving Credit Facility. As of September 30, 2023 and December 31, 2022, the Company had no outstanding balance under the Prior Revolving Credit Facility. The Company was in compliance with all covenants of the Prior A&R Credit Agreement as of September 30, 2023. Upon entry into the Second A&R Credit Agreement, the Company had $350.0 million of funds available under the Current Revolving Credit Facility.

Convertible Senior Notes

0.25% Convertible Senior Notes due 2025

On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted.

The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions.

During the three months ended September 30, 2023 and December 31, 2022, none of the conditional conversion features of the Notes were triggered, and therefore, the Notes are not convertible during the fourth quarter of 2023, commencing on October 1, 2023, and were not convertible during the first quarter of 2023, commencing on January 1, 2023. Accordingly, the Company classified the Notes as a long-term liability in its Condensed Consolidated Financial Statements as of both September 30, 2023 and December 31, 2022. Whether the Notes will be convertible following the fourth fiscal quarter of 2023 will depend on the satisfaction of the conversion conditions in the future.

Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that could occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be.

If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of September 30, 2023, none of the criteria for a fundamental change or a conversion rate adjustment had been met.

As of September 20, 2023, the Company may redeem for cash all or any portion of the Notes, at its option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes.

The debt issuance costs associated with the Notes are being amortized to interest expense over the term of the Notes using an effective interest rate of 0.80%. As of September 30, 2023, the remaining life of the Notes and the related issuance cost accretion is approximately 2.0 years.

The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of September 30, 2023, the if-converted value of the Notes did not exceed the principal amount.

The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
Principal amount	$	575,000	$	575,000
Unamortized debt issuance costs	(6,113)		(8,429)
Convertible senior notes, net	$	568,887	$	566,571

The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Contractual coupon interest	$	359	$	359	$	1,078	$	1,078
Amortization of debt issuance costs	$	773	$	768	$	2,316	$	2,298

Convertible Note Hedge and Warrant Transactions

In connection with the issuance of the Notes in September 2020, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock.

The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Condensed Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes.

Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Condensed Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants.

XML

Lessor Leases

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Lessor Leases

Lessor Leases

Sales-Type Leases

The Company enters into multi-year, sales-type lease agreements, with the leases varying in length from one to ten years. The Company optimizes cash flows by selling a majority of its sales-type leases, other than those relating to U.S. government hospitals and Advanced Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold.

The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Sales-type lease revenues	$	14,388	$	10,115	$	27,960	$	34,033
Cost of sales-type lease revenues	(7,141)		(5,357)		(14,183)		(16,963)
Selling profit on sales-type lease revenues	$	7,247	$	4,758	$	13,777	$	17,070

The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
Net minimum lease payments to be received	$	62,470	$	50,755
Less: Unearned interest income portion	(9,221)		(6,345)
Net investment in sales-type leases	53,249		44,410
Less: Current portion (1)	(11,618)		(11,486)
Long-term investment in sales-type leases, net	$	41,631	$	32,924

_________________________________________________

(1)    The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.

The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value.

The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	3,828
2024	13,431
2025	11,351
2026	9,053
2027	7,286
Thereafter	17,521
Total future minimum sales-type lease payments	62,470
Present value adjustment	(9,221)
Total net investment in sales-type leases	$	53,249

Operating Leases

The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Rental income	$	1,330	$	2,327	$	5,459	$	7,220

Lessor Leases

Lessor Leases

Sales-Type Leases

The Company enters into multi-year, sales-type lease agreements, with the leases varying in length from one to ten years. The Company optimizes cash flows by selling a majority of its sales-type leases, other than those relating to U.S. government hospitals and Advanced Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold.

The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Sales-type lease revenues	$	14,388	$	10,115	$	27,960	$	34,033
Cost of sales-type lease revenues	(7,141)		(5,357)		(14,183)		(16,963)
Selling profit on sales-type lease revenues	$	7,247	$	4,758	$	13,777	$	17,070

The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
Net minimum lease payments to be received	$	62,470	$	50,755
Less: Unearned interest income portion	(9,221)		(6,345)
Net investment in sales-type leases	53,249		44,410
Less: Current portion (1)	(11,618)		(11,486)
Long-term investment in sales-type leases, net	$	41,631	$	32,924

_________________________________________________

(1)    The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.

The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value.

The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	3,828
2024	13,431
2025	11,351
2026	9,053
2027	7,286
Thereafter	17,521
Total future minimum sales-type lease payments	62,470
Present value adjustment	(9,221)
Total net investment in sales-type leases	$	53,249

Operating Leases

The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Rental income	$	1,330	$	2,327	$	5,459	$	7,220

XML

Lessee Leases

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Lessee Leases

Lessee Leases

The Company has operating leases for office buildings, data centers, office equipment, and vehicles. The Company’s leases have initial terms of one to twelve years. As of September 30, 2023, the Company did not have any additional material operating leases that were entered into, but not yet commenced.

The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	3,340
2024	12,266
2025	9,604
2026	8,942
2027	7,334
Thereafter	8,054
Total operating lease payments	49,540
Present value adjustment	(6,078)
Total operating lease liabilities (1)	$	43,462

_________________________________________________

(1)    Amount consists of a current and long-term portion of operating lease liabilities of $10.6 million and $32.8 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities in the Condensed Consolidated Balance Sheets.

Operating lease costs were $2.6 million and $4.0 million for the three months ended September 30, 2023 and 2022, respectively, and $8.2 million and $12.8 million for the nine months ended September 30, 2023 and 2022, respectively. Short-term lease costs and variable lease costs were not material for the three and nine months ended September 30, 2023 and 2022. The Company recorded impairment and abandonment charges to operating lease right-of-use assets of $7.8 million during the nine months ended September 30, 2023, and $0.3 million and $5.4 million during the three and nine months ended September 30, 2022, respectively, in connection with restructuring activities to reduce its real estate footprint and for optimization of certain leased facilities. The impairment and abandonment charges were recorded to selling, general, and administrative expenses on the Company’s Condensed Consolidated Statements of Operations. Refer to Note 16, Restructuring Expenses, for additional information regarding the Company’s restructuring activities.

The following table summarizes supplemental cash flow information related to the Company’s operating leases for the nine months ended September 30, 2023 and 2022:

	Nine Months Ended September 30,
	2023		2022
	(In thousands)
Cash paid for amounts included in the measurement of lease liabilities	$	10,100	$	13,178
Right-of-use assets obtained in exchange for new lease liabilities	$	1,758	$	12,177

The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
Weighted-average remaining lease term, years	4.6		5.0
Weighted-average discount rate, %	5.7	%	5.7	%

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Purchase Obligations

In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. As of September 30, 2023, the Company had non-cancelable purchase commitments of $118.7 million, of which $78.1 million are expected to be paid within the year ending December 31, 2023.

Ransomware Incident

During the nine months ended September 30, 2023, the Company did not incur any material expenses or recoveries related to the previously disclosed ransomware incident. During the three months ended September 30, 2022, the Company incurred $1.0 million of expenses related to the ransomware incident, and during the nine months ended September 30, 2022, the Company incurred $13.5 million of expenses related to the ransomware incident, partially offset by $11.1 million of expected insurance recoveries. Expenses include costs to investigate and remediate the ransomware incident, as well as legal and other professional services, all of which were expensed as incurred. For the three and nine months ended September 30, 2022, the Company included net expenses related to the ransomware incident in cost of revenues of $0.1 million and $0.3 million, respectively; in research and development of $0.2 million and $0.2 million, respectively; and in selling, general, and administrative expenses of $0.7 million and $1.9 million, respectively, in the Company’s Condensed Consolidated Statements of Operations.

As of September 30, 2023, the Company has incurred $13.6 million of cumulative expenses related to the ransomware incident since it was detected, partially offset by $11.6 million of insurance recoveries, all of which have been received as of September 30, 2023.

Legal Proceedings

The Company is currently involved in various legal proceedings.

As required under ASC 450, Contingencies, the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any material accrual for contingent liabilities associated with any current legal proceedings based on its belief that any potential material loss, while reasonably possible, is not probable. Furthermore, any possible range of loss in such matters cannot be reasonably estimated at this time. The Company believes that it has valid defenses with respect to legal proceedings pending against it. However,

litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of legal proceedings or because of the diversion of management’s attention and the creation of significant expenses, regardless of outcome.

The Company is not a party to any legal proceedings that management believes may have a material impact on the Company’s financial position or results of operations.

XML

Income Taxes

9 Months Ended

Sep. 30, 2023

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

The Company generally provides for income taxes in interim periods based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. For the nine months ended September 30, 2023, the Company recorded a provision for income taxes of $4.4 million by applying its estimated annual effective tax rate to its year-to-date measure of ordinary income and adjusted for $5.6 million of discrete income tax expense primarily from equity compensation. For the nine months ended September 30, 2022, the Company recorded a benefit from income taxes of $1.0 million by applying its estimated annual effective tax rate to its year-to-date measure of ordinary income and included a net discrete income tax benefit of $6.9 million, primarily due to a tax benefit from equity compensation.

The 2023 annual effective tax rate before discrete items differed from the statutory rate of 21% primarily due to the favorable benefit of the research and development credits and a foreign-derived intangible income (“FDII”) benefit deduction, partially offset by unfavorable impact of the non-deductible compensation and equity charges and Global Intangible Low-Taxed Income (“GILTI”) tax inclusion. The 2022 annual effective tax rate before discrete items differed from the statutory rate of 21% primarily due to the unfavorable impact of state income taxes, non-deductible compensation and equity charges, and GILTI tax inclusion, partially offset by the favorable impact of research and development credits and an FDII deduction.

On August 16, 2022, the Inflation Reduction Act of 2022 (the “IRA”) was signed into law and introduced a 15% corporate alternative minimum tax for tax years beginning after December 31, 2022 and levies a 1% excise tax on net stock repurchases after December 31, 2022. These provisions did not have an impact on the Company’s provision for income taxes for the nine months ended September 30, 2023.

As of September 30, 2023 and December 31, 2022, the Company had gross unrecognized tax benefits of $10.1 million and $9.3 million, respectively. The Company recognizes interest and penalties related to uncertain tax positions in interest and other income (expense), net in the Condensed Consolidated Statements of Operations. Accrued interest and penalties are included within other long-term liabilities on the Condensed Consolidated Balance Sheets. As of September 30, 2023 and December 31, 2022, the amount of accrued interest and penalties was $0.4 million and $0.2 million, respectively.

The Company files income tax returns in the United States and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examinations by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, France, and the United Kingdom. With few exceptions, as of September 30, 2023, the Company was no longer subject to U.S., state, and foreign tax examinations for years before 2019, 2018, and 2018, respectively.

Although the Company believes it has adequately provided for unrecognized tax benefits, the provisions on these positions may change as revised estimates are made or the underlying matters are settled or otherwise resolved. It is not possible at this time to reasonably estimate changes in the unrecognized tax benefits within the next twelve months.

XML

Employee Benefits and Share-Based Compensation

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Employee Benefits and Share-Based Compensation

Employee Benefits and Share-Based Compensation

Share-Based Compensation Expense

The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Cost of product and service revenues	$	2,213	$	2,203	$	6,489	$	6,607
Research and development	1,917		3,054		5,220		7,912
Selling, general, and administrative	10,852		12,053		31,404		36,212
Total share-based compensation expense	$	14,982	$	17,310	$	43,113	$	50,731

During the three and nine months ended September 30, 2023, the Company capitalized approximately $1.1 million and $3.3 million, respectively, of non-cash share-based compensation expense to internal-use and external-use software development costs related to internal labor. The Company did not capitalize any material non-cash share-based compensation expense to inventory during the three and nine months ended September 30, 2023 and 2022, or any material non-cash share-based compensation expense to internal-use and external-use software development costs during the three and nine months ended September 30, 2022.

Employee Stock Purchase Plan (“ESPP”)

The following assumptions were used to value shares under the ESPP for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Expected life, years	0.5 - 2.0		0.5 - 2.0		0.5 - 2.0		0.5 - 2.0
Expected volatility, %	32.0% - 63.9%		28.8% - 44.8%		31.7% - 63.9%		28.8% - 45.6%
Risk-free interest rate, %	0.2% - 5.5%		0.1% - 3.2%		0.1% - 5.5%		0.1% - 3.2%
Dividend yield, %	—	%	—	%	—	%	—	%

For the nine months ended September 30, 2023 and 2022, employees purchased approximately 353,000 and 316,000 shares of common stock, respectively, under the ESPP at a weighted-average price of $46.68 and $67.63, respectively. As of September 30, 2023, the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $2.0 million and is expected to be recognized over a weighted-average period of 1.6 years.

Stock Options

The following assumptions were used to value stock options granted pursuant to the Company’s 2009 Equity Incentive Plan, as amended, (the “2009 Plan”) for the nine months ended September 30, 2023. There were no stock options granted during the three months ended September 30, 2023, and the three and nine months ended September 30, 2022.

	Nine Months Ended September 30,
	2023
Expected life, years	3.2
Expected volatility, %	44.8	%
Risk-free interest rate, %	3.7	%
Estimated forfeiture rate, %	10.0	%
Dividend yield, %	—	%

The following table summarizes the stock option activity under the 2009 Plan during the nine months ended September 30, 2023:

	Number of Shares	Weighted-Average Exercise Price		Weighted-Average Remaining Years	Aggregate Intrinsic Value
	(In thousands, except per share data)
Outstanding at December 31, 2022	2,434	$	68.65	6.1	$	7,887
Granted	200	55.60
Exercised	(157)	41.85
Expired	(177)	80.44
Forfeited	(180)	74.17
Outstanding at September 30, 2023	2,120	$	67.96	5.0	$	3,418
Exercisable at September 30, 2023	1,801	$	66.84	4.9	$	3,418
Vested and expected to vest at September 30, 2023 and thereafter	2,103	$	67.90	5.0	$	3,418

The weighted-average fair value per share of options granted during the nine months ended September 30, 2023 was $19.48. The intrinsic value of options exercised during the three months ended September 30, 2023 and 2022 was $0.5 million and $7.6 million, respectively, and during the nine months ended September 30, 2023 and 2022 was $3.1 million and $23.1 million, respectively.

As of September 30, 2023, total unrecognized compensation cost related to unvested stock options was $5.3 million, which is expected to be recognized over a weighted-average vesting period of 0.9 years.

Restricted Stock Units (“RSUs”)

The following table summarizes the RSU activity under the 2009 Plan during the nine months ended September 30, 2023:

	Number of Shares	Weighted-Average Grant Date Fair Value		Weighted-Average Remaining Years	Aggregate Intrinsic Value
	(In thousands, except per share data)
Outstanding at December 31, 2022	1,117	$	115.75	1.6	$	56,297
Granted (Awarded)	675	64.44
Vested (Released)	(252)	117.13
Forfeited	(304)	112.82
Outstanding and unvested at September 30, 2023	1,236	$	87.89	1.7	$	55,649

As of September 30, 2023, total unrecognized compensation cost related to RSUs was $78.2 million, which is expected to be recognized over the remaining weighted-average vesting period of 3.1 years.

Restricted Stock Awards (“RSAs”)

The following table summarizes the RSA activity under the 2009 Plan during the nine months ended September 30, 2023:

	Number of Shares	Weighted-Average Grant Date Fair Value
	(In thousands, except per share data)
Outstanding at December 31, 2022	13	$	109.39
Granted (Awarded)	24	70.96
Vested (Released)	(13)	109.39
Outstanding and unvested at September 30, 2023	24	$	70.96

As of September 30, 2023, total unrecognized compensation cost related to RSAs was $1.0 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.6 years.

Performance-Based Stock Unit Awards (“PSUs”)

The following table summarizes the PSU activity under the 2009 Plan during the nine months ended September 30, 2023:

	Number of Shares	Weighted-Average Grant Date Fair Value
	(In thousands, except per share data)
Outstanding at December 31, 2022	135	$	147.42
Granted	65	122.29
Vested	(35)	127.40
Forfeited	(66)	153.68
Outstanding and unvested at September 30, 2023	99	$	129.36

As of September 30, 2023, total unrecognized compensation cost related to PSUs was approximately $6.7 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.4 years.

Summary of Shares Reserved for Future Issuance under Equity Incentive Plans

The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of September 30, 2023:

	Number of Shares
	(In thousands)
Stock options outstanding	2,120
Non-vested restricted stock awards	1,359
Shares authorized for future issuance	2,417
ESPP shares available for future issuance	3,250
Total shares reserved for future issuance	9,146

Stock Repurchase Programs

On August 2, 2016, the Company’s Board of Directors (the “Board”) authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2014 Repurchase Program”). During the first quarter of 2022, the 2014 Repurchase Program was completed, and as of September 30, 2023, the maximum dollar value of shares that may yet be purchased under the 2016 Repurchase Program was $2.7 million. The 2016 Repurchase Program does not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the 2016 Repurchase Program at any time.

During the nine months ended September 30, 2022, the Company repurchased approximately 389,300 shares of its common stock under the repurchase programs at an average price of $134.11 per share for an aggregate purchase price of approximately $52.2 million. During the three and nine months ended September 30, 2023 and the three months ended September 30, 2022, the Company did not repurchase any of its outstanding common stock under the 2016 Repurchase Program.

XML

Restructuring Expenses

9 Months Ended

Sep. 30, 2023

Restructuring and Related Activities [Abstract]

Restructuring Expenses

Restructuring Expenses

During the first quarter of 2022, the Company initiated certain domestic and international restructuring initiatives, in order to enhance and streamline certain engineering functions for its domestic operations, and to realign its international sales organization to better serve its customers in various international markets. During the third quarter of 2022, the Company initiated restructuring initiatives associated with the integration and functionalization of certain acquisitions, primarily the 340B Link business acquisition, to further accelerate the expansion of the Company’s pharmacy inventory management capabilities. During the three and nine months ended September 30, 2022, the restructuring plans incurred $1.8 million and $5.3 million, respectively, of employee severance costs and related expenses. As of September 30, 2023, there was no material unpaid balance related to these restructuring plans.

On November 23, 2022, the Company committed to a plan to reduce the Company’s headcount (the “Plan”), as part of the Company’s expense containment efforts being implemented due to ongoing macroeconomic headwinds. During the first quarter of 2023, as a result of continued exploration of expense containment measures, the Company committed to further reduce its headcount across many of its functions, and also committed to reduce its real estate footprint to align with its broader hybrid work strategy and in an effort to further reduce costs. During the three months ended September 30, 2023, the Company recorded an immaterial reversal of previously recognized restructuring expenses associated with the Plan. During the nine months ended September 30, 2023, the Company incurred $5.5 million of employee severance costs and related expenses, net of reversals, in connection with the Plan. As of September 30, 2023, the Company has incurred $22.9 million of cumulative restructuring expense, net of reversals, related to employee severance costs and related expenses since the inception of the Plan. As of September 30, 2023 and December 31, 2022, the unpaid balance related to the Plan was $1.0 million and $18.2 million, respectively.

Refer to Note 12, Lessee Leases, for information regarding the Company’s restructuring activities for the reduction of its real estate footprint and optimization of certain leased facilities.

The following table summarizes the total employee-related restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Cost of product and service revenues	$	(280)	$	444	$	102	$	600
Research and development	(25)		272		467		1,866
Selling, general, and administrative	(276)		1,078		4,885		2,855
Total restructuring expense, net of reversals	$	(581)	$	1,794	$	5,454	$	5,321

XML

Subsequent Events

9 Months Ended

Sep. 30, 2023

Subsequent Events [Abstract]

Subsequent Events

Subsequent Events

Second Amended and Restated Credit Agreement

On October 10, 2023, the Company entered into the Second A&R Credit Agreement with the lenders from time to time party thereto, Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Capital Markets LLC and TD Securities (USA) LLC as joint lead arrangers and Wells Fargo Bank, National Association, as administrative agent. The Second A&R Credit Agreement supersedes the Company’s Prior A&R Credit Agreement. Refer to Note 9, Debt and Credit Agreement, for additional information.

Restructuring Plan

On November 2, 2023, the Company announced a plan to reduce the Company’s headcount and real estate footprint (the “2023 Plan”) as part of the Company’s expense containment initiatives and other actions to reduce discretionary spending being implemented due to challenging industry dynamics and macroeconomic conditions. In connection with the 2023 Plan, the Company estimates that it will incur approximately $12 million to $18 million of nonrecurring restructuring and related charges, consisting of (i) approximately $9 million to $12 million of cash-based charges related to the reduction in headcount, which primarily consist of employee severance and benefits costs and (ii) approximately $3 million to $6 million of non-cash charges related to office closure, which the Company expects to incur the majority of charges in the fourth quarter of 2023 with remaining charges incurred in future periods. The Company expects to substantially complete the 2023 Plan, including cash payments, by the end of the second quarter of 2024, subject to local laws and consultation requirements.

XML

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net income	$ 5,553	$ 3,451	$ (15,000)	$ 16,774	$ 9,069	$ 8,213	$ (5,996)	$ 34,056

XML

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML

Organization and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of September 30, 2023 and December 31, 2022, the results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023 and 2022, and cash flows for the nine months ended September 30, 2023 and 2022. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 1, 2023, except as discussed in the section entitled “Recently Adopted Authoritative Guidance” below. The Company’s results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023, and cash flows for the nine months ended September 30, 2023 are not necessarily indicative of results that may be expected for the year ending December 31, 2023, or for any future period.

Principles of Consolidation

The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates.

The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. As of September 30, 2023, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities.

Segment Reporting

The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.

Recently Adopted and Issued Authoritative Guidance

Recently Adopted Authoritative Guidance

In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The update addresses diversity in practice by requiring that an acquirer recognize and measure contract assets and liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. The Company adopted ASU 2021-08 beginning January 1, 2023 and will apply the guidance prospectively to acquisitions occurring on or after the adoption date.

Recently Issued Authoritative Guidance

There was no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date.

Revenue Recognition

The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories:

Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements. Solutions in this category include, but are not limited to, XT Series automated dispensing systems and products related to the Central Pharmacy Dispensing Service and IV Compounding Service.

Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards, which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, are designed to improve patient engagement and adherence to prescriptions.

Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements.

Advanced Services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth®, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, other software solutions, and services related to the Central Pharmacy Dispensing Service and IV Compounding Service.

The following table summarizes revenue recognition for each revenue category:

Revenue Category	Timing of Revenue Recognition	Income Statement Classification
Connected devices, software licenses, and other	Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer	Product
Consumables	Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer	Product
Technical services	Over time, as services are provided, typically ratably over the service term	Service
Advanced Services	Over time, as services are provided	Service

A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”) and Federal agencies that purchase under a Federal Supply Schedule Contract with the Department of Veterans Affairs (the “GSA Contract”). GPOs are often fully or partially owned by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company also pays the Industrial Funding Fee (“IFF”) to the Department of Veterans Affairs under the GSA Contract. The Company considers these fees consideration paid to customers and records them as reductions to revenue.

Fair Value Hierarchy

The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period.

XML

Revenues (Tables)

9 Months Ended

Sep. 30, 2023

Revenue Recognition [Abstract]

Summary of Revenue Recognition for Revenue Categories

The following table summarizes revenue recognition for each revenue category:

Revenue Category	Timing of Revenue Recognition	Income Statement Classification
Connected devices, software licenses, and other	Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer	Product
Consumables	Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer	Product
Technical services	Over time, as services are provided, typically ratably over the service term	Service
Advanced Services	Over time, as services are provided	Service

Disaggregation of Revenues by Revenue Type

The following table summarizes the Company’s revenues disaggregated by revenue type for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Connected devices, software licenses, and other	$	167,560	$	226,415	$	500,182	$	650,125
Consumables	21,195		20,150		62,724		56,121
Technical services	57,303		53,914		167,851		156,386
Advanced Services	52,605		47,580		157,508		135,641
Total revenues	$	298,663	$	348,059	$	888,265	$	998,273

Disaggregation of Revenues by Geographical Location

The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
United States	$	272,649	$	315,755	$	785,794	$	898,269
Rest of world (1)	26,014		32,304		102,471		100,004
Total revenues	$	298,663	$	348,059	$	888,265	$	998,273

_________________________________________________

(1)    No individual country represented more than 10% of total revenues.

Contract Asset and Liabilities

The following table reflects the Company’s contract assets and contract liabilities:

	September 30, 2023		December 31, 2022
	(In thousands)
Short-term unbilled receivables, net (1)	$	20,275	$	25,763
Long-term unbilled receivables, net (2)	13,159		14,744
Total contract assets	$	33,434	$	40,507
Short-term deferred revenues, net	$	124,991	$	118,947
Long-term deferred revenues	55,053		37,385
Total contract liabilities	$	180,044	$	156,332

_________________________________________________

(1)    Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets.

(2)    Included in other long-term assets in the Condensed Consolidated Balance Sheets.

XML

Net Income (Loss) Per Share (Tables)

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Basic and Diluted Net Income Per Share

The basic and diluted net income (loss) per share calculations for the three and nine months ended September 30, 2023 and 2022 were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands, except per share data)
Net income (loss)	$	5,553	$	16,774	$	(5,996)	$	34,056
Weighted-average shares outstanding – basic	45,333		44,441		45,117		44,304
Effect of dilutive securities from stock award plans	262		943		—		1,293
Effect of convertible senior notes	—		435		—		1,162
Weighted-average shares outstanding – diluted	45,595		45,819		45,117		46,759
Net income (loss) per share – basic	$	0.12	$	0.38	$	(0.13)	$	0.77
Net income (loss) per share – diluted	$	0.12	$	0.37	$	(0.13)	$	0.73
Anti-dilutive weighted-average shares related to stock award plans	2,727		810		3,536		689
Anti-dilutive weighted-average shares related to convertible senior notes and warrants	11,816		5,908		11,816		5,908

XML

Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Components

Balance sheet details as of September 30, 2023 and December 31, 2022 are presented in the tables below:

	September 30, 2023		December 31, 2022
	(In thousands)
Inventories:
Raw materials	$	56,566	$	75,854
Work in process	2,738		9,280
Finished goods	56,840		62,415
Total inventories	$	116,144	$	147,549
Other current assets:
Funds held for customers, including restricted cash (1)	$	30,967	$	56,703
Net investment in sales-type leases, current portion	11,618		11,486
Prepaid income taxes	125		1,702
Other current assets	7,526		7,471
Total other current assets	$	50,236	$	77,362
Other long-term assets:
External-use software development costs, net	$	69,872	$	80,760
Unbilled receivables, net	13,159		14,744
Deferred debt issuance costs	1,235		2,058
Other long-term assets	6,500		7,455
Total other long-term assets	$	90,766	$	105,017
Accrued liabilities:
Operating lease liabilities, current portion	$	10,617	$	10,761
Customer fund liabilities	30,967		56,703
Advance payments from customers	10,549		11,556
Rebate liabilities	50,878		42,802
Group purchasing organization fees	5,290		7,723
Taxes payable	14,178		9,642
Other accrued liabilities	27,906		33,468
Total accrued liabilities	$	150,385	$	172,655

_________________________________________________

(1)    Includes restricted cash of $15.9 million and $22.5 million as of September 30, 2023 and December 31, 2022, respectively.

Schedule of Accumulated Other Comprehensive Income (Loss)

The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Beginning balance	$	(14,176)	$	(17,372)	$	(17,087)	$	(8,407)
Other comprehensive loss	(2,953)		(6,770)		(42)		(15,735)
Ending balance	$	(17,129)	$	(24,142)	$	(17,129)	$	(24,142)

XML

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Balances

The following table represents the property and equipment balances as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
Equipment	$	95,891	$	91,391
Furniture and fixtures	4,898		5,154
Leasehold improvements	17,821		19,510
Purchased software and internal-use software development costs	97,860		76,327
Construction in progress	28,369		28,223
Property and equipment, gross	244,839		220,605
Accumulated depreciation and amortization	(137,959)		(126,644)
Total property and equipment, net	$	106,880	$	93,961

Summary of Geographic Information for Property and Equipment, Net

The following table summarizes the geographic information for property and equipment, net, as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
United States	$	102,729	$	89,989
Rest of world (1)	4,151		3,972
Total property and equipment, net	$	106,880	$	93,961

_________________________________________________

(1)    No individual country represented more than 10% of total property and equipment, net.

XML

External-Use Software Development Costs (Tables)

9 Months Ended

Sep. 30, 2023

Research and Development [Abstract]

Schedule of Capitalized Computer Software

The carrying amounts of external-use software development costs as of September 30, 2023 and December 31, 2022 were as follows:

	September 30, 2023		December 31, 2022
	(In thousands)
Gross carrying amount	$	236,024	$	225,004
Accumulated amortization	(166,152)		(144,244)
External-use software development costs, net (1)	$	69,872	$	80,760

_________________________________________________

(1)     Included in other long-term assets in the Condensed Consolidated Balance Sheets.

Schedule of Future Amortization Expenses For Capitalized Software Development Costs

The estimated future amortization expenses for external-use software development costs were as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	6,787
2024	24,747
2025	17,608
2026	12,069
2027	6,114
Thereafter	2,547
Total	$	69,872

XML

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in Carrying Amount of Goodwill

The following table represents changes in the carrying amount of goodwill:

	(In thousands)
Balance as of December 31, 2022	$	734,274
Foreign currency exchange rate fluctuations	54
Balance as of September 30, 2023	$	734,328

Carrying Amounts and Useful Lives of Intangible Assets

The carrying amounts and useful lives of intangible assets as of September 30, 2023 and December 31, 2022 were as follows:

	September 30, 2023
	Gross carrying amount		Accumulated amortization		Foreign currency exchange rate fluctuations		Net carrying amount		Useful life (years)
	(In thousands, except for years)
Customer relationships	$	311,089	$	(113,844)	$	(1,482)	$	195,763	4 - 30
Acquired technology	84,876		(64,792)		—		20,084		4 - 20
Backlog	1,800		(1,575)		—		225		2
Trade names	9,200		(7,418)		—		1,782		5 - 12
Patents	2,430		(1,423)		—		1,007		2 - 20
Non-compete agreements	600		(600)		—		—		3
Total intangibles assets, net	$	409,995	$	(189,652)	$	(1,482)	$	218,861

 

	December 31, 2022
	Gross carrying amount		Accumulated amortization		Foreign currency exchange rate fluctuations		Net carrying amount		Useful life (years)
	(In thousands, except for years)
Customer relationships	$	311,089	$	(99,177)	$	(1,514)	$	210,398	4 - 30
Acquired technology	92,066		(64,299)		—		27,767		4 - 20
Backlog	1,800		(900)		—		900		2
Trade names	9,200		(6,633)		—		2,567		5 - 12
Patents	2,430		(1,306)		—		1,124		2 - 20
Non-compete agreements	600		(450)		—		150		3
Total intangibles assets, net	$	417,185	$	(172,765)	$	(1,514)	$	242,906

Estimated Future Amortization Expense for Intangible Assets

The estimated future amortization expenses for amortizable intangible assets were as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	7,483
2024	23,093
2025	21,056
2026	18,061
2027	16,754
Thereafter	132,414
Total	$	218,861

XML

Convertible Senior Notes (Tables)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Convertible Debt Balances

The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
Principal amount	$	575,000	$	575,000
Unamortized debt issuance costs	(6,113)		(8,429)
Convertible senior notes, net	$	568,887	$	566,571

Summary of Components of Interest Expense

The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Contractual coupon interest	$	359	$	359	$	1,078	$	1,078
Amortization of debt issuance costs	$	773	$	768	$	2,316	$	2,298

XML

Lessor Leases (Tables)

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Income Recognized from Sales-Type Leases

The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Sales-type lease revenues	$	14,388	$	10,115	$	27,960	$	34,033
Cost of sales-type lease revenues	(7,141)		(5,357)		(14,183)		(16,963)
Selling profit on sales-type lease revenues	$	7,247	$	4,758	$	13,777	$	17,070

Components of Sales-Type Lease Receivables

The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
	(In thousands)
Net minimum lease payments to be received	$	62,470	$	50,755
Less: Unearned interest income portion	(9,221)		(6,345)
Net investment in sales-type leases	53,249		44,410
Less: Current portion (1)	(11,618)		(11,486)
Long-term investment in sales-type leases, net	$	41,631	$	32,924

_________________________________________________

(1)    The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.

Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases

The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	3,828
2024	13,431
2025	11,351
2026	9,053
2027	7,286
Thereafter	17,521
Total future minimum sales-type lease payments	62,470
Present value adjustment	(9,221)
Total net investment in sales-type leases	$	53,249

Income Recognized from Operating Leases

The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Rental income	$	1,330	$	2,327	$	5,459	$	7,220

XML

Lessee Leases (Tables)

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities

The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows:

	September 30, 2023
	(In thousands)
Remaining three months of 2023	$	3,340
2024	12,266
2025	9,604
2026	8,942
2027	7,334
Thereafter	8,054
Total operating lease payments	49,540
Present value adjustment	(6,078)
Total operating lease liabilities (1)	$	43,462

_________________________________________________

(1)    Amount consists of a current and long-term portion of operating lease liabilities of $10.6 million and $32.8 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities in the Condensed Consolidated Balance Sheets.

Summary of Supplemental Cash Flow Information and Weighted-Average Remaining Lease Term and Discount Rate

The following table summarizes supplemental cash flow information related to the Company’s operating leases for the nine months ended September 30, 2023 and 2022:

	Nine Months Ended September 30,
	2023		2022
	(In thousands)
Cash paid for amounts included in the measurement of lease liabilities	$	10,100	$	13,178
Right-of-use assets obtained in exchange for new lease liabilities	$	1,758	$	12,177

The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of September 30, 2023 and December 31, 2022:

	September 30, 2023		December 31, 2022
Weighted-average remaining lease term, years	4.6		5.0
Weighted-average discount rate, %	5.7	%	5.7	%

XML

Employee Benefits and Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Share-Based Compensation Expense

The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Cost of product and service revenues	$	2,213	$	2,203	$	6,489	$	6,607
Research and development	1,917		3,054		5,220		7,912
Selling, general, and administrative	10,852		12,053		31,404		36,212
Total share-based compensation expense	$	14,982	$	17,310	$	43,113	$	50,731

Assumptions Used to Value ESPP Shares

The following assumptions were used to value shares under the ESPP for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Expected life, years	0.5 - 2.0		0.5 - 2.0		0.5 - 2.0		0.5 - 2.0
Expected volatility, %	32.0% - 63.9%		28.8% - 44.8%		31.7% - 63.9%		28.8% - 45.6%
Risk-free interest rate, %	0.2% - 5.5%		0.1% - 3.2%		0.1% - 5.5%		0.1% - 3.2%
Dividend yield, %	—	%	—	%	—	%	—	%

Assumptions Used to Value Stock Options Granted

The following assumptions were used to value stock options granted pursuant to the Company’s 2009 Equity Incentive Plan, as amended, (the “2009 Plan”) for the nine months ended September 30, 2023. There were no stock options granted during the three months ended September 30, 2023, and the three and nine months ended September 30, 2022.

	Nine Months Ended September 30,
	2023
Expected life, years	3.2
Expected volatility, %	44.8	%
Risk-free interest rate, %	3.7	%
Estimated forfeiture rate, %	10.0	%
Dividend yield, %	—	%

Summary of Share Option Activity

The following table summarizes the stock option activity under the 2009 Plan during the nine months ended September 30, 2023:

	Number of Shares	Weighted-Average Exercise Price		Weighted-Average Remaining Years	Aggregate Intrinsic Value
	(In thousands, except per share data)
Outstanding at December 31, 2022	2,434	$	68.65	6.1	$	7,887
Granted	200	55.60
Exercised	(157)	41.85
Expired	(177)	80.44
Forfeited	(180)	74.17
Outstanding at September 30, 2023	2,120	$	67.96	5.0	$	3,418
Exercisable at September 30, 2023	1,801	$	66.84	4.9	$	3,418
Vested and expected to vest at September 30, 2023 and thereafter	2,103	$	67.90	5.0	$	3,418

Summary of Restricted Stock Unit Activity

The following table summarizes the RSU activity under the 2009 Plan during the nine months ended September 30, 2023:

	Number of Shares	Weighted-Average Grant Date Fair Value		Weighted-Average Remaining Years	Aggregate Intrinsic Value
	(In thousands, except per share data)
Outstanding at December 31, 2022	1,117	$	115.75	1.6	$	56,297
Granted (Awarded)	675	64.44
Vested (Released)	(252)	117.13
Forfeited	(304)	112.82
Outstanding and unvested at September 30, 2023	1,236	$	87.89	1.7	$	55,649

Summary of Restricted Stock Awards Activity

The following table summarizes the RSA activity under the 2009 Plan during the nine months ended September 30, 2023:

	Number of Shares	Weighted-Average Grant Date Fair Value
	(In thousands, except per share data)
Outstanding at December 31, 2022	13	$	109.39
Granted (Awarded)	24	70.96
Vested (Released)	(13)	109.39
Outstanding and unvested at September 30, 2023	24	$	70.96

Summary of Performance-Based Restricted Stock Activity

The following table summarizes the PSU activity under the 2009 Plan during the nine months ended September 30, 2023:

	Number of Shares	Weighted-Average Grant Date Fair Value
	(In thousands, except per share data)
Outstanding at December 31, 2022	135	$	147.42
Granted	65	122.29
Vested	(35)	127.40
Forfeited	(66)	153.68
Outstanding and unvested at September 30, 2023	99	$	129.36

Ordinary Shares Reserved for Future Issuance Under Equity Incentive Plans

The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of September 30, 2023:

	Number of Shares
	(In thousands)
Stock options outstanding	2,120
Non-vested restricted stock awards	1,359
Shares authorized for future issuance	2,417
ESPP shares available for future issuance	3,250
Total shares reserved for future issuance	9,146

XML

Restructuring Expenses (Tables)

9 Months Ended

Sep. 30, 2023

Restructuring and Related Activities [Abstract]

Total Restructuring Expense Recognized in the Condensed Consolidated Statements of Operations

The following table summarizes the total employee-related restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(In thousands)
Cost of product and service revenues	$	(280)	$	444	$	102	$	600
Research and development	(25)		272		467		1,866
Selling, general, and administrative	(276)		1,078		4,885		2,855
Total restructuring expense, net of reversals	$	(581)	$	1,794	$	5,454	$	5,321

XML

Organization and Summary of Significant Accounting Policies - Narrative (Details)	9 Months Ended
	Sep. 30, 2023 segment
Accounting Policies [Abstract]
Number of operating segments	1
Number of reportable segments	1

XML

Revenues - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Fees to GPOs	$ 3,600	$ 4,800	$ 9,500	$ 13,300
Short-term deferred revenues, net	124,991		124,991		$ 118,947
Deferred cost of sales	12,400		12,400		15,800
Deferred revenues recognized	20,100		106,200
Short-term deferred revenues, gross					134,700
Long-term deferred revenues	$ 55,053		$ 55,053		$ 37,385
Deferred revenue, period	10 years		10 years
Remaining performance obligation	$ 344,800		$ 344,800
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, period	10 years		10 years

XML

Revenues - Disaggregation of Revenues by Revenue Type (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue from External Customer [Line Items]
Revenues	$ 298,663	$ 348,059	$ 888,265	$ 998,273
Connected devices, software licenses, and other
Revenue from External Customer [Line Items]
Revenues	167,560	226,415	500,182	650,125
Consumables
Revenue from External Customer [Line Items]
Revenues	21,195	20,150	62,724	56,121
Technical services
Revenue from External Customer [Line Items]
Revenues	57,303	53,914	167,851	156,386
Advanced Services
Revenue from External Customer [Line Items]
Revenues	$ 52,605	$ 47,580	$ 157,508	$ 135,641

XML

Revenues - Disaggregation of Revenues by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue from External Customer [Line Items]
Revenues	$ 298,663	$ 348,059	$ 888,265	$ 998,273
United States
Revenue from External Customer [Line Items]
Revenues	272,649	315,755	785,794	898,269
Rest of world
Revenue from External Customer [Line Items]
Revenues	$ 26,014	$ 32,304	$ 102,471	$ 100,004

XML

Revenues - Contract Asset and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Revenue Recognition [Abstract]
Short-term unbilled receivables, net	$ 20,275	$ 25,763
Long-term unbilled receivables, net	13,159	14,744
Total contract assets	33,434	40,507
Short-term deferred revenues, net	124,991	118,947
Long-term deferred revenues	55,053	37,385
Total contract liabilities	$ 180,044	$ 156,332

XML

Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income (loss)	$ 5,553	$ 3,451	$ (15,000)	$ 16,774	$ 9,069	$ 8,213	$ (5,996)	$ 34,056
Weighted-average shares outstanding – basic (in shares)	45,333			44,441			45,117	44,304
Weighted-average shares outstanding — diluted (in shares)	45,595			45,819			45,117	46,759
Net income (loss) per share – basic (in dollars per share)	$ 0.12			$ 0.38			$ (0.13)	$ 0.77
Net income (loss) per share – diluted (in dollars per share)	$ 0.12			$ 0.37			$ (0.13)	$ 0.73
Stock Award Plans
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effect of dilutive securities (in shares)	262			943			0	1,293
Anti-dilutive weighted-average shares (in shares)	2,727			810			3,536	689
Convertible Senior Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effect of dilutive securities (in shares)	0			435			0	1,162
Convertible Senior Notes and Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted-average shares (in shares)	11,816			5,908			11,816	5,908

XML

Cash and Cash Equivalents and Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 446,840	$ 330,362	$ 266,402
Cash equivalents	429,700	301,000
Convertible Senior Notes | Convertible Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of long-term debt	518,600	501,400
Long-term debt	$ 568,887	$ 566,571

XML

Balance Sheet Components - Balance Sheet Components (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventories:
Raw materials	$ 56,566	$ 75,854
Work in process	2,738	9,280
Finished goods	56,840	62,415
Total inventories	$ 116,144	$ 147,549
Other current assets:
Restricted Cash, Statement of Financial Position [Extensible Enumeration]	Total other current assets	Total other current assets
Funds held for customers, including restricted cash	$ 30,967	$ 56,703
Net investment in sales-type leases, current portion	11,618	11,486
Prepaid income taxes	125	1,702
Other current assets	7,526	7,471
Total other current assets	50,236	77,362
Other long-term assets:
External-use software development costs, net	69,872	80,760
Unbilled receivables, net	13,159	14,744
Deferred debt issuance costs	1,235	2,058
Other long-term assets	6,500	7,455
Total other long-term assets	$ 90,766	$ 105,017
Accrued liabilities:
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total accrued liabilities	Total accrued liabilities
Operating lease liabilities, current portion	$ 10,617	$ 10,761
Customer fund liabilities	30,967	56,703
Advance payments from customers	10,549	11,556
Rebate liabilities	50,878	42,802
Group purchasing organization fees	5,290	7,723
Taxes payable	14,178	9,642
Other accrued liabilities	27,906	33,468
Total accrued liabilities	150,385	172,655
Restricted cash	$ 15,900	$ 22,500

XML

Balance Sheet Components - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance at beginning of period	$ 1,163,565	$ 1,142,541	$ 1,130,137	$ 1,092,637	$ 1,074,741	$ 1,146,689	$ 1,130,137	$ 1,146,689
Other comprehensive income (loss)	(2,953)	1,432	1,479	(6,770)	(6,410)	(2,555)	(42)	(15,735)
Balance at end of period	1,187,436	1,163,565	1,142,541	1,135,395	1,092,637	1,074,741	1,187,436	1,135,395
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance at beginning of period	(14,176)	(15,608)	(17,087)	(17,372)	(10,962)	(8,407)	(17,087)	(8,407)
Other comprehensive income (loss)	(2,953)	1,432	1,479	(6,770)	(6,410)	(2,555)
Balance at end of period	$ (17,129)	$ (14,176)	$ (15,608)	$ (24,142)	$ (17,372)	$ (10,962)	$ (17,129)	$ (24,142)

XML

Property and Equipment - Property, Plant and Equipment Balances (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 244,839	$ 220,605
Accumulated depreciation and amortization	(137,959)	(126,644)
Total property and equipment, net	106,880	93,961
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	95,891	91,391
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,898	5,154
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	17,821	19,510
Purchased software and internal-use software development costs
Property, Plant and Equipment [Line Items]
Property and equipment, gross	97,860	76,327
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 28,369	$ 28,223

XML

Property and Equipment - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 6.7	$ 5.8	$ 19.6	$ 16.7

XML

Property and Equipment - Summary of Geographic Information for Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 106,880	$ 93,961
United States
Property, Plant and Equipment [Line Items]
Property and equipment, net	102,729	89,989
Rest of world
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 4,151	$ 3,972

XML

External-Use Software Development Costs - Schedule of Capitalized Computer Software (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Research and Development [Abstract]
Gross carrying amount	$ 236,024	$ 225,004
Accumulated amortization	(166,152)	(144,244)
External-use software development costs, net	$ 69,872	$ 80,760

XML

External-Use Software Development Costs - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Research and Development [Abstract]
Amortization of capitalized software development costs	$ 7.1	$ 7.3	$ 21.9	$ 21.5

XML

External-Use Software Development Costs - Schedule of Future Amortization Expenses For Capitalized Software Development Costs (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Research and Development [Abstract]
Remaining three months of 2023	$ 6,787
2024	24,747
2025	17,608
2026	12,069
2027	6,114
Thereafter	2,547
External-use software development costs, net	$ 69,872	$ 80,760

XML

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Goodwill [Roll Forward]
Balance at beginning of period	$ 734,274
Foreign currency exchange rate fluctuations	54
Balance at end of period	$ 734,328

XML

Goodwill and Intangible Assets - Carrying Amounts and Useful Lives of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 409,995	$ 417,185
Accumulated amortization	(189,652)	(172,765)
Foreign currency exchange rate fluctuations	(1,482)	(1,514)
Net carrying amount	218,861	242,906
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	311,089	311,089
Accumulated amortization	(113,844)	(99,177)
Foreign currency exchange rate fluctuations	(1,482)	(1,514)
Net carrying amount	$ 195,763	$ 210,398
Customer relationships | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	4 years	4 years
Customer relationships | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	30 years	30 years
Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 84,876	$ 92,066
Accumulated amortization	(64,792)	(64,299)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 20,084	$ 27,767
Acquired technology | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	4 years	4 years
Acquired technology | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	20 years	20 years
Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,800	$ 1,800
Accumulated amortization	(1,575)	(900)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 225	$ 900
Useful life	2 years	2 years
Trade names
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 9,200	$ 9,200
Accumulated amortization	(7,418)	(6,633)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 1,782	$ 2,567
Trade names | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	5 years	5 years
Trade names | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	12 years	12 years
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,430	$ 2,430
Accumulated amortization	(1,423)	(1,306)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 1,007	$ 1,124
Patents | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	2 years	2 years
Patents | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	20 years	20 years
Non-compete agreements
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 600	$ 600
Accumulated amortization	(600)	(450)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 0	$ 150
Useful life	3 years	3 years

XML

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense of intangible assets	$ 7.7	$ 8.7	$ 24.1	$ 26.7

XML

Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining three months of 2023	$ 7,483
2024	23,093
2025	21,056
2026	18,061
2027	16,754
Thereafter	132,414
Net carrying amount	$ 218,861	$ 242,906

XML

Debt and Credit Agreement (Details) - Line of Credit	Oct. 10, 2023 USD ($)	Mar. 29, 2023	Nov. 15, 2019 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Sep. 22, 2020
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Minimum
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments		0.15%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Maximum
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments		0.30%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Applicable Margin | Minimum
Debt Instrument [Line Items]
Spread on variable interest rate		1.25%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Applicable Margin | Maximum
Debt Instrument [Line Items]
Spread on variable interest rate		2.00%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Federal Funds
Debt Instrument [Line Items]
Spread on variable interest rate		0.50%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | One Month Adjusted Term Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Spread on variable interest rate		1.00%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | One Month Secured Overnight Financing Rate (SOFR) Applicable Margin | Minimum
Debt Instrument [Line Items]
Spread on variable interest rate		0.25%
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | One Month Secured Overnight Financing Rate (SOFR) Applicable Margin | Maximum
Debt Instrument [Line Items]
Spread on variable interest rate		1.00%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Subsequent Event
Debt Instrument [Line Items]
Maximum secured net leverage ratio	3.00
Minimum interest coverage ratio	3.00
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Minimum | Subsequent Event
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments	0.20%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Maximum | Subsequent Event
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments	0.35%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Applicable Margin | Minimum | Subsequent Event
Debt Instrument [Line Items]
Spread on variable interest rate	1.50%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Applicable Margin | Maximum | Subsequent Event
Debt Instrument [Line Items]
Spread on variable interest rate	2.25%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Federal Funds | Subsequent Event
Debt Instrument [Line Items]
Spread on variable interest rate	0.50%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | One Month Adjusted Term Secured Overnight Financing Rate (SOFR) | Subsequent Event
Debt Instrument [Line Items]
Spread on variable interest rate	1.00%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | One Month Secured Overnight Financing Rate (SOFR) Applicable Margin | Minimum | Subsequent Event
Debt Instrument [Line Items]
Spread on variable interest rate	0.50%
Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | One Month Secured Overnight Financing Rate (SOFR) Applicable Margin | Maximum | Subsequent Event
Debt Instrument [Line Items]
Spread on variable interest rate	1.25%
Revolving Credit Facility
Debt Instrument [Line Items]
Long-term line of credit				$ 0	$ 0
Revolving Credit Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Term of debt instrument			5 years
Maximum borrowing capacity			$ 500,000,000
Remaining borrowing capacity				$ 500,000,000	$ 500,000,000
Revolving Credit Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Calendar Quarters Up To and Including March 31, 2021
Debt Instrument [Line Items]
Maximum secured net leverage ratio						3.50
Revolving Credit Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Calendar Quarters After March 31, 2021
Debt Instrument [Line Items]
Maximum secured net leverage ratio						3.00
Revolving Credit Facility | Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Subsequent Event
Debt Instrument [Line Items]
Term of debt instrument	5 years
Maximum borrowing capacity	$ 350,000,000
Accordion feature, higher borrowing capacity option	$ 250,000,000
EBITDA, prior year, percentage	100.00%
Remaining borrowing capacity	$ 350,000,000
Incremental Loan Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity			250,000,000
Letter of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity			15,000,000
Letter of Credit | Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Subsequent Event
Debt Instrument [Line Items]
Maximum borrowing capacity	15,000,000
Swing Line Loan | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 25,000,000
Swing Line Loan | Wells Fargo Securities, JP Morgan Chase Bank, PNC Capital Markets and TD Securities | Subsequent Event
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 25,000,000

XML

Convertible Senior Notes - Narrative (Details)	Dec. 13, 2021 USD ($) $ / shares	Sep. 25, 2020 USD ($) day $ / shares shares	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Purchase of convertible note hedge		$ 100,600,000
Proceeds from sale of warrants		51,300,000
Convertible Note Hedge
Debt Instrument [Line Items]
Deferred tax asset related to the convertible note hedge transaction		$ 25,800,000
Convertible Note Hedge Rights
Debt Instrument [Line Items]
Options and warrants to purchase shares (in shares) | shares		5,900,000
Strike price (in dollars per share) | $ / shares		$ 97.32
Warrants
Debt Instrument [Line Items]
Options and warrants to purchase shares (in shares) | shares		5,900,000
Strike price (in dollars per share) | $ / shares		$ 141.56
Convertible Senior Notes
Debt Instrument [Line Items]
Debt instrument, convertible, principal amount of notes, minimum	$ 1,000
Debt instrument, convertible, maximum cash	1,000
Debt instrument, convertible, consideration in excess, amount	$ 1,000
Convertible Senior Notes | Convertible Debt
Debt Instrument [Line Items]
Interest rate		0.25%
Principal amount		$ 575,000,000	$ 575,000,000	$ 575,000,000
Additional principal amount subject to purchasers' option		75,000,000
Proceeds from issuance of convertible senior notes, net of issuance costs		559,700,000
Debt issuance costs incurred and capitalized		$ 15,300,000
Conversion ratio		0.0102751
Conversion price (in dollars per share) | $ / shares	$ 97.32
Repurchase price as a percent of principal amount		100.00%
Aggregate principal amount of Notes that must be outstanding and not subject to redemption if the Company redeems less than all of the Notes		$ 150,000,000
Effective interest rate		0.80%
Remaining life of debt discount and issuance cost accretion			2 years
Maximum number of shares issuable upon conversion (in shares) | shares		5,900,000
Convertible Senior Notes | Convertible Debt | Period 1
Debt Instrument [Line Items]
Threshold trading days | day		20
Threshold consecutive trading days | day		30
Threshold percentage of stock price trigger		130.00%
Convertible Senior Notes | Convertible Debt | Period 2
Debt Instrument [Line Items]
Threshold trading days | day		5
Threshold consecutive trading days | day		10
Threshold percentage of stock price trigger		98.00%

XML

Convertible Senior Notes - Convertible Debt Balances (Details) - Convertible Debt - Convertible Senior Notes - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Sep. 25, 2020
Debt Instrument [Line Items]
Principal amount	$ 575,000,000	$ 575,000,000	$ 575,000,000
Unamortized debt issuance costs	(6,113,000)	(8,429,000)
Convertible senior notes, net	$ 568,887,000	$ 566,571,000

XML

Convertible Senior Notes - Summary of Components of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Debt Instrument [Line Items]
Amortization of debt issuance costs			$ 3,139	$ 3,121
Convertible Senior Notes | Convertible Debt
Debt Instrument [Line Items]
Contractual coupon interest	$ 359	$ 359	1,078	1,078
Amortization of debt issuance costs	$ 773	$ 768	$ 2,316	$ 2,298

XML

Lessor Leases - Narrative (Details)	Sep. 30, 2023
Minimum
Lessor, Lease, Description [Line Items]
Term of sales-type leases	1 year
Maximum
Lessor, Lease, Description [Line Items]
Term of sales-type leases	10 years

XML

Lessor Leases - Income Recognized from Sales-Type Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Sales-type lease revenues	$ 14,388	$ 10,115	$ 27,960	$ 34,033
Cost of sales-type lease revenues	(7,141)	(5,357)	(14,183)	(16,963)
Selling profit on sales-type lease revenues	$ 7,247	$ 4,758	$ 13,777	$ 17,070

XML

Lessor Leases - Components of Sales-Type Lease Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Leases [Abstract]
Net minimum lease payments to be received	$ 62,470	$ 50,755
Less: Unearned interest income portion	(9,221)	(6,345)
Net investment in sales-type leases	53,249	44,410
Less: Current portion	(11,618)	(11,486)
Long-term investment in sales-type leases, net	$ 41,631	$ 32,924

XML

Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Leases [Abstract]
Remaining three months of 2023	$ 3,828
2024	13,431
2025	11,351
2026	9,053
2027	7,286
Thereafter	17,521
Net minimum lease payments to be received	62,470	$ 50,755
Present value adjustment	(9,221)	$ (6,345)
Total net investment in sales-type leases	$ 53,249

XML

Lessor Leases - Income Recognized from Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Rental income	$ 1,330	$ 2,327	$ 5,459	$ 7,220

XML

Lessee Leases - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 2,600	$ 4,000	$ 8,200	$ 12,800
Impairment and abandonment of operating lease right-of-use assets related to facilities		$ 300	$ 7,815	$ 5,390
Minimum
Lessee, Lease, Description [Line Items]
Term of operating leases	1 year		1 year
Maximum
Lessee, Lease, Description [Line Items]
Term of operating leases	12 years		12 years

XML

Lessee Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Leases [Abstract]
Remaining three months of 2023	$ 3,340
2024	12,266
2025	9,604
2026	8,942
2027	7,334
Thereafter	8,054
Total operating lease payments	49,540
Present value adjustment	(6,078)
Total operating lease liabilities	43,462
Current portion of operating lease liabilities	10,617	$ 10,761
Long-term portion of operating lease liabilities	$ 32,845	$ 39,405
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued liabilities	Accrued liabilities

XML

Lessee Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 10,100	$ 13,178
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 1,758	$ 12,177

XML

Lessee Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details)	Sep. 30, 2023	Dec. 31, 2022
Leases [Abstract]
Weighted-average remaining lease term	4 years 7 months 6 days	5 years
Weighted-average discount rate	5.70%	5.70%

XML

Commitments and Contingencies (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Loss Contingencies [Line Items]
Non-cancelable purchase commitments		$ 118.7
Non-cancelable purchase commitments expected to be paid within the year		78.1
Loss contingency, expense	$ 1.0	0.0	$ 13.5
Expected insurance recoveries	11.1
Loss contingency, expense incurred to date		13.6
Loss contingency, cumulative expected insurance recoveries		$ 11.6
Cost of product and service revenues
Loss Contingencies [Line Items]
Ransomware incident, expense, net of insurance recoveries	0.1		0.3
Research and development
Loss Contingencies [Line Items]
Ransomware incident, expense, net of insurance recoveries	0.2		0.2
Selling, general, and administrative
Loss Contingencies [Line Items]
Ransomware incident, expense, net of insurance recoveries	$ 0.7		$ 1.9

XML

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Provision for (benefit from) income taxes	$ 1,829	$ 543	$ 4,405	$ (995)
Tax expense (benefit)			5,600	$ (6,900)
Unrecognized tax benefits	10,100		10,100		$ 9,300
Accrued interest and penalties	$ 400		$ 400		$ 200

XML

Employee Benefits and Share-Based Compensation - Shared-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 14,982	$ 17,310	$ 43,113	$ 50,731
Cost of product and service revenues
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	2,213	2,203	6,489	6,607
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	1,917	3,054	5,220	7,912
Selling, general, and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 10,852	$ 12,053	$ 31,404	$ 36,212

XML

Employee Benefits and Share-Based Compensation - Assumptions Used to Value ESPP Shares (Details) - Employee Stock	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility (minimum)	32.00%	28.80%	31.70%	28.80%
Expected volatility (maximum)	63.90%	44.80%	63.90%	45.60%
Risk-free interest rate (minimum)	0.20%	0.10%	0.10%	0.10%
Risk-free interest rate (maximum)	5.50%	3.20%	5.50%	3.20%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 months	6 months	6 months	6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	2 years	2 years	2 years	2 years

XML

Employee Benefits and Share-Based Compensation - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Aug. 02, 2016	Nov. 04, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, amount capitalized	$ 1,100,000		$ 3,300,000
Shares purchased under ESPP (in shares)			353,000	316,000
The 2016 Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of shares authorized for repurchase under stock repurchase programs (up to)					$ 50,000,000
Remaining value of shares authorized for repurchase under stock repurchase programs	$ 2,700,000		$ 2,700,000
Number of shares repurchased (in shares)	0	0	0	389,300
Average price of repurchased shares (in dollars per share)				$ 134.11
Aggregate purchase price of treasury stock				$ 52,200,000
2014 Share Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of shares authorized for repurchase under stock repurchase programs (up to)						$ 50,000,000
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average price of shares purchased (in dollars per share)			$ 46.68	$ 67.63
Unrecognized compensation cost	$ 2,000,000		$ 2,000,000
Weighted average period of compensation cost not yet recognized			1 year 7 months 6 days
2009 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)	0	0	200,000	0
Weighted-average fair value of options granted (in dollars per share)			$ 19.48
Intrinsic value of options exercised	$ 500,000	$ 7,600,000	$ 3,100,000	$ 23,100,000
Unrecognized compensation cost of unvested stock options	5,300,000		$ 5,300,000
2009 Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized			10 months 24 days
2009 Plan | RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	78,200,000		$ 78,200,000
Weighted average period of compensation cost not yet recognized			3 years 1 month 6 days
2009 Plan | RSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	1,000,000		$ 1,000,000
Weighted average period of compensation cost not yet recognized			7 months 6 days
2009 Plan | PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 6,700,000		$ 6,700,000
Weighted average period of compensation cost not yet recognized			1 year 4 months 24 days

XML

Employee Benefits and Share-Based Compensation - Assumptions Used to Value Stock Options Granted (Details) - Stock Options	9 Months Ended
	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	3 years 2 months 12 days
Expected volatility	44.80%
Risk-free interest rate	3.70%
Estimated forfeiture rate	10.00%
Dividend yield	0.00%

XML

Employee Benefits and Share-Based Compensation - Summary of Share Option Activity (Details) - 2009 Plan - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Number of Shares
Outstanding at beginning of period (in shares)			2,434,000
Granted (in shares)	0	0	200,000	0
Exercised (in shares)			(157,000)
Expired (in shares)			(177,000)
Forfeited (in shares)			(180,000)
Outstanding at end of period (in shares)	2,120,000		2,120,000		2,434,000
Exercisable at end of period (in shares)	1,801,000		1,801,000
Vested and expected to vest at end of period (in shares)	2,103,000		2,103,000
Weighted-Average Exercise Price
Outstanding at beginning of period (in dollars per share)			$ 68.65
Granted (in dollars per share)			55.60
Exercised (in dollars per share)			41.85
Expired (in dollars per share)			80.44
Forfeited (in dollars per share)			74.17
Outstanding at end of period (in dollars per share)	$ 67.96		67.96		$ 68.65
Exercisable at end of period (in dollars per share)	66.84		66.84
Vested and expected to vest at end of period (in dollars per share)	$ 67.90		$ 67.90
Weighted-Average Remaining Years
Outstanding			5 years		6 years 1 month 6 days
Exercisable			4 years 10 months 24 days
Vested and expected to vest			5 years
Aggregate Intrinsic Value
Outstanding	$ 3,418		$ 3,418		$ 7,887
Exercisable	3,418		3,418
Vested and expected to vest	$ 3,418		$ 3,418

XML

Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - RSUs - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Number of Shares
Outstanding at beginning of period (in shares)	1,117
Granted (Awarded) (in shares)	675
Vested (Released) (in shares)	(252)
Forfeited (in shares)	(304)
Outstanding and unvested at end of period (in shares)	1,236	1,117
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share)	$ 115.75
Granted (Awarded) (in dollars per share)	64.44
Vested (Released) (in dollars per share)	117.13
Forfeited (in dollars per share)	112.82
Outstanding and unvested at end of period (in dollars per share)	$ 87.89	$ 115.75
Weighted-Average Remaining Years
Outstanding and unvested	1 year 8 months 12 days	1 year 7 months 6 days
Aggregate Intrinsic Value
Outstanding and unvested	$ 55,649	$ 56,297

XML

Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Award Activity (Details) - RSAs - 2009 Plan shares in Thousands	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Number of Shares
Outstanding at beginning of period (in shares) | shares	13
Granted (Awarded) (in shares) | shares	24
Vested (Released) (in shares) | shares	(13)
Outstanding and unvested at end of period (in shares) | shares	24
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 109.39
Granted (Awarded) (in dollars per share) | $ / shares	70.96
Vested (Released) (in dollars per share) | $ / shares	109.39
Outstanding and unvested at end of period (in dollars per share) | $ / shares	$ 70.96

XML

Employee Benefits and Share-Based Compensation - Summary of Performance-Based Restricted Stock Activity (Details) - Performance-Based Restricted Stock - 2009 Plan shares in Thousands	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Number of Shares
Outstanding at beginning of period (in shares) | shares	135
Granted (Awarded) (in shares) | shares	65
Vested (Released) (in shares) | shares	(35)
Forfeited (in shares) | shares	(66)
Outstanding and unvested at end of period (in shares) | shares	99
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 147.42
Granted (Awarded) (in dollars per share) | $ / shares	122.29
Vested (Released) (in dollars per share) | $ / shares	127.40
Forfeited (in dollars per share) | $ / shares	153.68
Outstanding and unvested at end of period (in dollars per share) | $ / shares	$ 129.36

XML

Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) shares in Thousands	Sep. 30, 2023 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	9,146
Stock options outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	2,120
Non-vested restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	1,359
Shares authorized for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	2,417
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	3,250

XML

Restructuring Expenses - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ (581,000)	$ 1,794,000	$ 5,454,000	$ 5,321,000
Q1 2022 Plan
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		$ 1,800,000		$ 5,300,000
Unpaid balance related to restructuring plan	0		0
Q4 2022/Q1 2023 Plan
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			5,500,000
Restructuring and related cost, cost incurred to date	22,900,000		22,900,000
Unpaid balance related to restructuring plan	$ 1,000,000		$ 1,000,000		$ 18,200,000

XML

Restructuring Expenses - Total Restructuring Expense Recognized in the Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring expense, net of reversals	$ (581)	$ 1,794	$ 5,454	$ 5,321
Cost of product and service revenues
Restructuring Cost and Reserve [Line Items]
Restructuring expense, net of reversals	(280)	444	102	600
Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring expense, net of reversals	(25)	272	467	1,866
Selling, general, and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring expense, net of reversals	$ (276)	$ 1,078	$ 4,885	$ 2,855

XML

Subsequent Events (Details) - Subsequent Event $ in Millions	Nov. 02, 2023 USD ($)
Minimum
Subsequent Event [Line Items]
Restructuring charges, expected cost	$ 12
Minimum | Employee Severance and Termination
Subsequent Event [Line Items]
Restructuring charges, expected cost	9
Minimum | Facility Closing
Subsequent Event [Line Items]
Restructuring charges, expected cost	3
Maximum
Subsequent Event [Line Items]
Restructuring charges, expected cost	18
Maximum | Employee Severance and Termination
Subsequent Event [Line Items]
Restructuring charges, expected cost	12
Maximum | Facility Closing
Subsequent Event [Line Items]
Restructuring charges, expected cost	$ 6